Protocol  I4V-MC-JAIA(b)  
 
 
A Randomized, Double -Blind, Placebo- Controlled, Parallel -Group, Phase 3 Study of Baricitinib 
in Patients  with Systemic Lupus Erythematosus  
 
[STUDY_ID_REMOVED] 
 
Approval Date: 20 -Apr-2020 
 
 
I4V-MC-JAIA(b) Clinical Protocol Page 1
LY3009104Protocol I4V -MC-JAIA(b)
A Randomized, Double -Blind, Placebo -Controlled, 
Parallel-Group, Phase 3 Study  of Baricitinib in Patients 
with Systemic Lupus Ery thematosus
EUDRA CTA 2017-005027-25
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_487017] (LY3009104), unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorit ies:  This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Baricitinib (LY3009104)
Eli Lilly and Company
Indiana polis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_11007]: 26 April 2018
Amendm ent (a) Electronically Signed and Approved by [CONTACT_11007] :  07 December 2018
Amendm ent (b) Electronically Signed and Approved by [CONTACT_57968].
Approval Date: 20-Apr-2020 GMT
I4V-MC-JAIA(b) Clinical Protocol Page 2
LY3009104Table of Contents
Section Page
Protocol I4V-MC-JAIA(b) A Rando mized, Double-Blind, 
Placebo-Controlled, Parallel -Group, Phase [ADDRESS_1155919] ivities....................................................................................................... 13
3.Introduction ...................................................................................................................... 22
3.1.Study Rationale............................................................................................................ 22
3.2.Background.................................................................................................................. 23
3.3.Benefit/Risk Assessment .............................................................................................. [ADDRESS_1155920] ions.................................................................................................... 44
6.4.Screen Failures ............................................................................................................. 44
7.Treatments ........................................................................................................................ 45
7.1.Treatments Administered ............................................................................................. 45
7.1.1.Packaging and Labelling ...................................................................................... 45
7.2.Method of Treatment Assignment ................................................................................ 46
7.2.1. Selection and Timing o f Doses............................................................................. 46
7.2.2. Dose Adjustment for Renal Impairment ............................................................... 46
7.3.Blinding....................................................................................................................... 47
7.4.Dosage Modification .................................................................................................... 47
7.5.Preparation/Handling/Storage/Accountabilit y............................................................... 47
7.6.Treatment Compliance .................................................................................................47
7.7.Concomitant Therapy ................................................................................................... 48
7.7.1. Permitted Changes and Addit ions to Concomitant Therapy .................................. 49
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155921] to Follow -up......................................................................................................... 55
9.Study Assessments and Procedures ................................................................................... 56
9.1.Efficacy Assessments ................................................................................................... 56
9.1.1. Primary Efficacy  Assessment ............................................................................... 56
[IP_ADDRESS]. Systemic Lupus Ery thematosus Di sease Act ivity 
Index-2000..................................................................................................... 56
[IP_ADDRESS]. British Isles Lupus Assessment Group 2004 Index .......................................... 56
[IP_ADDRESS]. Physician’s Global Assessment of Disease Activit y........................................ [ADDRESS_1155922] oratory Efficacy Assessments ................................................ 57
[IP_ADDRESS]. Systemic Lupus Ery thematosus Responder Index........................................... 57
[IP_ADDRESS]. Systemic Lupus Ery thematosus Di sease Act ivity 
Index-2000..................................................................................................... 57
[IP_ADDRESS]. British Isles Lupus Assessment Group 2004 Index .......................................... 57
[IP_ADDRESS].Physician’s Global Assessment of Disease Activit y........................................ 57
[IP_ADDRESS]. Safety of Estrogens in Lupus Ery thematosus Nati onal 
Assessment (SELENA) -Systemic Lupus Ery thematosus 
Disease Act ivity Index (SLEDAI) Flare Index ................................................ 57
[IP_ADDRESS]. Cutaneous Lupus Ery thematosus Di sease Area and 
Severity Index................................................................................................ 58
[IP_ADDRESS]. Lupus Low Disease Act ivity State.................................................................. 58
[IP_ADDRESS]. Tender/Swollen Jo int Count (28 Joints) .......................................................... 58
[IP_ADDRESS]. Systemic Lupus Internat ional Collaborating 
Clinics/American College of Rheumatology  Damage 
Index.............................................................................................................. 58
[IP_ADDRESS]. British Isles Lupus Assessment Group Based Composite 
Lupus Assessment .......................................................................................... 58
[IP_ADDRESS]. Health Outcomes and Qualit y of Life Measures .............................................. 59
[IP_ADDRESS].1. Worst Pain Numeric Rat ing Scale ............................................................. 59
[IP_ADDRESS].2. Worst Joint Pain Numeric Rating Scale ..................................................... 59
I4V-MC-JAIA(b) Clinical Protocol Page 4
LY30091049.[IP_ADDRESS]. Worst Fatigue Numeric Rating Scale ........................................................ 59
[IP_ADDRESS].4. Joint Stiffness Duration ............................................................................. 59
[IP_ADDRESS].5. Joint Stiffness Severit y Numeric Rat ing Scale........................................... 59
[IP_ADDRESS].6. Patient’s Global Impression of Severity.................................................... 59
[IP_ADDRESS].7. Patient’s Global Impression of Change..................................................... 60
[IP_ADDRESS].8. Medical Outcomes Short- Form 36-Item Health 
Survey Version2 (SF-36v2)..................................................................... 60
[IP_ADDRESS].9. Functional Assessment of Chronic Illness Therapy –
Fatigue Scale ............................................................................................ 60
[IP_ADDRESS].10. Work Productivit y and Activity Impairment 
Questionnaire–Lupus................................................................................ 60
[IP_ADDRESS].11. European Qualit y of Life–5 Dimensi ons–5 Levels.................................... 60
9.1.3. Appropriateness of Assessments .......................................................................... 61
9.2.Adverse Events ............................................................................................................ 61
9.2.1. SeriousAdverse Events ........................................................................................ 62
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... [ADDRESS_1155923] ....................................................................... 63
9.2.3. Complaint Handling ............................................................................................. 63
9.3.Treatment of Overdose .................................................................................................63
9.4.Safety........................................................................................................................... 63
9.4.1. Electrocardiograms .............................................................................................. 63
9.4.2. V ital Signs........................................................................................................... 64
9.4.3. Physical Examinat ion........................................................................................... 64
9.4.4. Laboratory  Tests.................................................................................................. 64
9.4.5. Columbia-Suicide Severit y Rating Scale .............................................................. 64
9.4.6. 16 -Item Quick Inventory  of Depressive Symptom atology:  
Self-Report........................................................................................................... [ADDRESS_1155924] x-Ray and Tuberculo sis Testing .................................................................. 65
9.4.8. Hepatitis B Virus  DNA Moni toring..................................................................... 65
9.4.9. Hepatic Safety Monitoring................................................................................... 66
9.4.10. Safety Monitoring................................................................................................ 67
[IP_ADDRESS]. Venous Thromboembo lic Event Assessment .................................................. 67
9.5.Pharmacokinet ics......................................................................................................... 67
9.6.Pharmacodynamics ...................................................................................................... 69
9.7.Pharmacogeno mics...................................................................................................... 69
9.7.1. Whole Blood Samples for Pharmacogenet ic Research .......................................... 69
9.8.Biomarkers................................................................................................................... 69
9.9.Medical Resource Utilizat ion and Healt h Economics ................................................... 70
10.Statistical Considerations .................................................................................................. 71
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155925] ical Considerat ions........................................................................ 72
[IP_ADDRESS]. Analysis Methods ........................................................................................... 72
[IP_ADDRESS]. Missing Data Imputation ................................................................................ 74
[IP_ADDRESS]. Multiple Comparisons/Mult iplicity.................................................................75
10.3.2. Treatment Group Comparabilit y........................................................................... 78
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 78
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 78
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 78
[IP_ADDRESS]. Treatment Compliance .................................................................................... 78
10.3.3. Efficacy Analyses ................................................................................................ 78
[IP_ADDRESS]. Primary Analyses ........................................................................................... 78
[IP_ADDRESS].Major Secondary  Analyses ............................................................................. 79
[IP_ADDRESS]. Other Secondary  and Expl oratory Analyses .................................................... 79
10.3.4. Safety Analyses.................................................................................................... 79
[IP_ADDRESS]. Adverse Events ............................................................................................... 79
[IP_ADDRESS].Clinical Laboratory  Tests................................................................................ 80
[IP_ADDRESS]. Vital Signs, Physical Findings, and Other Safet y 
Evaluation...................................................................................................... 80
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 80
10.3.6. Interim Analyses .................................................................................................. 80
11.References ........................................................................................................................ 82
12.Appendices ....................................................................................................................... 86
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155926] ....................... 52
TableJAIA.5. Analysis Populat ions..................................................................................... 72
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155927] of Figures
Figure Page
FigureJAIA.1. Illustration of study design for Clinical Protocol I4V -MC-JAIA.................... 33
FigureJAIA.2. Illustration of graphical mult iple testing procedure with init ial α 
allocation and weights. .................................................................................. 77
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155928] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 87
Appendix 2. Clinical Laboratory  Tests............................................................................... 92
Appendix 3. Study Governance Considerat ions.................................................................. 94
Appendix 4. Hepatic Monitoring Tests for Treatment -Emergent Abnormalit y.................... 99
Appendix 5. Monitoring Tests for Confirmed VTE .......................................................... 100
Appendix 6. Protocol Amendment I4V -MC-JAIA(b) Summary -A Randomized, 
Double-Blind, Placebo-Controlled, Parallel -Group, Phase 3 St udy of 
Baricitinib in Patients with Systemic Lupus Ery thematosus ......................... 101
I4V-MC-JAIA(b) Clinical Protocol Page 9
LY30091041.Synopsis
Title of Study:
A Randomized, Double -Blind, Placebo-Controlled, Parallel -Group, Phase 3 Study  of Baricitinib 
in Patients with systemic lupus erythematosus (SLE).
Rationale:
Systemic lupus ery thematosus i s a chroni c, often debilitating, multisystem, autoimmune disease 
that is characterized by [CONTACT_492290] B cells and elevated autoantibodies, which 
directly damage the body’s cells and tissues.  Systemic lupus erythematosus can affect mult iple 
organ systems simultaneously  or sequen tially, and fo llows a highly  variable clinical course 
where periods of relat ively stable disease are fo llowed by [CONTACT_629276]/or peri ods of persistently 
active disease; all o f which can ult imately lead to irreversible damage to tissues and organ 
systems.
Baricitinib is an oral , reversible, selective inhibitor of Janus kinase (JAK)1 and JAK2 (Fridman 
et al. 2010).  This activit y profile suggests that baricit inib may inhibit cy tokines implicated in 
SLE, most notably  type I interferon (IFN; JAK1/ tyrosine kinase [TYK]2), interl eukin (IL -6; 
JAK1/JAK2/TYK2), and ty pe II IFNγ, as well as other cy tokines that m ay have a rol e in SLE, 
including IL- 23 (JAK2/TYK2), granulocy te–-macrophage colony st imulating factor 
(JAK2/JAK2) and IL -12 (JAK2/TYK2).  In a recent ly completed Phase 2 study  (I4V-MC-JAHH 
[JAHH]), baricit inib demo nstrated clinical efficacy in pat ients with SLE.  Bari citinib plus 
standard of care was superior to pla cebo plus standard of care in the proportion of pat ients 
achieving remissio n of rash and/or arthrit is as defined by [CONTACT_832675] 2000 (SLEDAI- 2K), as well as the proportion of pat ients achieving a 
Systemic Lupus E rythematosus Responder Index -4 (SRI-4) response at Week 24. 
Given the efficacy of baricit inib demo nstrated in clinical trials for treating 
autoimmune/autoinflammatory  diseases invo lving joints, skin, and kidney (including SLE), the 
acceptable safety profile of baricitinib observed through the current stage of development, and a 
continuing unmet medical need in pat ients with SLE, there is a co mpelling rat ionale for the 
initiation of a Phase 3 program to evaluate baricit inib in treatment of SLE.
I4V-MC-JAIA(b) Clinical Protocol Page 10
LY3009104Objective(s)/Endpoints:
Objectives Endpoints
Primary
To evaluate the effect of baricitinib [ADDRESS_1155929] -of-care (SoC) therapy compared 
with placebo and SoC on SLE disease activity.Proportion of patients achieving an SRI-4 response at 
Week 52, defined as:
Reduction of ≥4 points from baseline in 
SLEDAI-2K score; and
No new British Isles Lupus Assessment Group 
(BILAG) A andno more than 1 new BILAG B 
disease activity score; and
No worsening (defined as an increase of ≥0.3points 
[10 mm] from baseline) in the Physician’s Global 
Assessment of Disease Activity.
MajorSecondary
To evaluate the effect of baricitinib 4 -mg QD plus 
SoC compared to placebo plus SoC on SLE 
disease activity.Proportion of patients achieving an SRI-4 response 
at Week 24 .
Proportion of patients achieving a lupus low disease 
activity state(LLDAS)responseat Week 52.
To evaluate the corticosteroid sparing effect of 
baricitinib 4 -mg QD plus SoC compared to 
placebo plus SoC.Proportion of patients receiving >7.5 mg prednisone 
(or equivalent) at baseline able to decrease dose by  
≥25% to a prednisone equivalent dose of ≤7.5 mg/day 
maintained between Week 40 and Week 52.
To evaluate the effect of b aricitinib 4 -mg QD plus 
SoC compared to placebo plus SoC on SLE flares.Time to first severe flare over 52 weeks .
To evaluate the effect of baricitinib 4 -mg QD plus 
SoC compared to placebo plus SoC on 
patient-reported outcomes (PROs).Change from baseline in Worst Pain NRS at Week 
52.
Change from baseline in FACIT -Fatiguetotal score
at Week 52 .
To evaluate the effect of baricitinib 2 -mg QD plus 
SoC compared to placebo plus SoC on SLE 
disease activity.Proportion of patients achieving an SRI-4 response
atWeek 52.
Proportion of patients achieving an SRI-4 response 
at Week 24.
Proportion of patients achieving a lupus low disease 
activity state(LLDAS)responseat Week 52.
To evaluate the corticosteroid sparing effect of 
baricitinib 2 -mg QD plus SoC compare d to 
placebo plus SoC.Proportion of patients receiving >7.5 mg prednisone 
(or equivalent) at baseline able to decrease dose by  
≥25% to a prednisone equivalent dose of ≤7.5 mg/day 
maintained between Week 40 and Week 52.
To evaluate the effect of baricitinib 2 -mg QD plus 
SoC compared to placebo plus SoC on SLE flares.Time to first severe flare over 52 weeks .
To evaluate the effect of baricitinib 2 -mg QD plus 
SoC compared to placebo plus SoC on 
patient-reported outcomes (PROs).Change from baseline in Worst Pain NRS at Week 52.
Change from baseline in FACIT -Fatigue total score 
at Week 52
Abbreviations :  BILAG = British Isles Lupus Assessment Group; FACIT-Fatigue= Functional Assessment of 
Chronic Illness Therapy -Fatigue; LLDAS=Lupus Low D isease Activity State; NRS = Numeric Rating Scale; 
QD = once daily; SLE = Systemic Lupus Erythematosus; SLEDAI -2K = Systemic Lupus Erythematosus Disease 
Activity Index 2000; SoC =standard of care; SRI -4 = Systemic Lupus Erythematosus Responder Index-4.
I4V-MC-JAIA(b) Clinical Protocol Page 11
LY3009104Summary of Study Design:
Study I4V-MC-JAIA(JAIA) is a Phase 3, mult icenter, randomized, double- blind, parallel -group, 
placebo-controlled, outpatient, [ADDRESS_1155930] therapi[INVESTIGATOR_832657], antimalarials, and immunosuppressants.
Treatment Arms and Duration:
At Week 0, p atients will be rando mized to 1 of 3 treatment groups: placebo once daily (QD), 
baricitinib 2-mg QD, or baricit inib 4-mg QD. The study duration will be up to 62 weeks 
(Screening Period: up to 6 weeks prior to randomiz ation; Double -Blinded Treatm ent Period: 
52weeks; [In some circumstances, due to COVID- 19 related logistical issues, Visit 16 may be 
completed outsi de of the protocol specified timeframe, thus the treatment period may be 
extended.  Where allowed locally, additional IP (typi[INVESTIGATOR_832658] 1extra month ’s supply) 
may be dispensed to prevent interruption of study  drug.]; Follow-up Period:approximately [ADDRESS_1155931] ).
Number of Patients:
The study  will include approximately  750 patients with SLE who will be rando mized 1:1:1 to 
receive placebo QD, baricit inib 2-mg QD, or baricitinib 4- mg QD (250 patients in each treatment 
group).An additional 10% (75 patients) may  be enrolled due to COVID -19 related trial impacts.
Statistical Analysis:
Unless otherwise specified, the efficacy and healt h outcome analyses will be conducted on the 
modified intent -to-treat (mITT) popul ation, which in cludes rando mized pat ients who receive at 
least [ADDRESS_1155932] postb aseline 
visit for the reason “Lost to Follow -up.”
Treatment comparisons of categorical efficacy and healt h outcomes variables will be made using 
a logistic regressio n analysis wit h Firth correction (Firth 1993; Heinze and Schemper 2001 ).  
Baseline disease act ivity, baseline corticosteroid dose, region, and treatment group will be 
explanatory  variables in the m odel.  The p-value and 95% confidence interval (CI) for the odds 
ratio from the logistic regressio n model will be used for primary  statistical inference.  Patients 
who discont inue treatment early, increased use of corticosteroids above the baseline dose other 
than the permitted burst ,as defined in the SAP , or have init iation of or an increase above the 
baseline dose in immunosuppressant or antimalarial treatment any t ime after baseline ,as defined 
in the SAP ,will be defined as nonresponders and the data will be imputed using the 
nonresponder imputation (NRI) method .
Treatment comparisons of continuous efficacy and healt h outcomes variables will be made using 
a restricted maximum likelihood -based mixed model for repeated measures (MMRM) analysis.  
The model will include treatment, baseline disease activit y, baseline corticosteroid dose, region, 
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155933] squares (LS) means will be used for the statist ical 
comparisons.
Time to first flare will be analyzed using a Cox proportional hazard s model with treatment 
group, baseline disease act ivity, baseline corti costeroid dose, and region fitted as explanatory  
variables.  Hazard ratios, 95% CI and p -values will be presented for treatment comparisons to 
placebo.
Missing data for patients who hav e COVID -19-related issues (that are not related to an adverse 
event of COVID -19 infection) may be imputed using alternat ive method, based on consultation 
with regulatory bodies,as appropriate.  Specific imputation methodologies, for this subgroup of 
patients, will be detailed in the SAP prior to the primary endpo int database lock.
I4V-MC-JAIA(b) Clinical Protocol Page 13
LY30091042.Schedule of A ctivities
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155934] 
dose + 4 
weeks
Study Day -42to -3 18 ± 
329 ± 
457 ± 
485 ± 
4113 
± 4141 
± 4169 
± 4197 
± 4225 
± 4253 
± 4281 
± 4309 
± 4337 
± 4365 ± 
4anylast dose + 
28  ± [ADDRESS_1155935] circumference X X X X X X
Vital signs (BP g, 
pulse, temperature)X X X X X X X X X X X X X X X X X X
Substance use 
(caffeine, alcohol, 
tobacco)X
ECGhX
Administer TB test i X
Read [COMPANY_003] test (if 
applicable) jX
Chest x-rayk X
Confirm SLE Criteria lX
Previous SLE therapy X X
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155936] 
dose + 4 
weeks
Study Day -42to -3 18 ± 
329 ± 
457 ± 
485 ± 
4113 
± 4141 
± 4169 
± 4197 
± 4225 
± 4253 
± 4281 
± 4309 
± 4337 
± 4365 ± 
4anylast dose + 
28  ± 5 
days
Review 
inclusion/exclusion 
criteria X X
Preexisting conditions X X
Adverse events X X X X X X X X X X X X X X X X X
Concomitant 
medicationsX X X X X X X X X X X X X X X X X X
C-SSRSmand
Self-Harm Supplement 
FormX X X X X X X X X X X X X X X X X X
Self-Harm Follow -up 
FormnX X X X X X X X X X X X X X X X X X
QIDS-SR16 X X X X X X X X
Randomization o Xo
Log in IWRS X XoX X X X X X X X X X X X X X X X
Investigational product 
dispensedX X X X X X X X X X X X X X Xc
Investigational product 
returned and 
compliance assessedX X X X X X X X X X X X X X X
ePRO (patient diary) 
dispensed /returned p,qXoX X X X X X X X X X X X X X XpXp Xp
Physician- Completed Scalesr
SLEDAI-2K X X X X X X X X X X X X X X X X X X
BILAG-2004 X X X X X X X X X X X X X X X X X X
Physician’s Global 
Assessment of Disease 
ActivityX X X X X X X X X X X X X X X X X X
SLEDAI Flare Index X X X X X X X X X X X X X X X X X
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155937] 
dose + 4 
weeks
Study Day -42to -3 18 ± 
329 ± 
457 ± 
485 ± 
4113 
± 4141 
± 4169 
± 4197 
± 4225 
± 4253 
± 4281 
± 4309 
± 4337 
± 4365 ± 
4anylast dose + 
28  ± 5 
days
SLICC/ACR Damage 
IndexX X X
CLASI X X X X X X X X X X X X X X X X X
Tender/swollen joint 
count (28 joints)X X X X X X X X X X X X X X X X X X
Patient Questionnaires
Worst Pain NRS q X X X X X X X X X X X X X X X X X X
Worst Joint Pain NRS qX X X X X X X X X X X X X X X X X X
Worst Fatigue NRS q X X X X X X X X X X X X X X X X X X
Joint Stiffness 
Duration qX X X X X X X X X X X X X X X X X X
Joint Stiffness Severity 
NRSqX X X X X X X X X X X X X X X X X X
Patient’s Global 
Impression of Severity 
(PGI-S)qX X X X X X X X X X X X X X X X X X
Patient’s Global 
Impression of Change 
(PGI-C)sX X X
SF-36v2 s X X X X X X
FACIT-Fatigues X X X X X X X X X X X X X X X X X X
WPAI-Lupuss X X X X X X X
EQ-5D-5Ls X X X X X X X X X X
Laboratory Tests
TSH X
HIV X
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155938] 
dose + 4 
weeks
Study Day -42to -3 18 ± 
329 ± 
457 ± 
485 ± 
4113 
± 4141 
± 4169 
± 4197 
± 4225 
± 4253 
± 4281 
± 4309 
± 4337 
± 4365 ± 
4anylast dose + 
28  ± 5 
days
Hepatitis C virus 
(HCV) antibody 
testingtX
Hepatitis B testing 
(HBsAg, HBcAb, 
HBsAb)X
HBV DNA u X X X X X X X X
Serum pregnancy test vX
Urine pregnancy test v X X X X X X X X X X X X X X X X X
FSHw X
Clinical chemistry x X X X X X X X X X X X X X X X X X X
Fasting lipid panel y X X X X X
Hematology X X X X X X X X X X X X X X X X X X
Iron studies (iron, 
TIBC, and ferritin)X X X X X
Urinalysis z X X X X X X X X X X X X X X X X X X
Urine Creatinine and 
Protein, RatioX X X X X X X X X X X X X X X X X X
ANA X X
anti-dsDNA X X X X X X X X X X X X X X X X X X
anti-Smith X
Autoantibodies 
(anti-Smith, anti -RNP, 
anti-SSA/Ro, 
anti-SSB/La)X X X X X
Anti-cardiolipin 
antibodies IgG, IgA, 
IgMX X X X X X X
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155939] 
dose + 4 
weeks
Study Day -42to -3 18 ± 
329 ± 
457 ± 
485 ± 
4113 
± 4141 
± 4169 
± 4197 
± 4225 
± 4253 
± 4281 
± 4309 
± 4337 
± 4365 ± 
4anylast dose + 
28  ± 5 
days
Anti-beta-2 
glycoprotein -I(IgG, 
IgM)X X X X X X X
Lupus anticoagulant 
(dRVVT)X X X X X X X
Complement (C3 and 
C4)X X X X X X X X X X X X X X X X X X
Immunoglobulins 
(IgG, IgA, IgM)X X X X X X X X
Lymphocyte subsets 
(T, B, NK, and T cell 
subsets)X X X X X X X X
Exploratory storage 
samples (serum and 
plasma)X X X X X
Exploratory storage 
samples (urine)X X X X X
Exploratory samples 
forstorage (RNA)X X X X X
Baricitinib plasma 
concentrations (PK 
sample)Xaa XaaXaaXaaXaa Xaa
Pharmacogenetic 
(DNA) collection bbX X X
I4V-MC-JAIA(b) Clinical Protocol Page 19
LY3009104Abbreviations:  ANA=antinuclear antibody; BILAG =British Isles Lupus Assessment Group; BP =blood pressure; CLASI =Cutaneous Lupus Erythematosus 
Disease Area and Severity Index; COVID-19 = coronavirus disease; C-SSRS=Columbia -Suicide Severity Rating Scale; dRVVT = Dilute Russell’s Viper 
Venom Time; dsDNA =double-stranded deoxyribonucleic acid; ECG =electrocardiogram; eGFR=estimated glomerular filtration rate ; ePRO=electronic 
patient-reported outcomes ; EQ-5D=EuroQol-5Dimensions; ET =early termination; FACIT -Fatigue=Functional Assessment of Chronic Illness 
Therapy-Fatigue; FSH =follicle‑stimulating hormone; HBcAb =hepatitis B core antibody; HBsAb =hepatitis B surface antibody; HBsAg =hepatitis B 
surface antigen; HBV DNA =hepatitis B virus deoxyribonucleic acid; HIV =human immunodeficiency virus; Ig =immunoglobulins; IWRS =interactive 
web-response sy stem; NRS = Numerical Rating Scale; PK=pharmacokinetics; PGI-C=Patient’s Global Impression of Change; [COMPANY_003]=purified protein 
derivative; QIDS-SR16=Quick Inventory of Depressive Symptomatology; RNA=ribonucleic acid; RNP =ribonucleoprotein; SF -36=Short-Form 36-item 
Health Survey; SLE =systemic lupus erythematosus; SLEDAI-2K = Systemic Lupus Erythematosus Disease Activity Index 2000; S LICC/ACR=Systemic 
Lupus Erythematosus International Collaborating Clinics /American College of Rheumatology ; SSA/Ro =Sjögren’s -Syndrome-related antigen A; 
SSB/La=Sjögren syndrome type B antigen/Lupus La protein; TB =tuberculosis; TIBC =total iron binding capacity; TSH =thyroid-stimulating hormone; 
V =visit; WPAI -Lupus=Work Productivity and Activity Impairment -Lupus.
aAt Visit 2, all baseline assessments must be performed and baseline laboratory samples must be drawn PRIOR to administration of thefirst dose of 
investigational product for randomized patients.
bPatients who complete the treatment period through Visit 16may be eligible to participate in the long-termextension study ( I4V-MC-JAIM [JAIM]).  For 
patients enrolled in JAIM, Visit 1 of Study JAIM shouldoccur on the same day as Visit 16 of Study I4V-MC-JAIA(JAIA).  In some circumstances, due to 
COVID-[ADDRESS_1155940] (IP ,typi[INVESTIGATOR_832658] 1extra month ’s supply) may be dispensed to prevent interruption of study drug during 
the treatment period.
dThose patients who discontinue from the study prior to Visit [ADDRESS_1155941] -treatment follow -up visit, 28 ±5days after the last dose of investigational product.  Pat ients who complete the 
treatment period through Visit 16and enter the long-term extension (LTE; JAIM) will not complete V isit [ADDRESS_1155942] 28±5days without IP can combine their 
Visit 16/ET with their Visit 801 (post-treatment follow -up visit).
fOne complete physical examination (excluding pelvic and rectal examinations) will be performed at Visit 1.  All subseq uentphysical examinations may be 
symptom-directed.  A complete physical examination may be repeated at the investigator’s discretion any time.
gAt each time point, [ADDRESS_1155943] one of the readings at each time point (Sec tion9.4.2.  Vital Signs).
h12-lead ECGs (single) will be performed locally and will be locally (machine) read.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155944](s) include [COMPANY_003], QuantiFERON® -TB Gold, and T SPOT®.  See Exclusion Criterion [2 9]for details of TB testing.  In countries where the 
QuantiFERON -TB Gold test or T -SPOT is available, either test may be used instead of the [COMPANY_003] TB test.  The Quant iFERON-TB Gold test m ust be performed 
centrally; the T-SPOT must be performed locally.  Note :  Exception:  Patients with a history of active or latent TB who have documented evidence of 
appropriate treatment, have no history of re -exposure since their trea tment was completed, have no clinical features of active TB, and have a screening chest 
x-ray with no evidence of active TB are not required to undergo the protocol -specific TB testing (i.e., [COMPANY_003], QuantiFERON® -TB Gold, orT SPOT® )but must 
have a chest x-ray  at screening (i.e:  chest imaging performed withinthe past6 months will not be accepted) .
jFor those patients with a [COMPANY_003] placed at Visit [ADDRESS_1155945] be read 2 to 3 days ( 48 to 72 hours )post-Visit 1.  P urified protein derivative does not need to be 
read at the site, but must be read by a trained medical professional and results must be presented to the site at Visit 2.
kA chest x -ray (posterior -anterior view) will be performed at screening unless chest imaging (excluding ultrasound) has been performedwithinthe past6 
months andthe imagingand report sare available for reviewby [CONTACT_093] .
lPrior to randomization, there must be documentation of a patient having met at least 4 of 11 Revised Criteria for Classi fication of Systemic Lupus 
Erythematosus according to the 1997 Update of the 1982 ACR criteria for classification of SLE (Tan et al. 1982; Hochberg et al. 1997) .  See Inclusion 
Criterion [3].
mSuicidal ideation and behavior subscales excerpt ; adapted for the assessment of [ADDRESS_1155946] also be 
entered into IWRS for appropriate dose adjustment to occur if necessary.
pePRO devices (daily patient diaries) should be dispensed to all patients at screening and will need to be collected from screen -failed patients.  Patients are 
encouraged to bring the ePRO device to every visit; however, if they do not bring the device, this wil l not be a protocol deviation.  For patients NOT entering 
the LTE, the patient diary will be returned at Visit 801or the patient’s last visit .  For patients entering the LTE, the patient diary will be returned at Visit 16.
qWorst Pain NRS, Worst Joint Pa in NRS, Worst Fatigue NRS, Joint Stiffness Duration, Joint Stiffness Severity NRS, and PGI-S will be collected on an 
electronic patient diary daily (ePRO device) starting atVisit 1 (screening) through Visit 16(or Visit 801 for those not entering the LTE Study JAIM) and 
should be completed prior to any clinical assessments on days when study visits occur.
rSLE assessments must be completed by a physician and will be documented on an eCOA (electronic clinical ou tcome assessment) device.
sPatient-reported questionnaires will be administered via an on-site eCOA device and should be administered prior to any clinical assessments.
tFor patients who are positive for HCV antibody, a follo w-up test for HCV RNA will be performed automatically .  Patients who are positive for HCV antibody 
and negative for HCV RNA may be enrolled.
uFor patients who are positive for HBcAb, a follow -up test for HBV DNA wi ll be performed automatically.  Patients who are positive for HBcAb and negative 
for HBV DNA may be e nrolled.  Any enrolled patient w ho is HBcAb positive, regardless of HBsAb status or level, must undergo HBV DNA testing per the 
schedule of events (see Section9.4.8for details of HBV DNA monitoring).
vFor all women of child -bearing potential, a serum pregnancy test (central laboratory) will be performed at Visit 1.  Urine pregnancy tests (local laboratory) 
will be performed at Visit 2 prior to randomization and at all subsequent study visits .
I4V-MC-JAIA(b) Clinical Protocol Page 21
LY3009104wFor female patients ≥50and <55years of age who have had a cessation of menses for at least [ADDRESS_1155947] will be performed to 
confirm non -child-bearing potential (FSH ≥40 mIU/ mL).
xClinical chemistry will include the following value calculated by [CONTACT_832676]: estimated glomerular filtration rate (eGFR; 
calculated using the Modification of Diet in Renal Disease [MDRD] isotope dilution mass spectrometry traceable method).
yFasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to sample collection .  If a patient attends these visits in a 
nonfasting state, the sample should still be collected.  T his will not be considered a protocol violation.
zUrine should be collected as a clean catch sample .
aaSee Section 9.5for details.
bbPatients choosing not to provide consent for whole blood samples to be collected for pharmacog enetic research will still be eligibl e to participate in the study.
I4V-MC-JAIA(b) Clinical Protocol Page 22
LY30091043.Introduction
3.1.Study Rationale
Baricitinib is anoral, reversible, selective inhibitor ofJanus kinase ( JAK)1 and JAK2 (Fridman 
et al. 2010).  This activit y profile suggests that baricit inib may inhibit cy tokines implicated in 
systemic lupus ery thematosus ( SLE), most notably type I interferon (IFN JAK1/TYK2), 
interleukin ( IL)-6 (JAK1/JAK2/TYK2), and type II IFN -, as well as other cy tokines that m ay 
have a role in SLE, including IL- 23 (JAK2/TYK2) , granulocy te-macrophage colony st imulating 
factor (JAK2/JAK2) and IL -12 (JAK2/TYK2) .  The potenti al impact of barici tinib on the IFN 
pathway is relevant to SLE, as clinical and preclinical studies have established that this pathway 
is involved in the pathogenesis o f SLE(Hoffman et al. 2017) .  Suppressing the IFN signature 
[CONTACT_832717] o f a monoclonal antibody that targets the ty pe I IFN receptor has been shown to 
be effective in SLE (Furie et al. 201 7).  Baseline gene expressio n in SLE, examined as part of the 
ILLUMINATE Phase 3 trials, demonstrated upregul ation of IL–6-related genes, IL -2 receptor, 
IL-12, and oncostatin M in patients with SLE compared to control subjects , all of which signal 
through the JAK /signal transducers and act ivators of transcript ion(STAT)pathways and would 
not be ant icipated to be direc tly modulated by  [CONTACT_742833] c strategies which only  target the IFN 
pathway(Hoffman et al . 2017).  Thus, baricit inib is ant icipated to be effective as it modulates 
not only IFN but also other potential SLE -relevant pathways, providin g a biologic rationale for 
its evaluation in this disease.
Baricitinib has dem onstrated clinical efficacy  and safety in patients with autoimmune (SLE , 
rheumatoid arthritis[RA; Taylor et al . 2015; Fleischmann et al. 2016; Genovese et al. 2016; 
Dougados et al. 2017] ) and autoinflammatory  diseases (Chroni c atypi[INVESTIGATOR_832659] [CANDLE ], Stimulator of Interferon Genes 
(STING)-Associated Vasculopathy Wit h Onset During Infancy [SAVI], Juvenile 
Dermatomyositis [JDM], and Aicardi -Goutières Syndrom e [AGS]) (Montealegre Sanchez et al. 
2018). A Phase [ADDRESS_1155948] of care (SoC) was superior to placebo plus SoC in the proportion of pat ients 
achieving remissio n of rash and/or ar thritis as defined by [CONTACT_832677] 2000 ( SLEDAI-2K)at Week 24 (67.3% baricit inib 4-mg, 58.1% 
baricitinib 2-mg, 53.3% placebo, p<0.05 for baricit inib 4-mg versus placebo ).  Patients treated 
with baricitinib 4-mg also had a higher Systemic Lupus Ery thematosus Responder Index -4 
(SRI-4) response rate at Week 24 compared to patients treated with placebo (64.4% baricit inib 
4-mg, 51.4% baricit inib 2-mg, 47.6% placebo, p<0.05 for baricit inib 4-mg versus placebo ) (Eli 
Lilly and Co mpany data on file, 2017 ).  Additionally,completed Phase 2 studies of baricit inib 
also demonstrated efficacy  in patients with moderate-to-severe plaque psoriasis (Papp et al. 
2016), diabetic kidney disease (Tuttle et al. 2015), and atopic dermat itis (Guttman -Yassky et al . 
2018).
Given the efficacy of baricit inib demo nstrated in clinical trials for treating 
autoimmune/autoinflammatory diseases invo lving joints, skin, and kidney (including SLE), the 
acceptable safet y profile of baricitinib observed through the current stage of development, and a 
I4V-MC-JAIA(b) Clinical Protocol Page 23
LY3009104continuing unmet medical need in pat ients with SLE, there is a co mpelling rat ionale for init iation 
of a Phase 3 program to evaluate baricit inib in the treatment of SLE.
3.2.Background
Systemic lupus ery thematosus i s a chroni c, often debilitating,multisystem, autoimmune disease 
that is characterized by [CONTACT_492290] B cells and elevate d autoantibodies, which 
directly damage the body’s cells and tissues.  Systemic lupus erythematosus can affect mult iple 
organ systems simultaneously  or sequent ially, and fo llows ahighly variableclinical course 
where periods of relatively stable disease a re followed by [CONTACT_629276]/or peri ods of persistently 
active disease ; all of whichcan ultimately lead to irreversible damage to tissues and organ 
systems.
Systemic lupus erythematosus i s predominately a disease of women ( approximately 9:1 female 
to male ratio), which can begin at any  age but m ost comm only begins in adolescence or early 
adulthood (Yu et al . 2017).  It affects 20 to 150 in 1,000,000 people in the US (UpToDat e® 2018 
[WWW]) and is more commo n in African-Americans (Lim et al. 2014; Somers et al. 2014), with 
as many as 1 in 537 African -American women afflicted with SLE (Somers et al. 2014).  
Additionally, SLE appears to be m ore severe in Afri can-Americans, Asian -Americans, and 
Latinos compared to Caucasians (Kaslow 1982; Alarcón et al. 2001).
Clinically, SLE presents with varying signs and symptoms, including fever, arthralgia/arthritis, 
skin rash, alopecia, pleurit is, pericar ditis, nephritis, vasculit is, stroke, seizure, leukopenia, 
thrombocytopenia, anemia, photosensit ivity, and the presence of autoantibodies reactive wit h 
nuclear ant igens.  Fatigue is the most prevalent symptom reported among patients with SLE 
(Avina-Zubieta et al. 2007 ).  Pain that interferes wit h daily living act ivities is also commo nly 
reported(Ozel and Argon 2015).  Skin and jo int disease are also among the most prevalent 
features of the illness .  Age, [LOCATION_003] African race/ethnicit y, SLEDAI -2K score, steroid use, and 
hypertensio n were associated with transit ion from no damage to dam age, and increa se(s) in 
preexisting damage (Bruce et al. 2015 ).  Over 60% of pat ients with SLE will develop clinically 
detectable organ damage within 2 to 7 years of diagnosis, as m easured by  [CONTACT_832678] (SLICC)/ American Co llege of Rheumatology
(ACR) damage index (Cooper et al. 2007 ).
Improvements in earlier diagnosis, treatment regimens, and medical care over the past several 
decades have reduced mortalit y in SLE.  However, patients conti nue to experience premature 
death, with cardio vasculardisease being the leading cause.  A recent meta -analysis of published 
data involving over 27,000 patients with SLE observed a 3 -fold increase in the risk of death in 
patients with SLE com pared with the general population (Yurkovi ch et al. 2014).  Morbidity 
remains substant ial as measured by [CONTACT_832679] h-related qualit y of 
life, loss o f work productivit y, pain, and fat igue (Avina- Zubieta et al . 2007; Ozel and Argon 
2015).  Thus, there remains substant ial unmet m edical need for individuals who haveSLE.
Standard of care (SoC) for SLE includes ant imalarial agents , corticosteroids, nonsteroi dal 
anti-inflammatory  drugs (NSAIDs), immunosuppressive agents, and cy totoxic agents; however, 
there are relat ively few drugs approved for the treatment of SLE.  For example, in the US, 
I4V-MC-JAIA(b) Clinical Protocol Page 24
LY3009104approved therapi[INVESTIGATOR_629259], ant imalarials, corticosteroids , and belimumab.  In 
general, treatment regimens are broadly similar around the world and are tailored to the severit y 
of diseaseand the specific organs invo lved.  Mild disease is often treated with low -dose 
corticosteroids, NSAIDs, and ant imalarials; while serious, organ -threatening or life -threatening 
disease is typi[INVESTIGATOR_629260] -dose corti costeroids and immunosuppressive agents.  In 
addition to thei r direct impact on disease, immunosuppressive agents are also utilized as so 
called“corticosteroid-sparing agents ”to reduce chroni c exposure to corticosteroids.
The current SoC therapi[INVESTIGATOR_832660] , including 
host defense, and have been associated with short- and long-term morbidity.  For example, 
long-term use of corti costeroids is associ ated with cataracts, osteoporosis, avascular necrosis, 
increased infect ion, cardiovascular events, hyperglycemia, and weight gain, while 
cyclophosphamide increases the risk of prematur e ovarian failure, serious infect ion, and cancer.
Although recent improvements in treatment regimens and medical care have reduced overall 
morbidity and mortality, many patients still have inco mpletely controlled disease and progress to 
end-stage organ invo lvement.  In addition, the disease increases mortalit y and negat ively impacts 
health-related qualit y of life.  New treatm ent options with an acceptable safet y profile that reduce 
disease activity, reduce flares, del ay organ damage, and reduce the requirement for 
corticosteroids and cy totoxic agents are urgently needed for patients with SLE.
Accordingly , pharmacol ogic intervent ions that target specific pathways associated with the 
pathology of SLE may provide novel therapeut ic approaches to dis ease management.  One of the 
signaling pathways implicated in SLE disease activit y is the type I IFN signaling pathway.  
Upregulation of genes associated with the activat ion of type I IFN signaling, referred to as a type 
I IFN signature, is observed in approximately 7 5% of patients with SLE (Hoffman et al. 2017 ).  
In SLE, a high ty pe I IFN si gnature was associ ated with increased di sease severi ty as measured 
by [CONTACT_629279], increased anti –double-stranded deoxy ribonucleic acid(anti-dsDNA), 
decreased co mplement, and increased risk of severe flares ( Hoffman et al. 2017).  Another 
cytokine implicated in the pathogenesis of SLE is IL -6.  Increased expression o f IL-[ADDRESS_1155949] ivity (Linker-Israeli et al. 1999, Illei et al. 2010).  Both 
type I IFNs and IL- 6 signal through the JAK/STAT pathway; t herefore, treatment of SLE with 
baricitinib or other JAK inhibitors is an area of intense interest.
3.3.Benefit/Risk Assessment
Phase 2 SLE Data
In the baricit inib Phase 2 SLE clinical Study  I4V-MC-JAHH (JAHH), significant benefit for 
baricitinib 4-mg once daily (QD) treatment over placebo was demonstrated for the primary 
efficacy endpoint of resolut ion of arthrit is and/or rash, the major secondaryefficacy endpo int of 
SRI-4 response, and important supporting measures such as flare and lupus low disease activit y 
score (LLDAS) after 24weeks of treatment.  Baricit inib 2-mg QD was numerically better than 
placebo across these measures although the results were not statist ically significant.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155950] 1 t reatment-emergent adverse event ( TEAE) during the 
24-week treatment period was 64.8% for placebo, 71.4% for baricit inib 2-mg QD, and 73.1% for 
baricitinib 4-mg QD.  The most comm on TEAEs (occurring in ≥5% of pati ents in either 
baricitinib dose group over 24 weeks) were viral upper respi[INVESTIGATOR_2826], urinary  tract 
infection,upper respi[INVESTIGATOR_39738], pharyngi tis, and headache .  The proportions of 
patients who reported vi ral upper respi [INVESTIGATOR_832661]-treated 
patients compared to pl acebo,but the proportions were similar for the baricit inib 2-mg and 4-mg 
dose groups. It is important to consider that in SLE, patients are at an increased risk for 
infections due to predisposing condit ions related to impaired cellular and humoral immune 
functions (Danza and Ruiz Irastorza 2013), as well as concomitant use of immunosuppressive 
agents such as corticosteroids .  In the Phase [ADDRESS_1155951] ic infection, and no reports of 
tuberculosis (TB) .  There were no malignancies or major adverse cardiovascular events (MACE) 
reported.  One serious adverse event (SAE)of deep vein thrombosis (DVT) was reported in the 
baricitinib 4-mg group, i n a patient with pre-existing antiphospho lipid antibodiesand pain in the 
affected limb (right calf) prior to study  entry, who was taking a conco mitant oral corticosteroid 
and celecoxib during the study .  
Risks Identified in the Baricitinib Program
Serious infect ions, venous thromboembo lism, hepatotoxi city, and fetal malformations were 
identified as important potential risks with baricit inib. Inclusion/Exclusi on criteria in the 
protocol limit enrolment of SLE patients who are at risk for these important potential risks.  
Although infect ions were seen in about half o f the SLE study population,the incidence rate of 
serious infect ion in patients exposed to baricit inib in the RA program was only 3.0 per 100 
patient-years.  During the controlled period (through 16 weeks), rates were similar in both 
baricitinib-and placebo-treated pati ents. The nonserious infections (upper respi[INVESTIGATOR_37193], herpes zoster, and herpes simplex) associated with baricitinib inthe RA program are 
readilydiagnosed, m anageable, and ty pi[INVESTIGATOR_832662]-term sequelae.  It is 
recommended that where indicated, herpes zoster vaccination be offered to patients prior to 
receiving baricitinib.
Increases in levels of alanineaminotransferase (ALT), aspartate aminotransferase (AST), and 
total bilirubin have been seen in patients with RA . Most of these increases improved with 
continued use or temporary  discontinuation of baricitinib with no long-term effects. No cases of 
severe drug- induced liver injury were observed wit h baricitinib treatm ent.
Fetal malformations were reported in toxicologystudies at higher doses than what i s used in 
human patients.  Only a small number of patients have beco me pregnant in baricit inib clinical 
trials, and there have been no reports of fetal malformations in these pregnancies. 
Venous thromboembo lic events (VTEs) have been determined to be an important pote ntial risk 
for baricitinib.  There was a numerical imbalance in reports of VTEs in the 24 -week 
placebo-controlled period of the Phase 3 trials o f patients with RA.  Available evidence does not 
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155952] been added to the protocol 
to limit participat ion ofpatients who are at an increased risk of VTE.
Therefore, in the context of the cumulat ive knowledge, the benefit/risk balance for baricit inib in 
the treatment of adult patients with SLE is assessed to be favorable.
More informat ion about the known and expected benefits, risks , SAEs, and reasonably 
anticipated adverse events (AEs) of baricit inib are to be found in the Investigator’s Brochure 
(IB).
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155953] -of-care (SoC) therapy compared 
to placebo and SoC on SLE disease activity.Proportion of patients achieving an SRI-4 response at 
Week 52, defined as:
Reduction of ≥4 points from baseline in 
SLEDAI-2K score; and
No new British Isles Lupus Assessment Group 
(BILAG) A andno more than 1 new BILAG B 
disease activity score; and
No worsening (defined as an increase of 
≥0.3points [10 mm] from baseline) in the 
Physician’s Global Assessment of Disease 
Activity.
Major Sec ondary (Multiplicity Controlled)
To evaluate the effect of baricitinib 4 -mg QD plus 
SoC compared to placebo plus SoC on SLE 
disease activity.Proportion of patients achieving an SRI-4 response 
at Week 24 .
Proportion of patients achieving a lupus low 
disease activity state (LLDAS)responseat Week 
52
To evaluate the corticosteroid sparing effect of 
baricitinib 4 -mg QD plus SoC compared to 
placebo plus SoC.Proportion of patients receiving >7.5 mg 
prednisone (or equivalent) at baseline able to 
decrease dose by ≥25% to a prednisone equivalent 
dose of ≤7.5 mg/day maintained between Week 40 
and Week 52.
To evaluate the effect of baricitinib 4 -mg QD plus 
SoC compared to placebo plus SoC on SLE flares.Time to first severe flare over 52 weeks .
To evaluate the e ffect of baricitinib 4- mg QD plus 
SoC compared to placebo plus SoC on 
patient-reported outcomes (PROs).Change from baseline in Worst Pain NRS at Week 
52.
Change from baseline in FACIT -Fatiguetotal 
scoreat Week 52 .
To evaluate the effect of baricitinib 2-mg QD plus 
SoC compared to placebo plus SoC on SLE 
disease activity.Proportion of patients achieving an SRI-4 response
at Week 52 .
Proportion of patients achieving an SRI-4 response 
at Week 24.
Proportion of patients achieving a lupus low 
disease activi ty state(LLDAS)responseat Week 
52
To evaluate the corticosteroid sparing effect of 
baricitinib 2 -mg QD plus SoC compared to 
placebo plus SoC.Proportion of patients receiving >7.5 mg 
prednisone (or equivalent) at baseline able to 
decrease dose by ≥25% to a prednisone equivalent 
dose of ≤7.5 mg/day maintained between Week 40 
and Week 52.
To evaluate the effect of baricitinib 2 -mg QD plus Time to first severe flare over 52 weeks .
I4V-MC-JAIA(b) Clinical Protocol Page 28
LY3009104SoC compared to placebo plus SoC on SLE flares.
To evaluate the effect of baricitinib 2 -mg QD plus 
SoC compared to placebo plus SoC on 
patient-reported outcomes (PROs).Change from baseline in Worst Pain NRS at Week 
52.
Change from baseline in FACIT -Fatiguetotal 
scoreat Week 52
Other Secondary (Non-Multiplicity Controlled)
[1]Toevaluate the effect of baricitinib 4 -mg or 2-mg 
QD plus SoC compared to placebo plus SoC on 
SLE disease activity.Change from baseline in total SLEDAI -2K scores
over time through Week 52.
Change from baseline in PGA score over time 
through Week 52.
Proportion of patients achieving an SRI-4 response 
over time through Week 52.
Proportion of patients achieving an SRI -5, -6, -7, 
and -8 response over time through Week 52.
Proportion of patients achieving reduction of ≥4 
points from baseline in SLEDAI -2K score at Week 
52.
Proportion of patients with no new British Isles 
Lupus Assessment Group (BILAG) A andno more 
than 1 new BILAG B disease activity score at 
Week 52.
Proportion of patients with no worsening (defined 
as an increase of ≥0.3 points [10 mm] fro m 
baseline) in the Physician’s Global Assessment of 
Disease Activity at Week 52.
Proportion of patients achieving a British Isles 
Lupus Assessment Group Based Composite Lupus 
Assessment (BICLA) response at Week 52, 
defined as: 
Reduction of all baseline BILAG A to B/C/D 
and baseline BILAG B to C/D, and no BILAG 
worsening in other organ systems, where 
worsening is defined as ≥1 new BILAG A or ≥2 
new BILAG B
No worsening from baseline in SLEDAI -2K, 
where worsening is defined as an increase from 
baseline of >0 points in SLEDAI -2K
No worsening from baseline in participants' 
lupus disease activity, where worsening is 
defined by [CONTACT_522104] ≥0.30 points on a 3 -point 
PGA visual analogue scale (VAS).
[2]To evaluate the corticosteroid sparing effect of 
baricitinib 4 -mgor 2-mg QD plus SoC compared 
to placebo plus SoC.Change from baseline in prednisone dose at 
Week52.
Proportion of patients taking corticosteroids at 
baseline able to discontinue use at Week 52 .
[3]To evaluate the effect of baricitinib 4 -mg or 2-mg 
QD plusSoC compared to placebo plus SoC on 
SLE flares.Time to first mild/moderate flare over 52 weeks.
Time to first flare (any severity) over 52 weeks.
Annualized mild/moderate flare rate
Annualized severe flare rate
I4V-MC-JAIA(b) Clinical Protocol Page 29
LY3009104Annualized flare rate (any severity)
[4]To evaluate the effect of baricitinib 4 -mg QD or 
2-mg QD plus SoC compared to placebo plus SoC 
on mucocutaneous manifestations of SLE.Proportion of patients with CLASI total activity 
score≥ 10 at baseline with ≥50% reduction in 
CLASI total activity score atWeek 52.
To evaluate the effect of baricitinib 4 -mg QD or 
2-mg QD plus SoC compared to placebo plus SoC 
on musculoskeletal manifestations of SLE.Change from baseline in tender joint count at 
Week 52.
Change from baseline in swollen joint count at 
Week 52.
To evaluate the effect of baricitinib 4 -mg QD or 
2-mg QD plus SoC compared to placebo plus SoC 
on individual organ system disease activity.Proportion of patients with improvement in each 
SLEDAI-2K organ system versus baseline at Week 
52.
Proportion of patients with worsening in each 
SLEDAI-2K organ system versus baseline at Week 
52.
To evaluate the effect of baricitinib 4 -mg QD or 
2-mg QD plus SoC compared to placebo plus SoC
on PROs.Change from baseline in Worst Fatigue NRS at 
Week 52.
Change from baseline in Worst Joint Pain NRS at 
Week 52.
Change from baseline in Joint Stiffness Duration at 
Week 52.
Change from baseline in Joint Stiffness Severity 
NRS at Week 52.
Change from baseline in Patient Global Impression 
of Severity at Week 52. 
Change from baseline in Patient Global Impression 
of Change at Week 52
Change from baseline in mental component score 
(MCS), physical component score (PCS), and 
domain scores in the Short -Form 36-item health 
survey version 2 (SF -36v2) acute at Week 52.
Change from baseline in the EQ -5D-5L at 
Week52.
Change from baseline in the WPAI -Lupus at Week 
52.
To measure baricitinib PK exposure and assess the 
relationship between exposure and efficacy.Population pharmacokinetics of baricitinib in 
patients with SLE.
Proportions of patients achieving SRI-4 by  
[CONTACT_832680].
Exploratory
To evaluate the effect of baricitinib 4 -mg QD or 
2-mg QD plus SoC compared to placebo plus SoC 
on damage.Change from baseline in SLICC/ACR damage 
index total score at Week 52.
I4V-MC-JAIA(b) Clinical Protocol Page 30
LY3009104To evaluate the effect of baricitinib 4 -mg QD or 
2-mg QD plus SoC compared to placebo plus SoC 
on serologic markers of SLE.Change from baseline in IFN signature [CONTACT_46431] 52 
weeks.
Change from baseline in anti -dsDNA level in 
patients with elevated anti -dsDNA at baseline over 
52 weeks.
Change from baseline in C3 and/or C4 levels in 
patients with low C3 and/or C4 at baseline over 52 
weeks.
To evaluate the effect of baricitinib [ADDRESS_1155954].Proportion of patients with high IFN signature 
[CONTACT_832718]-4 response at Week 52.
Abbreviations :  ACR=American College of Rheumatology; BILAG =British Isles Lupus Assessment Group; 
C3=complement 3; C4 =complement 4; CLASI =Cutaneous Lupus Erythematosus Disease Area and Severity 
Index; dsDNA=double-stranded deoxyribonucleic acid; EQ -5D-5L= European Quality of Life –5 Dimensions –
5 Levels; FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy –Fatigue Scale ; IFN=interferon ; 
MCS=Mental Component Score; NRS =Numeric Rating Scale; PCS =physical component score; 
PGA=Physician Global Assessment; PK =pharmacokinetic; QD =once daily; SF -36v2=Short-Form 36 -item 
health survey version 2; SLE =systemic lupus erythematosus ; SLEDAI-2K=Systemic Lupus Erythematosus 
Disease Activity Index 2000; SLICC =Systemic Lupus Erythematosus International Collaborating Clinics ; 
SoC=standard of care; SRI =Systemic Lupus Erythematosus Responder Index; WPAI -Lupus=Work 
Productivity and Activity Impairment Questionnaire -Lupus.
I4V-MC-JAIA(b) Clinical Protocol Page 31
LY30091045.Study Design
5.1.OverallDesign
Study I4V-MC-JAIA(JAIA) is a Phase 3, multicenter, randomized, double- blind, parallel -group, 
placebo-controlled, outpati ent, 52-week study  evaluating the efficacy  and safety of baricitinib 
4-mg and 2-mg in patients with SLE receiving standard therapy .
Approximately  750 patients will be rando mized at a 1:1:1 ratio to receive baricit inib 4-mg daily, 
baricitinib 2-mg daily, or placebo (250 patients per treatment group).  Patients will be str atified 
at randomization according to disease act ivity (total SLEDAI -2K at screening <10; ≥10), 
corticosteroid dose at baseline (<10 mg/day; ≥10 mg/day  prednisone or equivalent), and region 
(defined in the statistical analysis plan [SAP]).
All procedures t o be conducted during the study , including timing of all procedures, are indicated 
in the Schedule of Act ivities (Section 2).  Section7.7describes permitted concomitant therapy.  
Study governance considerations are described in detail in Appendix 3 .
FigureJAIA.1illustrates the study  design.
The study  consists of 3 periods:
Screening Period :  The screening period is up to 42 day s and begins when the patient signs the 
informed consent form  (ICF).  In exceptional circumstances, the screening window can be 
extended after consultation wit h the sponsor.  During the screening period, the site must confirm 
the patient meets all inclusio n and no exclusio n criteria for the study  (see Secti on6).  Screening 
procedures will be performed according to the Schedul e of Activities (Section 2).  Patient 
eligibility will be reviewed and confirmed by [CONTACT_832681] y review committee prior to 
randomization.  Eligible pat ients will be rando mized at Week 0 (Visit 2).
Treatment Period :
At Visit 2 (Week 0, baseline) after all assessments are completed and baseline laboratory  
samples obtained according to the Schedule of Activit ies, rando mized pat ients will take the first 
dose of invest igational product at the clinic and pharmacokinet ic (PK) samples will be drawn [ADDRESS_1155955] will be taken daily for 52 weeks . In some circumstances, due to 
COVID-19 related logistical issues, Visit 16 may be completed outside of the protocol specified 
timeframe, thus the treatment period may be extended.  Where allowed locally, addit ional IP 
(typi[INVESTIGATOR_832658] 1extra month ’s supply) may be dispensed to prevent interruption of 
study drug.  Clinical assessments and laboratory  samples, including addit ional PK sampling, will 
be obtained at scheduled visits according to the Schedule of Act ivities (Section2).  Special 
timing considerations of administration of invest igational product relative to PK sample 
collection at study  visits are described in Section9.5.
During the treatment period, in addit ion to randomized treatment, patients will also maintain 
their usual medication regimen for SLE , including background standard -of-care therapy  
I4V-MC-JAIA(b) Clinical Protocol Page 32
LY3009104consisting of corticosteroids, antimalarials, and/or immunosuppressants (see Section 6.1, 
Inclusion Criterion [8] and Secti on7.7for details).
Between Weeks [ADDRESS_1155956] igators are 
encouraged to taper corticosteroids according to clinical practice, with a goal of ≤7.5mg/day
prednisone (or equivalent) by  [CONTACT_10585] 40 (Vi sit 13).  In m ost cases, tapering should not be 
considered for at least [ADDRESS_1155957] ivity during an attem pted taper, the patient’s corticosteroid 
dose may be increased once, by  [CONTACT_8622] 10 m g/day, but may not exceed the baseline dose.  
Corticosteroid dose must be stable for 8 weeks prior to Wee k 24 (i.e., no changes between 
Weeks 16 and 24) and for 12 weeks prior to Week 52 (i.e., no changes between Weeks 40 and 
52).  This design minimizes confounding of assessments at Week [ADDRESS_1155958] igators should continue to a ssess benefit/risk for patients to remain in 
the trial and shoul d consider di scontinuing pat ients if sufficient clinical benefit is not observed 
with protocol permitted treatm ents.
Follow-up Period: Patients who com plete the treatm ent period of the study  through Week 52 
(Visit 16) are eligible to parti cipate in the long-term extension(LTE), Study  I4V-MC-JAIM
(JAIM). In some circumstances, due to COVID -[ADDRESS_1155959] -treatment follow-up visit (Visit 801) approximately [ADDRESS_1155960].
I4V-MC-JAIA(b) Clinical Protocol Page 33
LY3009104Abbreviations:  LD = last dose of investigational product; LTE = long -term extension; 
n =number of patients in each group; QD = once daily; V = visit; W =week
FigureJAIA.1. Illustration of study design for Clinical Protocol I4V -MC-JAIA.
5.2.Number of Participants
Approximately  [ADDRESS_1155961] scheduled procedure shown in the Schedule o f 
Activities(Section2) for the last patient.
5.4.Scientific Rationale for Study Design
This study  will be double-blinded and placebo -controlled to minimize bias .  The select ion of 
placebo as a com parator for this study  is warranted a s there are few approved therapi[INVESTIGATOR_832663], including corticosteroids, 
antimalarials, and/or immunosuppressants. In order to minimize the confounding effects of 
concomitant medicat ions, dosesof antimalarials andimmunosuppressants should remain stable 
during the treatment period (see Section 7.7).
The populat ion studied will include patients with active disease and varying degrees of SLE 
organ invo lvement; however, patients with severe active lupus nephrit is and act ive central 
nervous system (CNS )SLE are excluded as they would require aggressive tr eatment with 
medications that coul d confound the safet y and/or efficacy  results of the study .
The primary  efficacy endpoint of SRI -4 is consistent with FDA and EU guidance (FDA 2010; 
EMA 2015) and fo llows regulatory  precedent (FDA 2012) for assessing effic acy in SLE 
registration studies.  Furthermore, the SRI -4, as a composite index, detects overall improvements 
in disease activit y (SLEDAI -2K component) while ensuring there is not worsening in other 
organ systems (BILAG and Physician’s Glo bal Assessment components).  ScreeningPost-
Treatment
+Option to ente r LTE Study JAIM.Treatment
Corti cost eroid tapering permi tted. 
Corti cost eroid dose stable.W-6
V1W0
V2W1
V3W4
V4W12
V6W8
V5W16
V7W24
V9W20
V8W28
V10W36
V12W40
V13W48
V15W44
V14W52
V16W32
V11LD+4 W
V801bariciti nib 4 mg QD (n=250)
baricitinib 2 mg QD (n=250)
placebo QD (n=250)All Patients
Randomization Primary Endpoint+
++
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155962] up to Week 12, for pati ents who enter the study  with 
increased disease activit y.  This design prevents prem ature discont inuation of patients fro m the 
study while minimizing potential confounding effects on efficacy assessments at Weeks 24 and 
52 (the primary endpo int).
5.5.Justifica tion for Dose
The 4-mg and 2-mg QD doses of baricit inib selected for this study  are based on the Phase [ADDRESS_1155963] acebo across several relevant measures, including remissio n of arthrit is and/or 
rash (SLEDAI -2K), SRI-4, flare, and LLDAS.  Baric itinib 2-mg QD was numerically better than 
placebo across these measures, although the results were not statist ically significant.  Dose 
response patterns favoring baricit inib 4-mg were evident across measures and improvement was 
observed for both doses in patient-reported outcomes including worst pain and worst jo int pain.  
Pharmacokinet ic/pharmacodynamic (PK/PD) modeling suggests the maximum response after 
dosing wit h 2-mg was not attained by 24 weeks.  Therefore, there is potential that baricit inib 
2-mg will also demonstrate efficacy at Week 52.  No notable safet y findings emerged compared 
to the results from baricit inib studies for other indications.
In Phases 2 and 3 RA studies, b aricitinib 4-mg QD has demo nstrated consistent efficacy; 
baricitinib 2-mg QD was also effect ive, but was less consistent than 4-mg QDacross measures of 
efficacy and patient popul ations.  Both doses were acceptably safe and well tolerated in the 
context of the efficacy observed and the benefit/risk profiles of other disease-modifying 
antirheumatic drugs.  There was no substantial increase in efficacy  noted with doses higher than 
4-mg, where studied.
In the Phase [ADDRESS_1155964] ivity, with greater efficacy at the 
higher doses.  The 2- mg dose did show numeric improvements in efficacy co mpared with 
placebo.  The 8-mg and 10 -mg doses were associated with a higher rate of AEs related to 
laboratory  abnormalities (decreases in hemoglo bin, neutrophils, and lymphocytes), while the 
2-mg and 4-mg dose groups had a pattern of AEs similar to placebo.
Dose Adjustment for Renal Impairment
As detailed in the IB, baricit inib exposure increases with decreased renal function (Study 
I4V-MC-JADL [JADL]).  Based on PK simulat ions, dose adjust ment is not required for patients 
with estimated glo merular filtration rate (eGFR) ≥60 mL/min/1.73 m 2.  Patients with eGFR 
<60mL/min/1.73 m2at screening who are randomized to the 4 -mg dose will receive a dose of 
2-mg QD, which will ensure that exposures do not exceed those of the 4 -mg QD dose in patients 
I4V-MC-JAIA(b) Clinical Protocol Page 35
LY3009104with eGFR ≥60 mL/min/1.[ADDRESS_1155965] ion. 
See Section7.2.2for method of treatment assignmentin patients with renal impairment .
I4V-MC-JAIA(b) Clinical Protocol Page 36
LY30091046.Study Population
Prospective approval o f protocol deviations to recrui tment and enro llment criteria, also known as 
protocol waivers or exempt ions, are not permitted.
Study investigator(s) will review patient history  and screening test results at Visit [ADDRESS_1155966] be confirmed by  [CONTACT_832681] y review 
committee prior to randomization.
6.1.Inclusion Criteria
Patients are eligible to be included in the study  only if they meet all of the following criteria:
Type of Patient and Dise ase Characteristics
[1]Are at least 18 years of age.
[2]Have a clinical diagno sis of SLE at least 24 weeks pri or to screening .
[3]Have documentation of having met at least4 of 11 Revised Criteria for 
Classification of Systemic Lupus Erythematosus according to the 1997 Update of 
the 1982 ACR criteria for classification of SLE (Tan et al. 1982;Hochberg et al . 
1997)prior to randomizat ion.
[4]Have 1 or more of the fo llowing as assessed by [CONTACT_832682]:  a 
positive antinuclear antibody (ANA; titer ≥1:80), and/or a positive anti-dsDNA, 
and/or a posit ive anti-Smith (anti-Sm).  Patients with an ANA <1:80 at screening 
with documentati on of a historical ANA ≥1:80 may be eligible, as assessed by [CONTACT_832683].
Note:  The ANA , anti-dsDNA,and anti-Smithmeasurement smay be repeated by 
[CONTACT_832684], and the value result ing from 
repeat testing may be accepted for enrollment eligibilit y if it meets the eligibilit y 
criterion.
[5]Have a total  SLEDAI -2K score ≥[ADDRESS_1155967] 4 poi nts 
attributed to clinical items (no t including items requiring laboratory  value 
assessment) .  SLEDAI -2K items requi ring laboratory  values shoul d be assessed 
based on the results fro m the labs drawn during the screening period.
[6]Have a clinical SLEDAI -2K score ≥4 at Baseline (Visit 2); not including any 
items requi ring laboratory  valueassessment . 
[7]Have at least 1 BILAG A score or 2 BILAG B scores during the screening period.  
BILAGitems requi ring laboratory  values shoul d be assessed based on the results 
from the labs drawn duringthe screeningperiod.
I4V-MC-JAIA(b) Clinical Protocol Page 37
LY3009104Prior/Concomitant Therapy
[8]Are receiving at least one of the fo llowing SoC medi cations for SLE:
a.A single antimalarial (such as hydroxy chloroquine, chl oroquine, quinacrine) 
at a stable therapeuticdose for at least 8 weeks prior to screening (Visit 1).
b.A singleimmunosuppressant (such as m ethotrexate [MTX], azathioprine, 
mycopheno late, tacrolimus, lefluno mide, cyclo sporine) at a stable therapeutic
dose for at l east 8weeks prior to screening (Visit 1).
c.An oral corti costeroid, initiated at least 4 weeks prior to screening (Visit 1), at 
a stable dose ≤ 40 mg/day prednisone (or equivalent) for at least 2 weeks prior 
to screening (Visit 1) and through baseline (Visit 2).  If the patient is not 
receiving an ant imalarial or immunosuppressant, the do se of corticosteroid 
must be ≥ 7.5 mg/day prednisone (or equivalent).
Patient Characteristics
[9]Male or nonpregnant, nonbreastfeeding female patient
a.Patients of child -bearing potential who are abst inent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a same -sex relationship 
(as part of their preferred and usual lifest yle) must agree to either remain 
abstinent or stay  in a same-sex relationship wi thout sexual relationships with 
the opposite sex.  
b.Totalabstinence is defined as r efraining from  intercourse duri ng the ent irety 
of the study  and for at least [ADDRESS_1155968].
d.The following contraception methods are considered acceptable (the patient 
should choose 2, and [ADDRESS_1155969] ive [defined as less than 1% 
failure rate per y ear when used consistent ly and correctly ]):
Highly effective birth control methods:  
Combined (estrogen and progestogen containing) hormonal 
contraception associated with inhibit ion of ovulat ion:  oral, 
intravaginal, or transdermal
Progestogen -only containing hormonal contraceptio n associated 
with inhibition of ovulat ion:  oral, injectable , or implantable
intrauterine device (IUD)/intrauterine hormone -releasing system 
IUS)
I4V-MC-JAIA(b) Clinical Protocol Page 38
LY3009104vasectomized male (with appropriate post- vasectomy 
documentation of the absence of sperm in the ejaculate).
Effective birth control methods:
Male orfemale condo m with spermicide.  It should be noted that 
the use of male and female condo ms as a double barrier method is 
not considered acceptable due to the high failure rate when these 
methods are combined.
Diaphragm with spermicide
Cervical sponge
Cervical cap wit h spermicide
Note:  When local guidelines concerning highly effect ive or effect ive 
methods of birth control differ fro m the above, the local guidelines must 
be followed.
Patients of non ‒child-bearing potential are not required to use birth control and 
they are defined as:
Women who are infertile due to surgical sterilization (hysterectomy, 
bilateral oophorectomy, or tubal ligation)
Post-menopausal –defined eit her as
A woman at least [ADDRESS_1155970] 6 months of spontaneous amenorrhea with 
follicle-stimulating hormone >40 m IU/mL
Women aged [ADDRESS_1155971] 6 months of spontaneous amenorrhea
Women aged [ADDRESS_1155972] a diagnosis of menopause
Informed Consent
[10]Must read and understand the informed consent approved by  [CONTACT_832685] (Lilly),or its designee, and the institutional review board (IRB)/ethics 
review board (ERB) governing the site, and provide written informed consent. 
I4V-MC-JAIA(b) Clinical Protocol Page 39
LY30091046.2.Exclusion Criteria
Patients will be excluded from  study enrollment if they meet any o f the following criteria:
Medical Conditions
[11]Have severe active lupus nephrit isdefined clinically  and/or by [CONTACT_832686] (if available) wit hin the 24 
weeks prior to screening, or urine protein/creat inine ratio > 200mg/mmol (as an 
estimate of approximate proteinuria > 2 g/day) or eGFR (Modification o f Diet in 
Renal Disease [MDRD]) <40 mL/min/1.73 m2at screening, or as determined by  
[CONTACT_832687] y review commi ttee.
Note:  The lab measurements related to lupus nephritis may be repeated once by 
[CONTACT_501710] , and the values result ing from repeat 
testing may  be accepted for enrollment eligibilit y if they meet the eligibilit y 
criterion.
[12]Haveactive CNS lupus as defined by  [CONTACT_832688] -2K (seizure, psy chosis, organi c 
brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, and 
cerebrovascular accident).
[13]Have active fibromyalgia that, in the invest igator’s opi[INVESTIGATOR_3078] n, would make it 
difficult to appropriately assess SLE activit y for the purposes of this study .
[14]Have been treated for or had an act ive occurrence of a systemic inflammatory 
condition other than SLE such as, but not limited to, RA, juvenile chronic 
arthritis, spondyl oarthropathy , Crohn’s disease, ulcerative colit is, or psoriat ic 
arthritis within the 12 weeks prior to screening.  Patients with secondary 
Sjögren’s syndrome are not excluded.
[15]Have had any  major surgery  within [ADDRESS_1155973] igator in 
consultation wit h Lilly or its designee, would pose an unacceptable risk to the 
patient.
[16]Have screening electrocardiogra m (ECG) abnorm alities that, in the opi[INVESTIGATOR_3078] n of the 
investigator, are clinically  significant and indicate an unacceptable risk for the 
patient’s parti cipation in the study .
[17]Have experienced any of the fo llowing within 12 weeks of screening:  VTE
(DVT/pulmonary embolism [PE]), myocardial infarction (MI), unstable ischemic 
heart disease, stroke, or [LOCATION_001] Heart Associat ion Stage III/IV heart failure.
[18]Have a history  of recurrent ( ≥ 2) VTE (DVT/PE) .
[19]Have a history  or presence of cardiovascular, respi[INVESTIGATOR_696], hep atic, gastrointestinal, 
endocrine, hematological, neuro logical, or neuropsychiatric disorders or any  other 
serious and/or unstable illness that in the opi[INVESTIGATOR_3078] n of the invest igator, could 
constitute an unacceptable risk when taking invest igational product or interfere 
with the interpretation of data .
I4V-MC-JAIA(b) Clinical Protocol Page 40
LY3009104[20]Have a history  of lymphoproliferat ive disease; have signs or symptoms suggest ive 
of possible lymphoproliferat ive disease, including lymphadenopathy  or 
splenomegaly  (other than primarily  due to SLE); have act ive primary or recurrent 
malignant disease; or have been in remissio n from clinically significant 
malignancy for <5 yearsprior to randomizat ion.
The following may be exempted : 
a.Patients with cervical carcino ma in situ that has been resected with no evidence o f
recurrence or metastatic disease for at least [ADDRESS_1155974] 3 y ears may parti cipate in the 
study.
[21]Have a current or recent (<4 weeks prior to randomizat ion) clinically serious 
viral, bacterial, fungal, or parasit ic infectionor any other active or recent infect ion 
that in the opi[INVESTIGATOR_3078] n of the invest igator, would pose an unacceptable risk to the 
patient if parti cipating in the study .
Note:  For example, a recent viral upper respi[INVESTIGATOR_832664] .
[22]Have symptomatic herpes simplex at the time of rando mization.
[23]Have had symptomatic herpes zoster infect ion within 12 weeks pri or to 
randomization.
[24]Have a history  of disseminate d/complicated herpes zoster ( for example, 
ophthalmic zoster or CNS invo lvement).
[25]Have a posit ive test for hepatitis B virus (HBV)defined as:
a.positive for hepatitis B surface ant igen (HBsAg), or
b.positive for hepatitis B core antibody (HBcAb) and posit ive for hepatitis B 
virus deoxy ribonucleic acid (HBV DNA)
Note:  Patients who are HBcAb -positiveand HBV DNA- negative may be 
enrolled in the study but will require addit ional HBV DNA mo nitoring during 
the study.
[26]Have hepatitis Cvirus (HCV)infection (hepatitis C antibody-positiveand HCV
ribonucleic acid [RNA]-positive).
Note:  Patients who have documented anti -HCV treatm ent for a past HCV 
infection AND are HCV RNA -negative may be enrolled in the study .
[27]Have evidence of HIV infection and/or posit ive HIV ant ibodies.
[28]Have had househo ld contact [CONTACT_4490] a person with active TB and did not receive 
appropriate and documented prophylaxis for TB ..
[29]Have evidenc e of active TB or l atent TB
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155975] evidence of active TB, defined in this study  as the following:
Positive purified protein derivat ive ([COMPANY_003]) test ( ≥5 mm induration between 
approximately  2 and 3 days after applicat ion, regardl ess of vaccinat ion 
history), medical history, clinical features, and abnormal chest x -ray at 
screening.
QuantiFERON® -TB Gold test or T -SPOT® TB test (as available and if co mpliant 
with local TB guidelines) m ay be used instead of the [COMPANY_003] test.  Patients are 
excluded fro m the study if the test is not negative and there is clinical evidence of 
active TB.
Exception:  patients with a history of active TB who have documented evidence of 
appropriate treatment, have no history  of re-exposure since their treatment was 
completed, have no clinical fe atures of active TB, and have a screening chest x -ray 
with no evidence o f active TB may be enrolled if other entry  criteria met.  Such 
patients woul d not be requi red to undergo the protocol -specific TB testing for [COMPANY_003], 
QuantiFERON® -TB Gold test, or T -SPOT®.TB test but must have a chest x -ray at 
screening (i .e., chest imaging performed withinthe past6 months will not be 
accepted).
b.Have evidence of untreated/inadequately  or inappropri ately treated latent TB, 
defined in this study  as the following:
Positive [COMPANY_003] test, no clinical features consistent wit h active TB, and a 
chest x-ray with no evidence of active TB at screening; or
If the [COMPANY_003] test is positive and the patient has no medical history  or chest 
x-ray findings consistent wi th active TB, the patient may have a 
QuantiFERON® -TB Gold test or T -SPOT®.TB test (as available and if 
compliant with local TB guidelines).  If the test results are not negative, 
the patient will be considered to have latent TB (for purposes of this 
study); or 
QuantiFERON® -TB Gold test or T-SPOT®.TB test (as available and if 
compliant with local TB guidelines) may  be used instead of the [COMPANY_003] test.  
If the test results are posit ive, the patient will be considered to have latent 
TB.  If the test is not negative, the test may be repeated once within 
approximately  [ADDRESS_1155976] latent TB (for 
purposes of this study ).
Exception:  Patients who have evidence o f latent TB m ay be enrolled if he or 
she completes at least 4 weeks of appropriate treatment prior to randomizat ion 
and agrees to complete the remainder of treatment while in the trial.
I4V-MC-JAIA(b) Clinical Protocol Page 42
LY3009104Exception:  Patients with a history  of latent TB who have documented 
evidence of appropriate treat ment, have no history  of re-exposure since their 
treatment was com pleted, have no clinical features of act ive TB, and have a 
screening chest x -ray with no evidence of act ive TB may be enro lled if other 
entry criteria met.  Such pati ents woul d not be requi red to undergo the 
protocol-specific TB testing for [COMPANY_003], QuantiFERON® -TB Gold test, or 
T-SPOT®.TB test but must have a chest x- ray at screening (i.e., chest 
imaging performed withinthe past6 months will not be accepted).
[30]Have received parenteral  [i.e., intravenous, intramuscular , intra-articular] 
corticosteroids within 6weeks of screening (Vi sit 1), or are expected to requi re 
parenteral  corticosteroids during the study .
[31]Have received any o f the following medications: 
a.Biologic treatments for immunologic disease such as etanercept, i nfliximab, 
certolizumab, adalimumab, golimumab, tocilizumab, abatacept, ustekinumab , 
ixekizumab, secukinumab, or anakinr a within 4 weeks of screening.
b.Cyclophosphamide (or any other cytotoxic agent), belimumab, or anifrolumab 
(or another anti -IFN therapy ) within 12 weeks ofscreening .
c.Rituximab, any other B cell deplet ing therapi[INVESTIGATOR_014], or intravenous 
immunogl obulin (IVIg) within 24 weeks of screening .
[32]Have received a JAK inhibitor or TYK-2 inhibitor.
[33]Have been treated with probenecid that cannot be discontinued for the duration of 
the study.
[34]Have received plasmapheresis wit hin 12 weeks o f screening.
[35]Have been exposed to a live vaccine wit hin 12 weeks ofrandomization or are 
expected to need/ receive a live vaccine during the course of the study (with the 
exception of herpes zoster vaccinat ion).
Note:  All patients who have not previously received the herpes zoster vaccine by 
[CONTACT_832689] (per local guidelines) to do so prior t o randomizat ion; 
vaccination wit h live herpes zoster vaccine must occur >[ADDRESS_1155977].  Patients will not be rando mized if they were exposed 
to a live herpes zoster vaccinat ion within 4 weeks of planne d randomizat ion.  
Investigators should review the vaccinat ion status of their patients and fo llow the local 
guidelines for vaccinat ion of patients ≥[ADDRESS_1155978] ious disease prior to entering pati ents intothe study.
[36]Are current ly enrolled in or have discontinued within [ADDRESS_1155979] or nonapproved use of 
a drug or device or any  other type of medical research judged not to be 
scientifically or m edically compatible wit h this study .
I4V-MC-JAIA(b) Clinical Protocol Page 43
LY3009104[37]Have previously co mpleted or been rando mized and withdrawn fro m this study  or 
have received baricit inib in any other study .
Diagnostics Assessments
[38]Have screening laboratory  test values, including thyroi d-stimulating hormone 
(TSH), outside the reference range for the population that, in the opi[INVESTIGATOR_3078] n of the 
investigator, pose an unacceptable risk for the patient’s participation in the study . 
Patients who are receiving thy roxine as replacement therapy  may participate in 
the study, provided stable therapy  has been administered for ≥12 weeks and TSH 
is within the laboratory’s reference range.  Patientswho have TSH marginally 
outside the laboratory’s normal reference range andare receiving stable thyroxine 
replacement therapy  may participate if the treati ng physician has documented that 
the thyroxine replacement therapy  is adequate for the pat ient.
[39]Have any of the fo llowing specific abnormalit ies on screening laboratory  tests
from the central laboratory :
b.ALT or AST >[ADDRESS_1155980]
c.alkaline phosphatase (ALP) ≥[ADDRESS_1155981]
d.total bilirubin ≥1.[ADDRESS_1155982]
e.hemoglobin <9 g/dL (90.0 g/L)
f.total white blood cell count <2500 cells/µL (<2.50 x103/µL or <2.50 GI/L)
g.neutropeni a (absolute neutrophil count [ANC] <1200 cells/µL) 
(<1.20x103/µL or <1.20 GI/L)
h.lymphopenia (lymphocy te count < 500cells/µL) (<0. 50 x103/µL or 
<0.50GI/L)
i.thrombocytopenia (pl atelets <50,000 cells/µL) (<50 x103/µL or <50 GI/L)
In the case of any  of the aforementioned laboratory  abnormalities, the tests m ay 
be repeated once by [CONTACT_134095] , and values result ing 
from repeat testing may be accepted for enrollment eligibilit y if they meet the 
eligibility criterion.
Other Exclusions
[40]Are largely or wholly  incapacitated permi tting little or no self -care, such as being 
bedridden or confined to wheelchair.
[41]In the opi[INVESTIGATOR_1649] o f the investigator, are at an unacceptable risk for participat ing in 
the study.
[42]Have donated more than a single unit of blood within 4 weeks prior to screening 
or intend to donate blo od during the course of the study .
I4V-MC-JAIA(b) Clinical Protocol Page 44
LY3009104[43]Have a history  of intravenous drug abuse, other illicit drug abuse, or chronic 
alcohol abuse wit hin the 2 y ears prior to screening or are concurrently using, or 
expected to use during the study , illicit drugs (including m arijuana).
[44]Are unable or unwilling to make themselves available for the duration of the 
study and/or are unwilling to follow study  restrictions/procedures .
[45]Are investigator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.   Immediate family is defin ed as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted .
[46]Are Lilly or Incyte employees or theirdesignee.
6.3.Lifestyle Restrictions
Study participants shoul d be instructed not to donate blood or blood produc ts during the study  or 
for [ADDRESS_1155983].
6.4.Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) may be 
rescreened one time.  The interval between init ial screeningand rescreening Visit [ADDRESS_1155984] ivities,and will be assigned a new 
identification number.
I4V-MC-JAIA(b) Clinical Protocol Page 45
LY30091047.Treatments
7.1.Treatments Administered
This study involves a comparison of baricit inib tablets 4-mg or 2-mg administered orally QD 
with placebo tablets administered orally  QD. TableJAIA.3shows the treatment regimens.
TableJAIA.3. Treatment Regimens
Treatment GroupTreatments Administered
Day 1through Day 365
Baricitinib 4-mg QDa1 baricitinib 4 -mg tablet and 1 placebo tablet matching baricitinib 2 -mg
Baricitinib 2-mg QD 1 baricitinib 2 -mg tablet and 1 placebo tablet matching baricitinib 4 -mg
Placebo QD 2 placebo tablets: 1 matching baricitinib 4 -mg and 1 matching baricitinib 2 -mg
Abbreviations:  QD = once daily .
aPatients with estimated glomerular filtration rate <60 mL/min/1.[ADDRESS_1155985] igator or his or her designee is responsible for the following:
explaining t he correct use of the investigational agent(s) to the patient
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
at the end of the study  returning all unused medication to Li lly, or its designee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by [CONTACT_779], as allowed by [CONTACT_1769]
7.1.1.Packaging and Labelling
Lilly (or its designee) will provide the fo llowing primary  studymaterials:
tablets contain ing 4-mg of baricit inib
tablets containing 2 -mg of baricit inib
tablets containing placebo to match 4 -mg baricitinib
tablets containing placebo to match [ADDRESS_1155986] will be dispensed to the patient at the principal investigator’s study site.  
Investigational product packaging will contain enough tablets for the longest possible interval
between visit s.
Investigational product will be labeled according to the country ’s regulatory requirements.  
Patients will be instru cted to take 2 tablets, one tablet from each bottle , each day . 
I4V-MC-JAIA(b) Clinical Protocol Page 46
LY3009104Allinvestigational products will be stored, inventoried, reconciled, and destroy ed according to
applicable regulat ions. Investigational products will be supplied by [CONTACT_832690] h lot numbers,
expi[INVESTIGATOR_31637], and certificates of analysis (as applicable).
7.2.Method of Treatment Assignment
Patients who m eet all criteria for enrollment will be randomized in a 1:1:1 rati o (baricitinib 
4-mg; baricitinib 2-mg; placebo) to double -blind treatment at Visit 2.  Randomizat ion will be 
stratified by [CONTACT_221344] (total SLEDAI-2Kat screening <10; ≥10), corticosteroid dose (<10 
mg/day; ≥10mg/day prednisone or equi valent), and region (defined in the SAP).
Assignment to treatment groups will be determined by a co mputer-generated random sequence 
using an interactive web -response system (IWRS).  The IWRS will be used to assign packages 
containing double -blind invest igational product to each pati ent, starting at Visit 2 (Week 0), and 
at each visit subsequent through Visit 15 (Week 48) .  Each package of clinical trial material will 
supply sufficient study  medication at least for the number of weeks between visits.  Site 
personnel will confirm that they  have located the correct packages by  [CONTACT_45342] a confirmation 
number found on the packages of invest igational product into the IWRS before dispensing the 
packages to the patient.
7.2.1.Selection and Timing of Doses
Investigational product will be provided to patients fo llowing rando mization at Visit 2 (Week 0).
Two tablets (1 tablet fro m each bottl e) should be taken orally each day, without regard to food 
and, if possible, at approximately the same time every  day.Special timing considerat ions of 
administration of invest igational product relat ive to PK sample co llection at study  visits are 
described in Section 9.5.
7.2.2.Dose Adjust ment for Renal Impairment
The dose adjust ment for renal impairment will be managed by [CONTACT_832691].  The eGFR value from screening will be entered into IWRS at Visit 2, and 
IWRS will assign the treatment doses according ly. 
Patients with documented renal  impairment (defined as screening eGFR ≥40 to 
<60mL/min/1.73 m2), who are randomized to active treatment (either to the 
baricitinib 4-mg arm or the baricit inib 2-mg arm) will receive a baricit inib 2-mg QD 
dose by [CONTACT_8784]. 
No dose adjust ment will be made for p atients with screening eGFR ≥60 mL/min/1.[ADDRESS_1155987] ion8.1.1.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155988] igator has the sole responsibilit y for determining if unblinding 
of a patient’s treatm ent assignment is warranted.  Patient safet y must always be the first 
consideration in making such a determinat ion.  If the invest igator decides that unblinding is 
warranted, the invest igator should make every effo rt to contact [CONTACT_456] -designated medical 
monitor prior to unblinding a pat ient’s treatment assignment unless this could delay emergency 
treatment of the pati ent.  If a pati ent’s treatment assignment is unblinded, Lilly  must be notified 
immediately .
Emergency  unblinding for AEs m ay be perform ed through the IWRS.  This option may be used 
ONLY if the patient’s well-being requires knowledge of the patient’s treatment assignment. All 
calls result ing in an unblinding event are recorded and reported by  [CONTACT_8784].
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient 
must be discont inued from the study.  In cases where there are ethical reason s to have the patient 
remain in the study , the investigator must obtain specific approval fro m a Lilly-designated 
medical mo nitorfor the patient to continue in the study .
7.4.Dosage Modification
During this study , treatment assignment and dose adj ustment of investigational product will be 
followed strictly as indicated in Sect ions7.1and7.2.
See Section7.7for permitted concomitant therapy .
7.5.Preparation/Handling/Storage/Accountability
All investigational product (used and partially used) will be returned to the sponsor or destroyed
at site levelwith the sponsor’s wri tten approval . In some cases, sites may destroy the material if
during the invest igative site select ion, the evaluator has verified and documented that the site has
appropriate facilit ies and written procedures to dispose of clinica l trial materials.
Storage and handling instructions are provided on the invest igational product packaging and 
should be followed.
7.6.Treatment Compliance
Patient compliance wi th investigational product will be assessed at Visit 3through Visit 16and 
at Early Termination during the treatment period by  [CONTACT_832692]. Deviations from 
the prescribed dosage regimen should be recorded in the electronic case report form (eCRF).
A patient treated with baricit inib or placebo will be considered significan tly noncompliant if he 
or she misses >20% of the prescribed doses during the treatment period, unless the pati ent’s 
investigat ional product was withheld by  [CONTACT_487074] y reasons.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155989] 
should be assessed to determine the reason for noncompliance and educated and/or managed as 
deemed appropri ate by [CONTACT_832693].
7.7.Concomitant Therapy
Patients will maintain thei r usual medicat ion regimen for SLE and for any  other concomitant 
diseases throughout the study unless specifically  excluded in the protocol (see Sect ion6.2, 
Exclusion Criteria).  Patients taking these medicat ions should be on chronic s table doses at the 
time of rando mization, as specified by [CONTACT_832694] (Section 6.1, Inclusion Criterion 
[8]).  
Permitted concomi tantbackground standard of care medicat ions for SLE include:
A single antimalarial (such as hydroxy chloroquine, chl oroquine, quinacrine) 
at a stable therapeuti c dose for at least 8 weeks prior to screening (Visit 1).  
Doses should remain stable throughout the tr eatment period.
A single i mmunosuppressant (such as MTX, azathioprine, mycopheno late, 
tacrolimus, lefluno mide, cyclosporine) at a stable therapeut ic dose for at least 
8weeks prior to screening (Visit 1).  Doses shoul d remain stable throughout 
the treatmen t period.
An oral corti costeroid, initiated at least 4 weeks prior to screening (Visit 1), at 
a stable dose ≤40 mg/day prednisone (or equivalent) for at least 2 weeks prior 
to screening (Visit 1) and through baseline (Visit 2).  If the patient is not 
receiving an ant imalarial or immunosuppressant, the dose of corticosteroid 
must be ≥7.5 mg/day prednisone (or equivalent).  See Section 7.7.1for 
permitted changes to corticosteroid dosing.
Any changes to the patient’s medicat ion must be discussed with the investigator.  Treatments for 
SLE or other concurrent illnesses may be reduc ed for safet y reasons. Patients should be 
instructed to consult the invest igator or other appropriate study personnel at the site before taking 
any new medicat ions or supplements.
Additional medications are to be avo ided during the study  unless required to treat an AE or for 
the treatment of an ongo ing medical problem.  Between Weeks 0 and 12 and between Weeks 24 
and 36, steroids for non -SLE reasons may  be permi tted on a short -term (no more than 14 day s) 
basis.  Patients must be back to prior dose within 1 4 days (or by [CONTACT_10585]14/Week 38) from the 
initiation of the high -dose steroi ds for non -SLE reasons (whichever is sooner).  If the need for 
concomitant medicat ion arises, inclusio n or continuation of the patient may  be at the di scretion 
of the invest igator after consul tation with Lilly or its desi gnee. Any  additional medicat ion 
whether prescription or over -the-counter, used at baseline and/or during the course of the study  
must be documented in the eCRF with start and stop dates.
I4V-MC-JAIA(b) Clinical Protocol Page 49
LY30091047.7.1.Permitted Changes and Addition s to Concomitant Therapy
Changes to corticosteroid dosing arepermitted during the treatment period as follows.
Corticosteroid Tapering
Investigators are encouraged to taper corticosteroids according to clinical practice with a goal of 
≤7.5 mg/day predniso ne (or equivalent) by  [CONTACT_10585] 40 (Visit 13).
Tapering may occur from Week 0 through Week 16 and from Week 24 (after complet ion of 
Visit9) through Week 40 (see FigureJAIA.1).  In most cases, tapering should not be considered 
for at least [ADDRESS_1155990] ivity during an attem pted taper, the patient’s cortico steroid 
dose may be increased once by [CONTACT_8622] 10 mg/day or up to the baseline dose (whichever is lower).  
The corticosteroid dose may not exceed the baseline dose.  
Corticosteroid dose must be stable for 8 weeks prior to Week 24 (i.e., no changes between 
Weeks 16 and 24) and for 12 weeks prior to Week 52 (i.e., no changes between Weeks 40 and 
52).  This design minimizes confounding of assessments at Week 24 and Week 52 (see 
FigureJAIA.1).
Corticosteroid Burst
A single corticosteroid burst is permitted for patients with increased disease activit y early the 
treatment period. 
During Weeks [ADDRESS_1155991] of up to 40 mg/day oral prednisone for up to 7 days (in addit ion to the 
regular dose, up to a maximum o f 60 mg/day prednisone or equivalent total daily dose).  The 
patient must be at or bel ow their preburst corti costeroid dose by [CONTACT_2671] [ADDRESS_1155992], a single 80 -mg intramuscular dose of m ethylprednisone (or equivalent) may be given 
during Weeks 0 through 11.
7.7.2.Prohibited Chang es in Concomitant Therapy
Initiation of or increase in dose of an ant imalarial or immunosuppressant is not permitted during 
the treatment period.  Patients requiring an init iation or increase above baseline dose of 
antimalarials or immunosuppressants ,as defined in the SAP ,during the treatment period will be 
discontinued f rom the study  drug (see Section 8.1.2). 
Patients requi ring an increase above th e baseline dose of corticosteroid for SLE during the 
treatment period, other than the permitted burst ,as defined in the SAP , will be discont inued from 
study drug (see Secti on8.1.2).
I4V-MC-JAIA(b) Clinical Protocol Page 50
LY30091047.8.Treatment after the End of the Study
7.8.1.Study Extensions
Patients who com plete this study through Week 52 (Visit 16) m ay be eligible to participate in 
Study JAIM, if enro llment criteria for Study JAIM are met.   In some circumstances, due to 
COVID-19 related logistical issues, patients who were unable to complete Visit 16 in the 
protocol specified timeframe and had study  drug temporarily interrupted , but otherwise 
completed the treatm ent period,maybe eligible to participate in Study  JAIM.
7.8.2.Treatment after Study Completion
Baricitinib will not be m ade available after conclusio n of the study  to patients except as 
described in Section 7.8.1.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155993] igator consult with Lilly (or its designee) before temporarily 
interrupting therapy  for reasons other than those defined in TableJAIA.4.  Retest timing and 
frequency  is at the invest igator’s discret ion.
Investigational product that was temporarily  interrupted because of an AE or abnormal 
laboratory  value not specifically cove red in TableJAIA.4may be restarted at the discretion o f 
the investigator.  Investigational product must be held in the fo llowing situations and m ay only 
be resumed as noted in the table.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155994] if the Following 
Abnormalities Occur: Investigational Product May be Resumed When:
WBC count <2000 cells/µL
(<2.00 x 103/µL or <2.00 GI/L)WBC count 2500 cells/µL
(≥2.50 x 103/µL or ≥2.50 GI/L)
ANC <1000 cells/ L 
(<1.00 x 103/µL or <1.00 GI/L)ANC ≥1200cells/µL
(≥1.2x 103/µL or ≥1.2GI/L)
Lymphocyte count < 300cells/µL
(<0.30 x 103/µL or <0. 30 GI/L)Lymphocyte count 500cells/µL
(≥0.50x 103/µL or ≥0.50GI/L)
Platelet count < 25,000/µL
(<25x 103/µL or <2 5 GI/L)Platelet count 50,000/µL
(≥50 x 103/µL or ≥50 GI/L)
eGFR <40 mL/min/1.73 m 2for patients with
screening eGFR ≥60 mL/min/1.73 m2eGFR 50mL/min/1.73 m 2
eGFR <30 mL/min/1.73 m 2for patients with 
screening eGFR ≥40 to <60 mL/min/1.73 m2eGFR 40 mL/min/1.[ADDRESS_1155995] >5x ULNALT and AST return to <[ADDRESS_1155996], and IP is not considered 
to be the cause of enzyme elev ation
Hemoglobin <8 g/dL (<80.0 g/L) Hemoglobin 9 g/dL (≥90.0 g/L)
Symptomatic herpes zoster All skin lesions have crusted and are resolving
Infection that, in the opi[INVESTIGATOR_871], 
merits the IP being withheldaResolution of infection that, in the opi[INVESTIGATOR_1070], merits the IP being restarted
Abbreviations:  ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; eGFR = estimated glomerular filtration rate; IP = investigational product; ULN = upper limit 
of normal; WBC = white blood cell.
aPermanent discontinuation of IP should be considered for patients who develop a serious infection that, in the 
opi[INVESTIGATOR_871], would pose an unacceptable risk if IP were resumed.
8.1.2.Permanent Discontinuation from Study Treatment
Possible reasons leading to permanent discontinuatio n of invest igational product:
Subject Decision
othe patient requests to discont inue investigational product.
Investigator Decision
othe investigator decides that the patient should be discontinued from 
investigat ional product.
Discontinuation due to a hepatic event or liver test abnormality.   Patients who are 
discontinued fro m investigational product due to a hepat ic event or liver tes t abnormalit y 
should have addi tional hepatic safety data collected via eCRF.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1155997] for abnormal liver tests should be
considered by [CONTACT_82378] a patient meets one of the fo llowing condi tions after 
consultation with the Lilly designated medical monitor:
ALT or AST >[ADDRESS_1155998]
ALT or AST >[ADDRESS_1155999]
ALT or AST >[ADDRESS_1156000] and eit her total bilirubin level (TBL) >[ADDRESS_1156001] or 
international normalized rati o (INR) >1.5 
ALT or AST >[ADDRESS_1156002] with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain, or tenderness, fever, rash, and/or eosinophil ia 
(>5%)
alkaline phosphatase (ALP) >[ADDRESS_1156003]
ALP >2.[ADDRESS_1156004] and TBL >[ADDRESS_1156005]
ALP >2.[ADDRESS_1156006] with the appearance of fat igue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Discontinuation due to other laboratory abnormalities:
white blood cell count <1000 cells/µL (1.00x103/µL or 1.00 GI/L)
absolute neutrophil count <500 cells/µL (0.50x103/µL or 0.50 GI/L)
lymphocy te count <200 cells/µL (0.20x103/µL or 0.20 GI/L)
hemoglobin <6.5 g/dL (<65.0 g/L).
Temporary interruption rules (see Section8.1.1) must be fo llowed where applicable.  For 
laboratoryvalues that meet permanent discont inuation thresholds, invest igational product should 
be discont inued.  However, if in the opi[INVESTIGATOR_3078] n of the investigator ,the laboratoryabnormality is due 
to intercurrent illness or another ident ified factor, laboratory  tests may be repeated .  The 
investigator may  be able to restart investigational product after consultat ion with the 
Lilly-designated m edical monitor, only when the laboratoryvalue meets resumption thresholds 
(TableJAIA.4) following the resol ution of the intercurrent illness or other ident ified factor .
Discontinuation due to other circumstances :
pregnancy
malignancy (except for successfully treated basal cell or squamous epi[INVESTIGATOR_629265])
hepatitis B virusDNA is detected with a value above the lower limit of quant itation
(see Section 9.4.8). 
occurrence of a VTE (DVT/PE) during the study
seriousinfection that in the opi[INVESTIGATOR_1649] o f the investigator, merits the 
investigat ional product being discont inued
I4V-MC-JAIA(b) Clinical Protocol Page 54
LY3009104if the patient, for any reason, requires treatment with another therapeutic agent 
that maybe effective for treatment of SLE that i s listed in the exclusio n 
criteria (see Section 6.2) or is nonco mpliant to the concomitant therapy 
requirements (see Secti on7.7.2) during the study.  D iscontinuation fro m the 
investigat ional product must occur prior to introduction of the new agent .
Throughout the trial, invest igators should continue to assess benefit/risk for patients to remain in 
the trial and shoul d consider di scontinuing pat ients if sufficient clinical benefit is not obser ved 
with protocol allowed concomitant treatments.
If a patient prematurely  discontinues invest igational product for any  reason, the patient is 
encouraged to remain in the study  through Week 52 (Visit 16) and fo llow the regul ar visit 
schedule per Section2(Schedule of Act ivities).
8.1.3.Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ify a patientwho did not meet enrollment criteria and was 
inadvertent ly enrolled, then the patient should be discontinued fro m study treatment unless there 
are extenuat ing circumstances that make it medically necessary for the patient to continue on 
study treatment.  If the invest igator and the sponsor -designated medical mo nitoragree it is 
medically appropriate to continue, the invest igator must obtain documented approval fro m the 
sponsor-designated medical mo nitorto allow the inadvertent ly enrolled pat ientto continue in the 
study with or without treatm ent with investigational product. Safetyfollow up is as outlined in 
Section 2(Schedule of Act ivities), Section9.2(Adverse Events), and Section 9.4(Safety) of the 
protocol.
8.2.Discontinuation from the Study
Patients will be discontinued in the fo llowing circumstances:
Enrollment in any other clinical study  involving an invest igational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study
Participation in the study  needs to be stopped for medical, safet y, regulatory, 
or other reasons consistent with applicable law s, regulations, and good clinical 
practice (GCP)
Subject decisio n
oThe patient requests to be withdrawn fro m the study
Patients discontinuing fro m the study prematurely for any  reason shoul d complete AE and other 
safety follow-up as indicated in the Early  Term Visit per Secti on2(Schedule of Act ivities), 
Section9.2(Adverse Events), and Section 9.4(Safety) of this protocol and proceed to the 
post-treatment follow up peri od.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156007] patients who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_779].
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156008] ivities, with the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix [ADDRESS_1156009] ivity, while the 
BILAG and Physician’s Glo bal Assessment of Disease Act ivity components ensure that the 
improvement in overall disease is not accompanied by  [CONTACT_629291].  
The SRI-4 response is defined as follows:
Reduction o f ≥4 points fro m baseline in SLEDAI -2K score (Section9.1.1.1);and
No new BILAG A andno more than 1 new BILAG B disease activit y scores
(Section9.1.1.2); and
No worsening (defined as an increase of ≥0.3 points [10 mm] from baseline) in 
Physician’s Global Assessment of Disease Activit y(Section9.1.1.3).
[IP_ADDRESS]. Systemic Lupus Erythematosus Disease Activity Index-[ADDRESS_1156010] 
disease manifestations across 9 organ systems .  It includes 24 clinical and laboratory  variables 
with manifestations graded by  [CONTACT_629290].  CNS:  S eizure, Psychosis, Organic 
Brain Syndro me, Visual Disturbance, Cranial Nerve Disorder, Lupus Headache, cerebrovascular 
attack; Vascular:  Vasculit is; Musculoskeletal:  Arthrit is, Myositis; Renal:  Urinary Casts, 
Hematuria, Proteinuria, Py uria; Mucocutaneou s:  Rash, Alopecia, Mucosal Ulcers; 
Cardiovascular and Respi[INVESTIGATOR_696] :  Pleurisy, Pericarditis; Immuno logic:  Low complement, 
Increased DNA Binding; Const itutional:  Fever; Hem atologic:  Thrombocy topenia, Leukopenia.
[IP_ADDRESS]. British Isles Lupus Assessment Group 2004Index
The BILAG -2004 Index is a validated global disease activit y index designed on the basis o f the 
physician’s intent ion to treat (ITT), focusing on changes in disease manifestations (not present, 
improving, same, wo rse, or new) occurring in the last 4 weeks compared with the previous 
4weeks. The instrument assesses 97 clinical signs, symptoms, and laboratory  parameters across 
9 organ system domains:  const itutional, mucocutaneous, neuropsy chiatric, musculoskeletal,
cardiorespi[INVESTIGATOR_696], gastrointestinal, ophthalmic, renal, and hematology .  A BILAG A disease 
activity score is severe disease activit y requiring high -dose oral or intravenous corticosteroids, 
immunomodulators, or high -dose anticoagulat ion along with high -dose corticosteroids or 
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156011] ivity score is moderate disease activit y requiring 
low-dose oral corticosteroids, intram uscular or intra -articular corti costeroid injections, topi[INVESTIGATOR_522093], antimal arials, or symptom atic therapy.  BILAG C 
corresponds to stable mild disease, BILAG D is inactive disease that was active previously, and 
BILAG E indicates the system was never invo lved.
[IP_ADDRESS]. Physician’s Global Assessment of Disease Activity
The Physician’s Glob al Assessment of Disease Activit y is the physician’s assessment of the 
patient’s overall disease act ivity due to SLE, as compared with all possible pat ients with SLE. 
The Physician’s Global Assessment of Disease Activit y is scored using a 100 -mm Visual Analog 
Scale (VAS), where 0 mm (measured from the left  starting point of the line) indicates no disease 
activity and 100 mm (measured fro m the left starting point of the line) indicates the most severe 
disease activity possible for all  patients with SLE (or death). The Physician’s Glo bal 
Assessment of Disease Act ivity score is indicated by  [CONTACT_7328] a verti cal tick mark on the line 
between 0 and 100 mm. There are benchmarks of 0 (0 mm), 1 (33 mm), 2 (67 mm), and 3 (100 
mm) on the line corresponding to no, mild , moderate, and severe SLE disease activit y, 
respectively .
9.1.2.Seconda ryand Exploratory Efficacy As sessments
Secondary  efficacy assessments will include the following:
[IP_ADDRESS]. Systemic Lupus Erythematosus Responder Index
The SRI-4 will be assessed at various time points up to Week 52.  For assessment descript ion, 
see Section 9.1.1.  The SRI -5, -6, -7, and -8 will also be assessed at various time points up to 
Week 52, and are similar to the SRI -4 except they require a reduction of ≥5, 6, 7, or 8 points 
(respectively) from baseline in SLEDAI -2K score (Section9.1.1.1).
[IP_ADDRESS]. Systemic Lupus Erythematosus Disease Activity Index-2000
The SLEDAI -2K will be assessed at vari ous time points up to Week 52.  For assessment 
description, see Section9.1.1.
[IP_ADDRESS]. British Isles Lupus Assessment Group 2004Index
The BILAG -2004 Index will be assessed at various time points up to Week 52.  For assessment 
description, see Section9.1.1.
[IP_ADDRESS]. Physician’s Global Assessment of Disease Activity
The Physician’s Global Assessment of Disease Activit y will be assessed at vari ous time points 
up to Week 52.  For assessment descript ion, see Section9.1.1.
[IP_ADDRESS]. Safety of Estrogens in Lupus Erythematosus National Assessment 
(SELENA) -Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) Flare Index
The SELENA -SLEDAI Flare Index (SFI) uses the SLEDAI score, disease act ivity scenarios, 
treatment changes, and Physician’s Glo bal Assessment of Disease Act ivity to define 
mild/moderate and severe flares.  The index takes into account the absolute change in total 
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156012] ivity.
[IP_ADDRESS]. Cutaneous Lupus Erythematosus Disease Area and Severity Index
The Cutaneous Lupus Ery thematosus Di sease Area and Severit y Index (CLASI) i s a validated 
scale used to assess cutaneous manifestations of SLE consisting of [ADDRESS_1156013] ivity is scored on the basis of ery thema, scal e/hyperkeratosis, mucous mem brane 
involvement, acute hair loss, and nonscarring alopecia.  Damage is scored in terms of 
dyspi[INVESTIGATOR_832665], including scarring alopecia.
[IP_ADDRESS]. Lupus Low Disease Activity State
The LLDASis defined as a low level o f disease activit y attained wi th orwithout use of low -dose 
steroids and/or tol erated standard maintenance doses of SoC medicat ions.
[IP_ADDRESS]. Tender/Swollen Joint Count (28 Joints)
The 28 joints to be examined and assessed as tender or not tender for tender jo int count and as 
swollen or not swollen for swollen jo int count include 14 jo ints on each side of the patient’s 
body: the 2 shoul ders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal jo ints, the 2 
interphalangeal jo ints of the thumb, the 8 proximal interphalangeal jo ints, and the 2 knees.
[IP_ADDRESS]. Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index
The SLICC/ACR Damage Index is scored on 41 items represent ing damage to 12 organ systems.  
The index records damage occurri ng in patients with SLE regardless o f its cause and includes 
specific co morbidities associated wi th SLE that may  be due to treatment -related toxicity.
[IP_ADDRESS]. British Isles Lupus Assessment Group Based Composite Lupus 
Assessment 
The BICLAis a composite index used to assess disease act ivity in SLE.  The BILAGcomponent 
is used to capture clinically meaningful improvement in disease act ivity, while the BILAG, 
SLEDAI-2K,and Physician’s Global Assessment of Disease Act ivity components ensure that the 
improvement in overall disease is not accompanied by  [CONTACT_629291].  
The BICLA response i s defined as follows:
Reduction o f all baseline BILAG A to B/C/D and baseline BILAG B to C/D, and no 
BILAG worsening in other organ systems, where worsening is defined as≥1 new BILAG 
A or ≥2 new BILAG B
No worsening fro m baseline in SLEDAI -2K, where worsening is defined as an increase 
from baseline of >0 points in SLEDAI -2K
No worsening fro m baseline in participants' lupus disease act ivity, where worsening is 
defined by [CONTACT_522104] ≥0.30 points on a 3 -point PGA visual analogue scale (VAS)
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156014] ivities(Section 2) in countries where the 
questionnaires have been translated into the nat ive language o f the region and linguist ically 
validated.
[IP_ADDRESS].1. Worst Pain Numeric Rating Scale 
The Worst Pain Numerical Rating Scale(NRS)is a single -item, patient-administered, 11 -point 
horizontal scale anchored at 0 and 10, with 0 representing “no pain” and 10 represent ing “pain as 
bad as you can imagine.” Overall severit y of a patient’s pain is indicated by  [CONTACT_832695] 24 hours. Data will be captured on a daily 
electronic patient diary.
[IP_ADDRESS].2. Worst Joint Pain N umeric Rating Scale
The Worst Joint Pain NRS is a single -item, patient-administered, 11 -point horizontal scale 
anchored at 0 and 10, with 0 representing “nojointpain” and 10 represent ing “joint pain as bad 
as you can imagine.” Overall severit y of a patient’s joint pain is indicated by [CONTACT_832696] o f joint pain in the last 24 hours.   Data will be 
captured on a daily electronic pat ient diary.
[IP_ADDRESS].3. Worst Fatigue Numeric Rating Scale
The Worst Fatigue NRS is a single -item, patient-administered, 11 -point horizontal scale 
anchored at 0 and 10, with 0 representing “no fat igue” and 10 represent ing “as bad as you can 
imagine.” Overall severit y of a patient’s fatigue is indicated by [CONTACT_832697] o f fatigue in the last 24 hours.   Data will be captured on a daily 
electronic patient diary.
[IP_ADDRESS].4. Joint Stiffness Duration
TheDuration of Joint Stiffness pat ient-reported o utcomes (PRO) is a single -item, 
patient-administered scale designed to capture info rmation on the self -reported length of time, in 
minutes, that a patient’s joint stiffness lasted each day . Patients report the duration of time by 
[CONTACT_832698]. Data will be captured 
on a daily electronic patient diary.
[IP_ADDRESS].5. Joint Stiffness Severity Numeric Rating Scale
The Joint Stiffness Severit y NRS is a single -item, patient-administered, 11 -point horizontal scale 
anchored at 0 and 10, with 0 representing “no jo int stiffness” and 10 represent ing “joint stiffness 
as bad as you can imagine.” Overall severit y of a patient’s joint stiffness is indicated by  [CONTACT_832699] 24hours.  Data will be 
captured on a daily  electroni c patient diary.
[IP_ADDRESS].6. Patient’s Global Impression of Severity
The Patient’s Global Impression of Severity is a single -item question asking the pat ient how they  
would rate thei r overall lupus symptoms over the last 24 hours.  The 5categories o f response 
range from “no symptoms” to “seve re”.  Data will be captured on a daily electronic patient diary .
I4V-MC-JAIA(b) Clinical Protocol Page 60
LY30091049.[IP_ADDRESS]. Patient’s Global Impression of Change
The Patient’s Global Impression of Change is a single -item question asking the pati ent how they  
would rate thei r change in overall lupus symptoms since t hey started the study .  The 7categories 
of response range from “very  much better” to “very  much worse.”  Data will be captured on an 
electronic tablet collected at site visits .
[IP_ADDRESS].8. Medical Outcomes Short -Form 36 -Item Health Survey Version 2 
(SF-36v2)
The SF-36v2 Acute m easure is a subject ive, generic, health -related quali ty of life instrum ent that
is patient-reported and consists of 36 questions covering 8 healt h domains: physical functioning,
bodily pain, role limitations due to phy sical problems, rol e limitations due to emotional
problems, general healt h perceptions, mental health, social funct ion, and vitalit y. Each domain is
scored by  [CONTACT_832700] a 0 to 100 scale wit h
higher scores indicat ing better healt hrelated quali ty of life. In addition, 2summary scores, the
PCS and the MCS, will be evaluated based on the 8 SF -36v2 Acute domains. The acute version
of this instrument has a 1 week recall period (Brazier et al. 1992; Ware and Sherbourne 1992 ).
Data will be captured on an electronic tablet collected at site visit s.
[IP_ADDRESS].9. Functional A ssessment of Chronic Illness Therapy–FatigueScale
The FACIT -Fatiguescale (Cella and Webster 1997) is a brief, 13- item,symptom-specific 
questionnaire that specifically  assesses the self-reported severit y offatigue and its impact upon 
daily activities and funct ioning. The FACIT -Fatigueuses 0(“not at all”) to 4 (“very  much”) 
NRSto assess fatigue and its impact in the past 7 days. Scores range fro m 0 to 52 with higher 
scores indicating less fatigue. Data will be captured on an electronic tablet collected at site 
visits.
[IP_ADDRESS].10. Work Productivity and Activity Impairment Questionnaire– Lupus 
The Work Productivit y and Activity Impairment Questionnaire -Lupus (WPAI -Lupus)records 
impairme nt due to Lupus during the past 7 day s.  The WPAI -Lupusconsists of 6 items grouped 
into four domains, absenteeism (work time missed), presenteesism (impairment at work / 
reduced on -the-job effectiveness), work productivity  loss (overall work impairment /a bsenteeism 
plus presenteeism), and activit y impairment.  Scores are calculated as impairment percentages 
(Reilly et al. 1993) wi th higher scores indicating greater impairment and less productivit y.  Data 
will be captured on an electronic tablet collected a t site visits.
[IP_ADDRESS].11. European Quality of Life –5 Dimensions –5 Levels
The European Qualit y of Life-5 Dimensi ons 5 Levels (EQ-5D 5L)is a standardized measure of 
health status in order to provide a simple, generic measure of health for clinical and econo mic 
appraisal.  The EQ -5D 5L consists of 2 components:  a descript ive system o f the respondent’s 
health and a rating of his/her curren t health state using a 0 -to 100-mm VAS.  The descri ptive 
system comprises the foll owing 5 dimensio ns:  mobility, self-care, usual act ivities, 
pain/disco mfort, and anxiet y/depression.  Each dimensi on has 5 levels:  no problems, slight 
problems, moderate pr oblems, severe problems, and extreme problems.  The respondent is asked 
to indicate his or her health state by  [CONTACT_13158] (or pl acing a cross) in the box associated with the 
most appropri ate statement in each of the 5 dimensions.  It should be noted that the numerals 1 to 
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156015] no arithmetic properties and should not be used as an ordinal score.  The VAS records the 
respondent’s self -rated heal th on a vert ical VAS where the endpo ints are labeled “best 
imaginable healt h state” and “worst imaginable health stat e.”  This informat ion can be used as a 
quantitative measure of healt h outcome.  The EQ- 5D 5L healt h states, defined by [CONTACT_20367] -5D 5L 
descriptive system, may be converted into a single summary index by [CONTACT_2931] a formula that 
essentially attaches values (als o called weights) to each of the levels in each dimension (EuroQol 
Group 2015 [WWW]). Data will be captured on an electronic tablet collected at site visit s.
9.1.3.Appropriateness of Assessments
All assessments and/or concepts includedin this study  are standar d, widely used, and generally 
recognized as reliable, accurate, and relevant .
9.2.Adverse Events
Investigators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unus ual, even if this event m ay be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of patientsduring the study.
Investigators must document their review of each laboratory  safety report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the patient to discontinue the investigational product before 
completing the study.  The patientshould be followed until the event resolves or stabilizes with 
appropriate diagnostic evaluation.  The frequency of fo llow-up evaluat ions of the AE is left to 
the discretion of the inves tigator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via eCRF the occurrence and nature of 
each patient ’s preexisting condit ions, except SLE, as it is the disease under treatment in the 
study.  In addition, site personnel will record any  change in the condit ion(s) and any new 
conditions as AEs. Investigators should record the fo llowing via eCRF for each AE:  start date, 
stop date (if applicable), severit y, and their assessment of the potential relatedness of each AE to 
protocol procedure or i nvestigational product, via eCRF.
The invest igator will interpret and document whether or not an AE has a reasonable possibili ty 
of being related to study  treatment, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the 
investigat ional product, study  device and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
I4V-MC-JAIA(b) Clinical Protocol Page 62
LY3009104Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via e CRF, clarifying if possible, the circumstances 
leading to any  dosage m odifications, ordiscontinuations o f treatment.
9.2.1.Serious Adverse Events
An SAE is any AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life-threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacity
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_824320] o ne of the other outcomes listed in the definit ion above.
All AEs occurring after signing the ICF are recorded in the eCRF and assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the patient has signed the ICF and has 
received inve stigational product.  However, if an SAE occurs after signing the ICF, but prior to 
receiving invest igational product, the SAE should be reported to the sponsor according to
SAE-reporting requirements and t imelines (see Section9.2) if it is considered reasonably 
possibly related to study  procedure.
Study site personnel  must alert Lilly or i ts designee of any SAE within [ADDRESS_1156016] igator, and submitted via fax to the Spo nsor’s global pat ient 
safety department.  This form includes a fax cover page that is pre -populated with the 
appropriate fax number.  The 24- hour notificat ion requirement refers to the init ial SAE 
information and all fo llow-up SAE information.  Patients with a serious hepatic AE should have 
additional data collected using the eCRF.
Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definition of an AE.  However, to fulfill regulatory requirements any pregnancy shou ld be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (thepatientdisposition CRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he or she considers the event reasonably  possibly related to 
the study treatment or study  participation, the investi gator must promptly notify Lilly.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156017] ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to in vestigational product or procedure.  
[LOCATION_002] 21 CFR 312.32 and European Unio n Clinical Trial Directive 2001/20/EC and the 
associated detailed guidance or national regulatory requi rements in parti cipating countries 
require the reporting of S[LOCATION_003]Rs.  Li lly has procedures that will be followed for the 
identification, recording and expedited reporting of S[LOCATION_003]Rs that are consistent with global 
regulations and the associated detailed guidance.
9.2.2.Adverse Event s of Special Interest
Adverse events of special interest (AESIs) will include the following:
infections(including TB, herpes zoster, or opportunist ic infections)
malignancies
hepatic events (see Section 9.4.9)
major adverse cardiac events (MACE) (see Section 9.4.10) 
venous thromboembolic e vents (DVT/PE) (see Section [IP_ADDRESS])
Sites will provide details on these AEs as instructed on the eCRF and may be asked for 
additional description by [CONTACT_11007].
9.2.3.Complaint Handling
Lilly collects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study participants, m onitor quality, and to 
facilitate process and product improv ements.
Patientswill be instructed to contact [CONTACT_81129] a 
complaint or probl em with the invest igational product so that the situation can be assessed.
9.3.Treatment of Overdose
Refer to the IB.
9.4.Safety
Any clinically  significant findings from ECG testi ng, physical examinat ion, vital signs 
measurements, or laboratory measurement sthat result in a diagnosis and that occur after the 
patient receives the first dose of study  treatment should be reported to Li lly or its designee as an 
AE via eCRF.
9.4.1.Electrocardiograms
A single 12-lead standard ECGwill be obtained locally at Visit 1 and read by  a qualified 
physician (the invest igator or qualified designee) at the site to determine whether the patient 
meets entry  criteria.
I4V-MC-JAIA(b) Clinical Protocol Page 64
LY3009104Electrocardiograms may be obtained at addit ional times, when deemed clinically necessary .
9.4.2.Vital Signs
For eachpatient, vital signs measurements (sitting blood pressure , heart rate , and temperature) 
should be conducted according to the Schedule o f Activities (Section 2).  Subjects should be 
seated and relaxed wit h both feet on the floor for at least [ADDRESS_1156018] igator.
9.4.3.Physical Examination
For each patient, phy sical examinations will beconducted according to the Schedule of 
Activities (Section2).  One complete physical examinat ion (excluding pelvic and rectal 
examinations) will be performed at Visit 1 (Screening) .  All remaining physical examinat ions 
throughout the study  should include a symptom -directed phy sical examinat ion.  A complete 
physical examinat ion may be repeated at the investigator’s discretion at any  time a patient 
presents with physical co mplaints.
9.4.4.Laboratory Tests
For each patient, laboratory  tests detailed in ( Appendix 2 ) should be conducted according to the 
Schedule of Act ivities (Section 2).
With the exception o f laboratory test resul ts that may  unblind the study , Lilly or i ts designee will 
provide the invest igator with the results of laboratory  tests analyzed by  a central vendor, if a 
central vendor is used for the clinical trial.
9.4.5.Columbia -Suicide Severity Rating Scale
The Columbia-Suicide Severi ty Rating Scale (C-SSRS)captures the occurrence, severit y, and 
frequency  of suicidal ideat ion and/or behavior during the assessment period.  The scale includes 
suggested questions to solicit the ty pe of information needed to determine if suicidal ideation 
and/or behavior occurred.  The C -SSRS is administered by  [CONTACT_832701] h care 
professional with at least 1year of patient care/clinical experience.  The tool was developed by 
[CONTACT_80506] h trial group for the purpose of being a counterpart to the 
Columbia Classificat ion Algorithm of Suicide Assessment categorization of suicidal events.  For 
this study, the scale has been adapted (with permission fro m the scale auth ors) to include only  
the portion of the scale that captures the occurrence of the 11 preferred ideat ion and behavior 
categories.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156019] ion, sites should not change the AE form.  If an event is serious or leads to 
discontinuat ion, this is an except ion where the SAE and/or AE leading to discont inuation should 
be included o n the AE form and the process for reporting SAEs should be fo llowed.
Suicide-related events (behavior and/or ideat ions) will be assessed and evaluated at every visit 
with the administrati on of the C-SSRS and the Self -Harm Supplement Form.  The Self-Harm 
Supplement Form  is a single quest ion to enter the number of suicidal behavior events, possible 
suicide behavi ors, or nonsui cidal self-injurious behavi ors.  If the number of behavioral events is 
greater than zero, it will lead to the complet ion of the Self -Harm Follow-up Form.  The 
Self-Harm Follow-up Form is a series of quest ions that provides a more detailed description o f 
the behavior cases.
[IP_ADDRESS]-Item Quick Inventory of Depressive Symptomatology :  
Self-Report
TheQIDS-SR16 is a self-administered, 16-item instrument intended to assess the existence and 
severity of symptom s of depressio n as listed in the American Psychiatric Associat ion’s 
Diagnostic and Stati stical Manual of Mental Disorders, 5th Edition (DSM -V)(APA 2013 ).  A 
patient is asked to consid er each statement as it relates to the way  they have felt for the past 
7days.  There i s a 4-point scale for each item ranging fro m 0 to 3.  The 16 items corresponding 
to 9 depression domains are summed to give a single score ranging fro m 0 to 27, with hig her 
scores denoting greater symptom severit y.  The domains assessed by [CONTACT_223970] 
(1)sad mood, (2) concentration, (3) self -criticism, (4) suicidal ideat ion, (5) interest, 
(6)energy/fatigue, (7) sleep disturbance (init ial, middle, and late ins omnia or hypersomnia), 
(8)decrease/increase in appetite/weight, and (9) psycho motor agitation/retardati on.
9.4.7.Chest x-Ray and Tuberculosis Testing
A posterior-anterior view chest x-raywill be obtained l ocally at screening (Visit 1), unless 
results from chest imaging (other than ultrasound) obtained wit hin [ADDRESS_1156020] ion.  In addi tion, patients will be tested at screening (Visit 
1) for evidence of active or latent TB as described in the exclusio n criteria, Secti on 6.2.
Investigators should fo llow local guidelines for m onitoring pat ients forTBif a patient is at high 
risk for acqui ring TB or reactivat ion of latent TB.
9.4.8.Hepatitis B Virus  DNA Monitoring
Hepatitis B virusDNA testi ng will be performed in enrolled pat ients who tested posit ive for 
HBcAb at screen ing.
Patients who are HBcAb -positive and HBV DNA -negative (undetectable) at Visit 1 will require 
HBV DNA mo nitoring every  3 months and at the patient’s last visit, regardless of their hepat itis 
B surface ant ibody (HBsAb) status.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156021] results:
If a single result is obtained with a value “below limit of quant itation,” the test 
should be repeated wi thin approximately 2 weeks.
If the repeat test result is “target not detected ,” monitoring may  resume a ccording 
to the study  schedule .
If the patient has 2or more test results with a value “below limit of quantitation”
during the study , HBV DNA testing should be performedapproximately  once per 
month for the remainder of the study  and referral  to a hepatologist is 
recommended .
If a result is obtained with a value above limit of quant itation at any time during 
the study, the patient will be permanent ly discont inued from investigational 
product (see to Section 8.1.2) and should be referred to a hepatology specialist 
immediately .
oIn selected cases, investigators may temp orarily continue investigational 
product in accordance wit h current immuno modulator management in the 
setting of HBV DNA posit ivity.  This opti on may be considered in 
consultation wit h Lilly (or its designee) and after evaluation of individual 
patient risks and benefits.
9.4.9.Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥[ADDRESS_1156022], ALP ≥[ADDRESS_1156023], or elevated TBL 
≥2xULN, liver testing ( Appendix 4 ) should be repeated wi thin [ADDRESS_1156024] ion8.1.2.
Hepatic Safety Data Collection
Additional safety data should be co llected via the eCRF if 1 or more of the fo llowing condi tions 
occur: 
Elevation of serum ALT to ≥[ADDRESS_1156025] on 2 or more consecutive blood tests
Elevated serum TBL to ≥ [ADDRESS_1156026] (except for cases of known Gilbert’s 
syndrome)
Elevation of serum ALP to ≥[ADDRESS_1156027] on 2 or more consecutive blood tests
Patient discont inued from treatment due to a hepatic event or abnormalit y of 
liver tests
Hepatic event considered to be a SAE
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156028] ionally 
independent Global Pat ient Safety (GPS) therapeutic area physician or clinical scient ist and 
periodically review trends in safet y data and l aboratory  analytes.  Any concerning trends in 
frequency  or severity noted by [CONTACT_566093]/or Lilly or its designeemay require further 
evaluation.
All deaths and SAE reports will be reviewed in a blinded manner b y Lilly during the clinical 
trial.  These reports will be reviewed to ensure completeness and accuracy but will not be 
unblinded to Lilly during the clinical trial .  If a death or clinical AE is deemed serious, 
unexpected, and possibly related to invest igational product, Lilly  GPS will be unblinded for 
regulatory reporting and safet y monitoring purposes .  These measures will preserve the integrit y 
of the data collected during this trial and minimize any potential for bias while providing for 
appropriate saf ety monitoring.
Investigators will mo nitor vital signs and carefully  review findings that may be associated with 
cardiovascular events. Adverse event reports and vital signs will be co llected at each study visit. 
The cardiovascular monitoring plan includ es the following:
Regular monitoring of lipid levels
Potential MACE (cardi ovascular death, my ocardial infarction, stroke), other 
cardiovascular events (such as hospi[INVESTIGATOR_10929], hospi[INVESTIGATOR_832666], serious arrhy thmia, resu scitated sudden death, cardi ogenic shock, coronary  
interventions), VTE (DVT/PE), arterial thromboembo lic events and noncardiovascular 
deaths will be ident ified by [CONTACT_832702] a blinded Clinical Event Committee for adjudicat ion at regul ar intervals .
[IP_ADDRESS]. Venous Thromboembolic Event Assessment
If a patient develops clinical features of a DVT or PE, appropriate local laboratory  tests and 
imaging should be performed, as necessary , for the diagnosi s of the event.  For confirmed cases, 
additional laboratory  testing is recommended as outlined in Appendix 5 .  All suspected VTE s
will be independent ly adjudicated by a blinded Clinical Event Committee .
9.5.Pharmacokinetics
A single venous blood sample will be drawn at the times indicated in the Scheduleof Activities 
(Section2).  These blood samples will be used to determine the plasma concentrations of 
baricitinibusinga validated liquid chromatography  tandem mass spectrom etry method.  Bl ood 
samples that will be used for other la boratory assessments ( for example, chemistry , hematology) 
maybe drawn at approximately the same time as the samples drawn to determine plasma 
I4V-MC-JAIA(b) Clinical Protocol Page 68
LY3009104concentrations of baricit inib, with the except ion of Visit 2 (Week 0), which requires separate 
sampling fro m other labs.  The timing will be as follows:
At Visit 2 (Week 0 ), patients will take their investigati onal product in the clinic , and PK 
samples will be drawn approximately  [ADDRESS_1156029] dose .
At Visit 4(Week 4),patients will be asked to take their investigational product at homeprior 
to visiting the clinic.  The clinic visit should be schedul ed so that the blood sample collected
during thi s visit is drawn 2 to 4 hours after the dose is taken at hom e.
At Visit 5(Week 8),patients will be asked to take their investigational product at homeprior 
to visiting theclinic.  The clinic visit should be scheduled so that the blood sample collected
during thi s visit is drawn 4 to 6 hours after the dose is taken at hom e.
For Visit 6(Week 12 ),and Visit 7 (Week 16 ),patients will take thei r investigational product
in the clinic , and a blood sample will be collectedat any time predose on the day  of the clinic 
visits.  If the patient has taken theoral dose prior to the visit, the sample may  be drawn 
anytime postdose, and the inabilit y to collect a predose sample will not be considered a 
protocol violation.
For anearly termination visitprior to Visit 7 (Week 16 ),a sample may be drawn anyt ime if 
the last dose of invest igational productwas taken within the last 48 hours. Ifthe early 
termination is due to an AE, then a sample should be drawn if the visit occurred prior to Visit 
16(Week 52 ).  
In the event of an SAE, up to 2 addit ional blood samples may  be taken at the investigator’s 
discretion.  If collected, the PK samples should be collected after the reported event, 
approximately  6 hours apart and within 24 hours of the pat ient’s last dose.
For visits where PK samples will be co llected, the actual date and [ADDRESS_1156030] patient visit for the study .
I4V-MC-JAIA(b) Clinical Protocol Page 69
LY30091049.6.Pharmacodynamics
Samples collected to measure pharmacodynamics markers including, but not limited to 
anti-dsDNA, com plement, and IFN signature, will be ident ified by [CONTACT_394104] (coded) 
and retained at a facilit y selected by [CONTACT_82395] a m aximum of [ADDRESS_1156031] ivities (Section 2) where local regulations allowand patients provides consent.  
Patients choosing not to provide consent for whole blood samples to be collected for 
pharmacogenet ic research will still be eligible to participate in t he study.
Samples will notbe used to conduct unspecified disease or populat ion genetic research either 
now or in the future.  Samples will be used to investigate variable response to baricit inib and to 
investigate genet ic variants though t to play a role in SLE.  Assessment of variable response may  
include evaluat ion of AEs or differences in efficacy.
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by [CONTACT_832703].
Samples will be retained at a facilit y selected by  [CONTACT_134115] a m aximum of 15years 
after the last patient visit for the study , or for a shorter period if local regulations and/or ethical 
review boards (ERBs)/ inst itutional review boar ds (IRBs) impose shorter time limits.  This 
retention period enables use o f new techno logies, response to regulatory  questions, and 
investigat ion of variable response that may not be observed unt il later in the development of 
baricitinib or after baricit inib become(s) commercially available.
Molecular techno logies are expected to improve during the [ADDRESS_1156032] ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
these questions through measurement o f biomolecules including deoxy ribonucleic acid (DNA), 
ribonucleic acid (RNA), proteins, lipi[INVESTIGATOR_805], and other cellular elements.
Serum, plasma, who le blood RNA, and urine samples for bio marker research will be co llected at 
the timesspecified in the Schedule o f Activities (Section 2)where local regulat ions allow.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156033] ion of baricitinib, and/or research 
method or i n validating diagnost ic tools or assay(s) related to SLE.
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by [CONTACT_832704].
Samples will be retained at a facilit y selected by  [CONTACT_134115] a m aximum 15years 
after the last patient visit for the study , or for a shorter period if local regulations and ERBs/IRBs 
impose shorter time limits.  This retention period e nables use of new technologies, response to 
regulatory questions, and invest igation of variable response that may not be observed unt il later 
in the development of baricit inib or after baricit inib become(s) commercially available.  Any 
samples remaining af ter 15 years will be destroyed.
9.9.Medical Resource Utilization and Health Economics
Health Economics and Medical Resource Utilizat ion parameters will not be evaluated in this 
study.
I4V-MC-JAIA(b) Clinical Protocol Page 71
LY300910410.Statistical Considerations
10.1.Sample Size Determination
Study JAIAwill aim to enroll  approximately  750patients ≥18 years of age in a 1:1:1 ratio 
between baricit inib 4-mg, 2-mg, and placebo .  The proposed samples size will ensure >90% 
power to detect an abso lute difference of 17% between a baricit inib treatment group an d the 
placebo treatm ent group assuming a 40% placebo response rate for the primary  endpoint using a 
2-sided αof 0.05.  The ant icipated effect size represents a clinically relevant difference.
An additional 10% (75 pati ents) may be enrolled due to COVID -19related trial impacts.
Sample size and power estimates were obtained from nQuery ® Advisor 7.0 using the χ2testof 
equal proportions.
I4V-MC-JAIA(b) Clinical Protocol Page 72
LY300910410.2.Populations for Analyses
For purposes of analysis, the following populat ions are defined as outlined in TableJAIA.5.
TableJAIA.5. Analysis Populations
Population Description
Modified Intent -to-Treat (mITT)
PopulationAll patients who are randomized and receive at least [ADDRESS_1156034] and who did not discontinue from the study for
the reason ‘Lost to Follow -up’at the first postbaseline visit. Patients will be
analyzed according to the investigational product to which they were
randomized.
10.3.Statistical Analyses
10.3.1.General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly or its designee.A detailed 
SAP describing the statist ical methodol ogies will be developed by  [CONTACT_47551] i ts designee.
Efficacyand safety analyses will be conducted on the mITT and safet y populations, respectively,
as described in in TableJAIA.5.
All tests of treatment effects will be conducted at a [ADDRESS_1156035] ification for making the change, will be described 
in the clinical study report.  Addit ional exploratory analyses of the data will be conducted as 
deemed appropri ate.  Complete details o f the planned analyses will be documented in the SAP.
For all analyses, Week 52 is considered to be equivalent to Visit 16, even if the timing of Visit 
16 was not within the protocol defined window.
[IP_ADDRESS]. Analysis Methods
Treatment comparisons of categorical efficacy and healt h outcomes variables will be made using 
a logistic regressio n analysis wit h Firth correction (Firth 1993; Heinze and Schemper 2 001).  
Baseline disease act ivity (total SLEDAI-2K<10; ≥10), baseline corticosteroid dose 
(<10mg/day; ≥10mg/day prednisone or equivalent) , region, and treatment group will be 
explanatory  variablesin the model. The p-value and 95% (unless otherwise spec ified) 
confidence interval (CI) for the odds ratio from the logist ic regressio n model will be used for 
I4V-MC-JAIA(b) Clinical Protocol Page 73
LY3009104primary statistical inference. The difference in percentages and 95% CI of the difference in 
percentages using the Newcombe -Wilson method without contin uity correction will beused for 
descriptive purposes, unless otherwise specified. Missing data will be imputed using 
nonresponder imputation (NRI), as described in Section [IP_ADDRESS].
The primary  analyses for all cont inuous efficacy and healt h outcome variables will use a 
restricted maximum likelihood -based mixed model for repeated measures (MMRM) analysis. 
The model will include treatment, baseline disease activit y (total SLEDAI-2K <10; ≥10), 
baseline corticosteroid dose (<10 m g/day; ≥10mg/day prednisone or equivalent) , region, visit, 
treatment-by-visit interaction as fixed categorical effects, and baseline value and baseline 
value-by-visit interact ion as fixed cont inuous effects to estimate change fro m baseline across 
postbaseline visits. The following covariance structures will be used to model the between -and 
within-patient errors: unstructured, heterogeneous Toeplitz, heterogeneous autoregressi ve, 
autoregressive (1), and heterogeneous compound symmetry.  The variance -covariance structure 
that results in the smallest Akaike informat ion criterion (AIC) will be used.   The Kenward -Roger 
method will be used to estimate the deno minator degrees of free dom. Type III tests for the 
least-squares (LS) means will be used for the statistical co mparisons. The LS m ean difference, 
standard error, p -value, and CIs will also be reported. Treatment group comparisons at specific 
study visits will be tested using the t-test obtained fro m the MMRM results.   Additional details 
of the MMRM method are described in Sect ion10.3.1.2.
Treatment comparisons of continuous efficacy and health outcome variables may also be made 
using analysis o f covariance (ANCOVA) .  This method m ay be usedwhen no repeated mea sures 
are collected (e.g., SLICC/ACR), or as a sensit ivity method to MMRM . Treatment, baseline 
disease activity (total SLEDAI-2Kat screening <10; ≥10), baselinecorticosteroi d dose 
(<10mg/day; ≥10mg/day prednisone or equivalent ), region, and baseline value will be included 
in the model. Type III tests for LS means will be used for statistical co mparison between 
treatment groups. The LS m ean difference, standard error, p -value, and 95% CI may also be 
reported. Any methods used to handle missing data will be specified in the SAP.
Time to first flare will be analyzed using a Cox proportional hazards model w ith treatment 
group,baseline disease act ivity (SLEDAI -2K <10; SLEDAI -2K ≥10), baseline corticosteroid 
dose (<10 mg/day; ≥10mg/day prednisone or equivalent) , and regionfitted as explanatory  
variables.  Hazard ratios, 95% CI and p -values will be presented for treatment comparisons to 
placebo.  Pati ents who discont inue treatment early will be censored at the time of last dose of the 
study drug.
Missing data for patients who have COVID -19-related issues (that are not related to an adverse 
event of COVID -19 infection) may be imputed using alternat ive method, based on consultation 
with regulatory bodies,as appropriate.  Specific imputation methodologies, for this subgroup of 
patients, will be detailed in the SAP prior to the primary  endpoint database l ock.
TheFisher exact test will be used for the AEs, discontinuat ions, and other categorical safet y data 
for between -treatment group com parisons.  Continuous vital signs, body  weight, and other 
continuous safet y variables including laboratory  variables will be ana lyzed by [CONTACT_832705] 
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156036] categorical safet y analyses (for 
example, “high”or “low”laboratory results) will also be produced.
[IP_ADDRESS]. Missing Data Imputation
As with any clinical study , patient dropou ts and consequent ly missing data areexpected.
Patients who discont inue treatment, unless they withdraw consent, will be encouraged to rem ain 
in the study  and follow the scheduled visits until the p rimary analysis t ime point at Week 52to 
provide the efficacy  and safet y data needed.  While every  effort will be made to reduce missing 
data, the missing data imputation metho ds described below will be used to provide a 
conservative approach for assessing efficacy endpo ints when patients hav e missing data.
The following imputati on rules will be used:
Nonresponder imputation (NRI) : For analysis o f categorical efficacy  and health 
outcomes variables such as SRI -4, missing data will be imputed using an NRI method.  
Patients who discont inue treatment early, increase use of corti costeroids above the 
baseline dose other than the permitted burst, as defined in the SAP , or have init iation of 
or an increase above baseline dose in immunosuppressant or antimalarial treatment ,as 
defined in the SAP ,any time after baseline will be defined as nonresponders. In some 
circumstances, due to COVID -[ADDRESS_1156037] the 
discontinued medicat ions.  These medicat ion changes may not define patients as 
nonresponde rs.
Mixed-model repeated measure (MMRM) :  For continuous variables, the primary analysis 
will be a MMRM analysis wit h a missing at random assumpt ion for handling missing 
data.  This analysis takes into account both missingness of data and the correlat ion of the 
repeated m easurements.  For pati ents who increase use of corticosteroids above the 
baseline dose other than the permitted burst, as defined in the SAP , or have init iation of 
or an increase above baseline dose in immunosuppressant or antimalarial treatment,as 
defined in the SAP ,any time after baseline, any observed data after that visit will be 
excluded fro m the MMRM analysis.  Observed data after permanent discont inuation o f 
investigat ional product will be analyzed as observed, with the exception of any data that 
occur after i ncreaseinuse of corticosteroids above the baseline dose other than the 
permitted burst , or initiation of or an increase above baseline dose in immunosuppressant 
or antimalarial treatment.In some circumstances, due to COVID -[ADDRESS_1156038] the discontinued medicat ions.  For these specific 
COVID-19 cases, data will be treated as observed.
I4V-MC-JAIA(b) Clinical Protocol Page 75
LY3009104Tippi[INVESTIGATOR_18275] :  Various “t ippi[INVESTIGATOR_11300]” analyses will be performed to evalua te 
the robustness of statist ical analyses for different object ives/estimands to the assumpt ions 
about missing data mechanism. This will be implemented by [CONTACT_832706] (del tas) quantifying the degree of departure from the missingness 
at random (MAR) assumpt ion by [CONTACT_832707]/or improving the imputed outcomes for patients treated with 
placebo.The tippi[INVESTIGATOR_832667] a loss of statistical significance when evaluat ing baricitinib 
relative to placebo. Additional details o f the tippi[INVESTIGATOR_832668].
Missing data for patients who have COVID -19-related issues (that are not related to an adverse 
event of COVID -19 infection) may be imputed using alternat ive methods, based on consultat ion 
with regulatory bodies,as appropriate.  Specific imputation methodologies, for this subgroup of 
patients, will be det ailed in the SAP prior to the primary endpo int database lock.
Sensitivity analyses that include all rando mized patients, including pat ients who did not receive 
any dose of invest igational product, will be performed on the primary  and select secondary  
outcome measures, if appropriate.  Addit ional sensitivity analyses, including addit ional methods 
of handling missing data or analyzing the data, that may  be required to sati sfy regulatory  needs 
will be specified in the SAP.
[IP_ADDRESS]. Multiple Comparisons/Multiplicity
Multiplicity-controlled analyses will be performed on the primary  and major secondary  
endpoints in order to control the overall family -wise Type I error rate at a 2 -sided α level of 0.05. 
The graphical mult iple testing procedure described in Bretz et al. (2011) will be used. The 
graphical approach is a closed testing procedure ;hence,it strongly controls the familywise error 
rate across all endpo ints (Alosh et al. 2014).  Details of the g raphical testing scheme (including 
testing order, interrelat ionships, Ty pe I error allo cation, and the associated propagation) are 
included below (see FigureJAIA.2).  The final graphical testing scheme will be prespecified in 
the SAP.
The following is a list of primary  and major secondary  objectivesto be tested :
Primary: Proportion of patients treated wi th baricitinib 4 -mg QD compared to placebo 
achieving SRI -4 response at Week 52.
Major Secondary :
Proportion of patients treated with baricit inib 4-mg QD compared to placebo 
achieving an SRI -4 response at Week 24.
Proportion of patients treated with baricit inib 4-mg QD compared to placebo 
receiving >7.5 mg prednisone (or equivalent) at baseline able to decrease dose by 
≥25% to a prednisone equivalent dose of ≤7.5 mg/day  maintained between 
Week40 and Week 52.
I4V-MC-JAIA(b) Clinical Protocol Page 76
LY3009104Time to first severe flare (through Week 52) for patients treated with baricit inib 
4-mg QD compared to pl acebo.
Proportion of patients treated with baricit inib 4-mg QD compared to placebo 
achieving an LLDAS response at Week 52.
Change from baseline in Worst Pain NRS at Week 52 for patients treated with 
baricitinib 4-mg QD co mpared to placebo 
Change from baseline in FACIT-Fatigueat Week 52 for patients treated with 
baricitinib 4-mg QD co mpared to placebo
Proportion of patients treated with baricit inib 2-mg QD compared to placebo 
achieving an SRI -4 response at Week 52.
Proportion of patients treated wi th baricitinib 2-mg QD compared to placebo 
achieving an SRI -4 response at Week 24.
Proportion of patients treated with baricit inib 2-mg QD compared to placebo 
receiving >7.5 mg prednisone (or equivalent) at baseline able to decrease dose by  
≥25% to a prednisone equivalent dose of ≤7.5 mg/day maintained between 
Week40 and Week 52.
Time to first severe flare (through Week 52) for pat ients treated with baricit inib 
2-mg QD compared to placebo.
Proportion of patients treated with baricit inib 2-mg QD compared to pl acebo 
achieving an LLDAS response at Week 52.
Change from baseline in Worst Pain NRS at Week 52 for patients treated with 
baricitinib 2-mg QD co mpared to placebo 
Change from baseline in FACIT-Fatigueat Week 52 for pat ients treated wi th 
baricitinib 2-mg QD co mpared to placebo
The sequent ially rejective, weighted Bonferroni mult iple testing procedure is completely 
specified by [CONTACT_832708] ( FigureJAIA.2).
I4V-MC-JAIA(b) Clinical Protocol Page 77
LY3009104Abbreviations:  CFB = change from baseline; LLDAS = Lupus Low Disease Activity 
State; SRI -4 = System Lupus Erythematosus Responder Index -4; TTE = time to event; 
W = week
Note:  All tests are 4 -mg compared to placebo unless otherwise specified.  Testing for 
baricitinib 2 -mg (compared to placebo) will occur in the same order as those 
prespecified for the [ADDRESS_1156039] Pain
w52 CFB
FACIT -F
w52 CFB
2mg
SRI-4 
w521.0α=0.05
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156040] be tested at α =0.05.  If the null hypothesis is not rejected, no 
further testing is conducted, as the α for that test is considered “spent” and cannot be passed to 
other endpoints.  If the null hypothesis is rejected, all α will be propagated to the next 
objective(s).  The testing process continues, with α propagated according to the weights on the 
corresponding edges displayed in FigureJAIA.2, as long as there i s at least one hypothesis that 
can be rejected at its allocated α level.  Each time a hy pothesis is rejected, the graph is updated to 
reflect the realloca tion of α, which is considered “recycled” by [CONTACT_487099]. (2014).  This iterative 
process of updat ing the graph and reallo cating α is repeated until all hypotheses have been tested 
or when no remaining hypotheses can be rejected at their corresponding α le vels.
10.3.2.Treatment Group Comparability
[IP_ADDRESS]. PatientDisposition
A detailed description o f patient disposition by [CONTACT_832709].  Frequency  counts and percentages will be presented for each treatment group.  
All patients who di scontinue from the study will be identified, and the extent of their 
participation in the study will be reported along with their reason for discont inuation.
[IP_ADDRESS]. Patient Characteristics
Demographic and baseline characterist ics will be summarized descript ively by [CONTACT_1570]. 
Descriptive statistics including number of patients, mean, standard deviat ion, median, minimum, 
and maximum will be provided for continuous measures, and frequen cy counts and percentages 
will be tabulated for categorical measures. No formal statist ical comparisons will be made 
among treatm ent groups unl ess otherwi se stated.  A complete list of patient characterist ics and 
baseline clinical measures will be provided in the SAP.
[IP_ADDRESS]. Concomitant Therapy
Concomitant medicat ions will be coded and descriptively  summari zed by [CONTACT_832710]. 
[IP_ADDRESS]. Treatment Compliance
Compliance withinvestigational product treatment for baricitinib and placebo will be assessed 
through counts of returned investigational product tablets.  A patient will be considered 
significantly noncompliant if he or she misses more than 20% of the prescribed doses during the 
study, that is,compliance <80%. Similarly, a patient will be considered significantly 
noncompliant if he or she is judged by  [CONTACT_487091].
10.3.3.Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The primary efficacy measure is SRI -4 response (defined in Sect ion9.1.1).  A logistic regressio n 
model with Firth correcti on (as described in Section10.3.1.1) will be used to test the treatment 
difference between baricit inib 4-mg and placebo in the proportion of pat ients achieving SRI-4
response at Week 52.  Missing data will be imputed using the NRI method described in
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156041] COVID -19-related issues (that are not 
related to an adverse event of COVID -19 infection) may be imputed using alternative method , 
based on consultation wi th regulatory bodies,as appropriate.  Specific imputation 
methodol ogies, for thi s subgroup of pat ients, will be detailed in the SAP prior to the primary 
endpoint database lock.
[IP_ADDRESS]. Major Secondary Analyses
The major secondary  comparisons will be based on the multiple testing procedure detailed in 
Section10.3.1.3.
Treatment comparisons in the proportion of pat ients achieving a binary response will be 
analyzed using logist ic regressio nwith Firth correcti on.  Treatment comparisons in the 
continuous measures will be analyzed using MMRM.  Treatment comparisons for t ime to first 
flare will be analyzed using a Cox proportional hazards model.  These methods ar e described in 
Section10.3.1.1.  Missing data for the binary  outcome measures will be imputed using the NRI 
method described in Section10.3.1.2.  Missing data for patients who have COVID -19-related 
issues (that are not related to an adverse event of COVID- 19 infection) may be imputed using 
alternative method, based on consultat ion with regulatory bodies as appropri ate.  Specific 
imputation methodologies, for thi s subgroup of patients, will be detailed in the SAP prior to the 
primary endpoint database lock.
[IP_ADDRESS]. Other Secondary and Exploratory Analyses
There will be no adjust ment for multiple comparisons.  Analyses will be conducted for the other 
secondary  and exploratory objectives, which include healt h outcomes, defined in Section9.1.1. 
The analysis methods will generally fo llow those specified in Sect ion10.3.1.1. Specific details 
of analyses will be specified in the SAP.
10.3.4.Safety Analyses
All safety data will be summarized by  [CONTACT_832711] y population.  
Safety assessments will include AEs, laboratory  analytes, vital signs, and questionnaires to 
assess the existence and severit y of depressio n.  Analyses will focus on comparisons of 
baricitinib to placebo, using the safet y analysis methods described in Sect ion10.3.1.1.
[IP_ADDRESS]. Adverse Events
Adverse events are classified based upon the Medical Dict ionary for Regulatory Activities 
(MedDRA). Treatment -emergent adverse events are defined as AEs that first occurred or 
worsened in seve rity on or after the date of the first dose of invest igational product. The number 
of TEAEs as well as the number and percentage of patients who experienced at least 1 TEAE 
will be summarized using MedDRA for each system organ class (or a body  system) andeach 
preferred term by [CONTACT_1570]. For events that are gender -specific, the deno minator and 
computati on of the percentage will only include patients from the given gender.
Serious adverse events (including deaths ), treatment-emergent AESIs, and AEs that lead to 
investigat ional product discontinuation or interruptio nwill also be summarized using MedDRA 
for each system organ class and each preferred term by [CONTACT_1570].   Potential AESIs will be 
I4V-MC-JAIA(b) Clinical Protocol Page 80
LY3009104identified by a standardized MedDRA query or a Lilly -defined MedDRA query .  Details of the 
AESIs (listed in Sect ion9.2.2) and other events of interest and analysis methods will be 
documented in the SAP or program safet y analysis plan. 
[IP_ADDRESS]. Clinical Laboratory Tests
All clinical laboratory  results will be descriptively summarized by [CONTACT_1570].  Individual 
results that are outside the norm al reference ranges will be flagged in data list ings.  Quant itative 
clinical hematology , chemistry , and urinalysis variables obtained at the baseline to postbaseline 
visits will be summarized as changes fro m baseline.  Categorical variables , including the 
incidence of abnormal values and incidence of AESIs, will be summarized by [CONTACT_832712].  Shift tables will be presented for selected 
measures.
[IP_ADDRESS]. Vital Signs, Physical Findings, and Other Sa fety Evaluation
Observed values and changes fro m baseline (predose or screening if missing) for vital signs and 
physical characteristics, and other continuous safety measures will be descript ively summarized 
by [CONTACT_832713].  Shift tables will be presented where appropriate .
Summary  tables or list ings for the C-SSRSand the Self -Harm Supplement Form  will be 
produced as needed.
The incidence, duration, and reasons of invest igational product interruptions will be summarized 
and compared desc riptively amo ng treatment groups.
Further analyses may  be perform ed and will be planned in the SAP.
10.3.5.Pharmacokinetic/Pharmacodynamic Analyses
All plasma baricit inib concentration -time data will be pooled and evaluated using populat ion PK 
methods.  A covariate screen of patient and study -specific factors will be included in the analyses 
based on factors investigated in previous and (if any) ongoing PK analyses, and on their 
relevance to the target populat ion.  Exploratory and/or m odel-based analyses ex amining the 
relationships between baricit inib exposure and efficacy and response endpoints will be 
conducted.  Other analyses of efficacy and safet y outcome measures m ay also be assessed as 
scientifically appropriate and warranted by [CONTACT_339583].  Detai ls about the analyses to be 
conducted will be contained in the PK/PD analysis plan.
10.3.6.Interim Analyses
A data monitoring committee (DMC) will oversee the conduct of all the Phase [ADDRESS_1156042] of members external to Lilly.  
This DMC will fo llow the rules defined in the DMC charter, focusing on potential and ident ified 
risks for thi s molecule and for this class of compounds.  Data monitoring committee membership 
will include, at a minimum, specialists with expertise in rheumatology , statistics, and other 
appropriate specialt ies.  This DMC for studies of patients with SLE maybe coordinated with the 
DMC(s) for other ongoing studies o f baricitinib in other indicat ions.Details of the DMC will be 
documented in a DMC charter.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156043] to review efficacy data to 
investigate the benefi t/risk relationship in the context of safet y observations for ongoing patients 
in the study .  
In addition to the planned safet y-related interim analyses, interim efficacy  analyses may be 
conducted pri or to com pletion of the study .  Usingpredefined thresho lds, the trial may be 
stopped if the probabilit y of the trial meeting its primary  efficacy endpoint falls below an 
acceptable level.  The DMC charter will describe the precise decisio n guidelines governing the 
interim analyses.  The tria l will not be stopped for posit ive efficacy; therefore, no alpha 
adjustment is needed.
In addition to the DMC members, a limited number of pre -identified individuals may  gain access 
to the limited unblinded data, as specified in the unblinding plan, prior to the final database lock, 
in order to init iate the popul ation PK/PD m odel development processes.  These analyses will not 
be considered interim analyses.  Information that may unblind the study  during the analyses will 
not be reported to study  sites or blinded study  team until the study  has been unblinded.
I4V-MC-JAIA(b) Clinical Protocol Page 82
LY300910411.References
Alarcón GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, Bastian HM, 
Friedman AW, Reveille JD. Sy stemic lupus ery thematosus in three ethnic groups. IX. 
Differences in damage accrual. Arthritis Rheum . 2001;44(12):2797-2806.
Alosh M, Bretz F, Huque M. Advanced mult iplicity adjustment methods in clinical tri als. 
StatMed. 2014;33(4):[ADDRESS_1156044].Clair W . 
Measurement of fatigue in systemic lupus ery thematosus: a sy stematic review. Arthritis 
Rheum. 2007;57(8):1348 -1357.
Brazier JE, Harper R, Jones NM, O’ Cathain A, Thomas KJ, Usherwood T, West lake L. 
Validating the SF -36 health survey questionnaire: new outcom e measure for primary  care. 
BMJ. 1992;305(6846):160-164.
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially reject ive 
multiple test procedures. Stat Med. 2009;28(4):586 -604.
Bruce IN, O’Keeffe AG, Farewell V, Hanly  JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez -
Guerrero J, Romero -Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, 
Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Petri M, Steinsson K, 
Dooley MA, Khamashta MA, Ramsey -Goldman R, Zom a AA, Sturfelt GK, Nived O, Aranow 
C, Mackay  M, Ramos-Casals M, van Vo llenhoven RF, Kalunian KC, Ruiz -Irastorza G, Lim S, 
Kamen DL, Peschken CA, Inanc M, Urowitz MB . Factors associated with damage accrual in 
patients with systemic lupus ery thematosus: resul ts from the Systemic Lupus International 
Collaborating Clinics (SLICC) Incept ion Cohort. Ann Rheum Dis. 2015;74(9):1706 -1713.
Cella D, Webster K. Linking outcomes manageme nt to quality-of-life measurement. Oncology
(Williston Park) . 1997;11(11A):[ADDRESS_1156045].Clair EW, Gilkeson GS, Dooley MA. Sociodemographic 
associations with early disease damage in pat ients with systemic lupus ery thematosus. 
Arthritis Rheum. 2007;57(6):[ADDRESS_1156046] ion risk in systemic lupus ery thematosus pati ents: suscept ibility 
factors and preventative strategies. Lupus. 2013;22(12):1286- 1294.
Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beatti e S, Witt S, de 
la Torre I, Gaich C, Rooney  T, Schlicht ing D, de Bono S, Emery P. Baricit inib in patients with 
inadequate response or intolerance to convent ional synthet ic DMARDs: results fro m the 
RA-BUILD study . Ann Rheum Dis . 2017;76(1):88 -95.
[EMA] European Medicines Agency. ICH E9 (R1) addendum on est imands and sensit ivity 
analysis in clinical trials to the guideline on statist ical principles for clinical trials. Step 2b ; 
2017.EMA/CHMP/ICH/436221/2017.
[EMA] European Medicines Agency. Guidance on clinical investigation o f medicinal products 
for the treatm ent of systemic lupus ery thematosus and lupus nephrit is; 2015.
I4V-MC-JAIA(b) Clinical Protocol Page 83
LY3009104The EuroQol Group. EQ -5D-5L User Guide. Version 2.1. April 2015. Available at:
https://euroqol.org/wp -content/uploads/2016/09/EQ -5D-5L_UserGuide_2015.pdf . Accessed 
April 10 2018.
[FDA] Food and Drug Administration. Guidance for Industry  Systemic Lupus Ery thematosus –
Developi[INVESTIGATOR_153165]; 2010.
[FDA] Food and Drug Administration. Benlysta Prescr ibing Informat ion, 2012. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125370s016lbl.pdf . Accessed 
April 10, 2018.
Firth D. Bias reduction of maximum likelihood estimates. Biometrika . 1993;80(1):27 -38.
Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spi[INVESTIGATOR_172360] A, Stanislav M, Zerbini 
CA, Gurbuz S, Dickson C, de Bono S, Schlicht ing D, Beattie S, Kuo WL, Rooney  T, Macias 
W, Takeuchi T. Baricit inib, methotrexate, or combinat ion in patients with rheumatoi d arthritis 
and no or limited prior d isease-modifying ant irheumatic drug treatment. Arthritis Rheumatol . 
2016. Doi: 10.1002/art.[ADDRESS_1156047] S, Rodgers JD, Yeleswaram S, Hollis 
G, Newton RC, Metcalf B, Friedman SM, Vaddi K . Selective inhibition of JAK1 and JAK2 is 
efficacious in rodent models of arthritis: preclinical characterizat ion of INCB028050. J 
Immunol. 2010;184(9):5298 -5307.
Friedewald WT, Levy RI, Fredrickson DS. Estimatio n of the concentration of low -density 
lipoprotein cho lesterol in plasma, wi thout use of the preparative ultracentrifuge.   Clin Chem . 
1972 Jun;18(6):499-502.
Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei G G, Drappa J, 
Wang L, Yoo S, CD1013 Study  Investigators. Anifro lumab, an ant i-interferon-α receptor 
monoclonal antibody , in moderate-to-severe systemic lupus erythematosus. Arthritis 
Rheumatol . 2017;69(2):376 -86.
Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beatti e SD, Koch AE, 
Cardillo TE, Rooney  TP, Macias WL, de Bono S, Schlicht ing DE, Smolen JS. Baricit inib in 
patients with refractory rheumatoi d arthritis. N Engl J Med . 2016;374(13):1243 -1252.
Guttman-Yassky E, Silverberg JI, Nem oto O,Forman SB, Wilke A, Prescilla R, de la Pena A, 
Nunes FP, Janes J, Gamalo M, Donley D, Paik J, DeLozier AM, Nicko loff BJ, Simpson EL.  
Baricitinib in adult patients with moderate -to-severe atopic dermat itis:  A phase 2 parallel, 
double-blind, rando mized, placebo-controlled, multiple -dose study . J Am Acad Dermatol . 
2018; [epub ahead of print].   Available at: http://dx.doi.org/10.1016/j.jaad.2018.01.018
Heinze G ,Schemper M. A so lution to the problem of monotone likelihood in Cox regression. 
Biometrics . 2001;57(1):114 -119.
Hochberg MC, for the Diagnostic and Therapeut ic Criteria Committee of the American College 
of Rheumatol ogy. Updating the American College of Rheumatology  revised criteria for the 
classification of systemic lupus ery thematosus [l etter]. Arthritis Rheum . 1997;40:1725.
Hoffman RW , Merrill JT, Alarcόn -Riquelme MM, Petri  M, Dow ER, Nantz E, Nisenbaum LK, 
Schroeder KM, Ko mocsar WJ, Perumal NB, Linnik MD, Airey DC, Liu Y, Rocha GV, Higgs 
I4V-MC-JAIA(b) Clinical Protocol Page 84
LY3009104RE. Gene expressio n and pharmacodynamic changes in 1,760 sy stemic lupus erythematosus 
patients from two phase III trials of BAFF blockade with tabalumab. Arthritis Rheumatol . 
2017;69(3):643- 654. 
IlleiGG, Shirota Y, Yarboro CH, Daruwalla J, Tackey  E, Takada K, Fl eisher T, Balow JE, 
Lipsky PE. Data on safety , preliminary  efficacy, and impact on circulating plasma cells from 
an open-label phase I dosage -escalation study. Arthritis Rheum . 2010;62(2):542 -552.
Kaslow RA. High rate of death caused by [CONTACT_832714] U.S. resi dents of 
Asian descent . Arthritis Rheum . 1982;25(4):[ADDRESS_1156048] C. The incidence and 
prevalence o f systemic lupus ery thematosus, 2002 -2004: The Georgia Lupus Registry .
Arthritis Rheum . 2014;66(2):357 -368.
Linker-IsraeliM, Wallace DJ, Prehn J, Michael D, Honda M, Taylor KD, Paul -Labrador M, 
Fischel-Ghodsian N, Fraser PA, Klinenberg JR. Association o f IL-6 gene alleles with systemic 
lupus erythematosus (SLE) and with elevated IL -6 expressio n. Genes and Immunity . 
1999;1:[ADDRESS_1156049] ivities in systemic lupus 
erythematosus. Agri.2015;27(4):181 -189.
Papp KA, Menter MA, Raman M, Disch D, Schlicht ing DE, Gaich C, Macias W, Zhang X, Janes 
JM. A rando mized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, 
in patients with moderate -to-severe psoriasis. Br J Dermatol . 2016;174(6):1266-1276.
Reilly MC, Zbrozek AS, Dukes EM. The validit y and reproducibilit y of a work productivit y and 
activity impairment instrument. PharmacoEconomics 1993;4(5):353 -365.
GA, Reinhardt A, RamseyS, WittkowskiH, HashkesPJ, BerkunY, SchalmS, Murias
Montealegre Sanchez S, DareJA, BrownD, StoneDL, GaoL, Klausmeier T, FoellD, de 
JesusAA, Chapelle DC, KimH, DillS, Colbert R, FaillaL, KostB, O'BrienM, ReynoldsJC, 
FolioLR, CalvoKR, PaulKM, Weir N, Brofferio A, SoldatosA, Biancotto A, CowenEW, 
DigiovannaJG, GadinaM, LiptonAJ, HadiganC, Holland SM, Fontana J, Alawad AS, Brown
RJ, RotherKI, HellerT, BrooksKM, KumarP, BrooksSR, Waldman M, SinghHK, Nickeleit
V, SilkM, Prakash A, JanesJM, Ozen S, WakimPG, BroganPA, MaciasWL, and Goldbach-
ManskyR.  JAK1/2 inhibit ion with baricitinib in the treatment of autoinflammatory  
interferonopathi es. J Clin Invest2018; Epub ahead of print .
Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P, Gordon C, Helmick CG, Wang L, 
Wing JJ, Dhar P, Leisen J, Shalt is D, McCune WJ. Populat ion-based incidence and prevalence 
of systemic lupus ery thematosus. Arthritis Rheum . 2014;66(2):369 -378.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, 
Winchester RJ. The 1982 revised criteria for the classificat ion of systemic lupus ery thematosus. 
Arthritis Rheum. 1982;25(11):1271 -1277.
Taylor PC, K eystone EC, van der Heijde D, Weinblatt ME, del Carmen Morales L, Gonzaga JR, 
Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney  T, Schlichting D, Macias 
W, de Bono S, Tanaka Y. Baricit inib versus placebo or adalimumab in rheumatoid arthrit is.  
I4V-MC-JAIA(b) Clinical Protocol Page 85
LY3009104Tuttle KR, Brosi us FC III, Adler SG, Kretzler M, Mehta RL, Tumlin JA, Liu J, Silk ME, 
Cardillo TE, Duffin KL, Haas JV, Macias WL, Janes JM. Baricit inib in diabet ic kidney 
disease: results fro m a phase 2, mult icenter, randomized, double -blind, placebo-controlled 
study [abstract]. In: American Diabetes Associat ion 75thScientific Sessio ns; 2015 June 5- 9; 
[LOCATION_011] (MA). Diabetes. 2015;64(Suppl 1A). Abstract 114 -LB.
UpToDate resource page.  Epi[INVESTIGATOR_832669]. 
2018.Available at: https://www.uptodate.com/contents/epi[INVESTIGATOR_145975]-and-pathogenesis -of-
systemic-lupus-
erythematosus?source=search_result&search=epi[INVESTIGATOR_145975]+and+pathogensis+of+systemic+l
upus&selectedTit le=1%7E150#H1. Accessed April 10, 2018.
Ware JE Jr, Sherbou rne CD. The MOS 36- item short-form health survey (SF-36), I: Conceptual 
framework and item select ion. Med Care . 1992;30(6):473 -483.
Yu T, Eni outina EY, Brunner HI, Vinks AA, Sherwin CM. Clinical pharmacokinet ics and 
pharmacodynamics of bio logic therapeut ics for treatment of systemic lupus ery thematosus. 
Clin Pharmacokinet . 2017;56(2):107 -125.
Yurkovich M, Vostretsova K, Chen W, Avina -Zubieta JA. Overall and cause -specific m ortality 
in patients with systemic lupus ery thematosus: a meta -analysis of observat ional studies. 
Arthritis Care Res . 2014;66(4):608 -616.
I4V-MC-JAIA(b) Clinical Protocol Page 86
LY300910412.Appendices
I4V-MC-JAIA(b) Clinical Protocol Page 87
LY3009104Appendix 1. Abbreviations and Definitions
Term Definition
ACR American College of Rheumatology
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporall y associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
AESI Adverse events of special interest
AGS Aicardi-Goutières Syndrome
ALP alkaline phosphatase
ALT alanine aminotransferase
ANA antinuclear antibody
ANC absolute neutrophil count
ANCOVA analysis of covariance
AST aspartate aminotransferase
BILAG British Isles Lupus Assessment Group
blinding/masking A double-blind study is one in which neither the [patient/subject]nor any of the 
investigator or sponsor staff who are involved in the treatment or clinical evaluation of 
the subjects are aware of the treatment received .
CANDLE Chronic atypi[INVESTIGATOR_832670] e
BPI [INVESTIGATOR_832671] (assay or test) that provides information that is essential for 
the safe and effective use of a corresponding therapeutic product
I4V-MC-JAIA(b) Clinical Protocol Page 88
LY3009104complaint A complaint is any written, electronic, or oral communication th at alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
CRP clinical research physician : Individual responsible for the medical conduct of the s tudy.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician or other medical officer.
CSR clinical study report
C-SSRS Columbia -Suicide Severity Rating Scale
COVID-[ADDRESS_1156050]
FACIT Functional Assessment of Chronic Illness Therapy -Fatigue
GCP good clinical practice
GPS Global Patient Safety
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
I4V-MC-JAIA(b) Clinical Protocol Page 89
LY3009104HCV hepatitis C virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IFN interferon
Ig immunoglobulin
IL interleukin
interim analysis An interim analysis is an analysis of clinical studydata, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
IL interleukin
investigational product Apharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial , including products already on the market when used or 
assembled (formulated or packaged) in a way different from the a uthorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
IRB institutional review board
ITT intention to treat : The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a patient (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients alloca ted to a treatment group should be followed up, assessed ,
and analyzed as members of that group irrespective of their compliance to the planned 
course of treatment.
IUD intrauterine device
IVRS/IWRS interactive voice -response sy stem/interactive web -response system
JAK Janus kinase
JDM juvenile dermatomyositis
LLDAS Lupus low disease activity state
LS least squares
LTE long-term extension
MACE major adverse cardiovascular events
MCS mental component score
MDRD Modification of Diet in Renal Disease
I4V-MC-JAIA(b) Clinical Protocol Page 90
LY3009104MedDRA Medical Dictionary for Regulatory Activities
MI myocardial infarction
mITT modified intent -to-treat population
MMRM mixed model for repeated measures
MTX methotrexate
NRI nonresponder imputation
NRS Numeric Rating Scale
NSAID nonsteroidal anti -inflammatory drug
PCS physical component score
PE pulmonary embolism
PK/PD pharmacokinetics/pharmacodynamics
[COMPANY_003] purified protein derivative
PPS per-protocol set : The set of data generated by [CONTACT_832715], according to the underlying scientific model.
PRO patient-reported outcomes
PSAP program safety analysis plan
QD once daily
QIDS-SR16 Quick Inventory of Depressive Symptomatology
QTc corrected QT interval
RA rheumatoid arthritis
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SAVI Stimulator of Interferon Genes (STING) -Associated Vasculopathy With Onset During 
Infancy
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study. 
SF-36v2 Short-Form 36-item Health Survey version 2
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156051] of care
SRI-4 Systemic Lupus Erythematosus Responder Index-4
STAT signal transducers and activators of transcription
S[LOCATION_003]Rs suspected unexpe cted serious adverse reactions
TB tuberculosis
TBL total bilirubin level
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, which and does not necessarily have to have a causal 
relationship with this treatment.
TSH thyroid-stimulating hormone
TYK tyrosine kinase
ULN upper limit of normal
VAS Visual Analog Scale
VTE venous thromboembolic event
WPAI-Lupus Work Productivity and Activity Impairment -Lupus
I4V-MC-JAIA(b) Clinical Protocol Page 92
LY3009104Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Tests a
Hematologyb Clinical Chemistry b
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocyte count (RBC) Potassium
Absolute reticulocyte count Total bilirubin
Mean cell volume (MCV) Direct bilirubin
Mean platelet volume Alkaline phosphatase (ALP)
Mean cell hemoglobin (MCH)
Mean cell hemoglobin concentration (MCHC)Alanine aminotransaminase (ALT)/serum glutamic pyruvic 
transaminase
Leukocytes (WBC)
Absolute count ofAspartate aminotransferase (AST)/serum glutamic oxaloacetic 
transaminase 
Neutrophils, segmented Blood urea nitrogen (BUN)
Neutrophils, juvenile (bands) Creatinine
Lymphocytes Estimated glomerular filtration rate (eGFR)c
Monocytes Uric acid
Eosinophils Calcium
Basophils Glucosed
Platelets Albumin
Cell morphology Creatine phosphokinase (CPK)
Differential and blood smeareTotal protein
Iron studies (iron, TIBC, and ferritin)
Lymphocyte subsets (T, B, NK, and T cell 
subsets)
Lipid Profiled,f
Urinalysisb,n Total cholesterol
Color High-density lipoprotein cholesterol (HDL -C)
Specific gravity Low-density lipoprotein cholesterol (LDL -C)
pH Triglycerides 
Urine Protein
Glucose Other Tests
Ketones Serum pregnancy test (females only)g
Blood Urine pregnancy test (females only)g
Bilirubin Follicle-stimulating hormone (FSH) (females only)h
Urobilinogen Hepatitis B surface antigen ( HBsAg)
Leukocyte esterase Hepatitis B surface antibody ( HBsAb)
Nitrite Hepatitis B core antibody (HBcAb ), total
Microscopic examination of sedimentjHepatitis C antibodyi
Urine creatinine HBV DNAk
Urine protein HCV RNAi
Urine protein-creatinine ratio Human immunodeficiency virus ( HIV) serology
[COMPANY_003] or QuantiFERON® -TB Gold, or T -SPOT®.TBl
Thyroid-stimulating hormone (TSH)
I4V-MC-JAIA(b) Clinical Protocol Page 93
LY3009104Abbreviations:  dRVVT=Dilute Russell’s Viper Venom Time; dsDNA=double-stranded deoxyribonucleic acid;
HBV DNA = hepatitis B virus deoxyribonucleic acid; HCV RNA = h epatitis C virus ribonucleic acid ;
Ig=immunoglobulin; mRNA = messenger ribonucleic acid; PK = pharmacokinetics; [COMPANY_003]=purified protein 
derivative; RBC = red blood cells; TIBC = total iron binding capacity; WBC = white blood cells.
aAll labs will be assayed/calculated by a Lil ly-designated laboratory unless otherwise noted.
bUnscheduled blood chemistry hematology, and urinalysis panels may be perfor med at the discretion of the 
investigator.
ceGFR for serum creatinine will be calculated by [CONTACT_629304] (MDRD) isotope dilution mass spectrometry traceable method.
dFasting laboratory values for glucose and lipi[INVESTIGATOR_629275], Week s 12, 24, 36, and 52. Patients 
should not eat or drink anything except water for [ADDRESS_1156052] HDL -C, triglycerides, cholesterol, and LDL -C (calculation from Friedewald et al. 
1972).
gFor all women of child -bearing potential, a serum pregnancy test (central laboratory) will be performed at 
Visit1. Urine pregnancy tests (local laboratory) will also be performed at each subsequent study visit per the 
Schedule of Activities.
hFor female patients ≥50 and <[ADDRESS_1156053] will be performed to confirm non -child-bearing potential (FSH ≥40 mIU/mL ).
iA confirmatory test of HCV RNA will be performed if the patient is positive for HCV antibody.
jMicroscopic examination of sediment will be performed if abnormalities are noted on the routine urinalysis.
kHBV DNA testing will be performed in patients who tested positive for HBcAb at screening.
lIn countries where the QuantiFERON ®-TB Gold test or T -SPOT®is available, either test may be used instead of 
the [COMPANY_003] TB test.  The QuantiFERON ®-TB Gold test must be performed centrally; the T -SPOT®must be 
performed locally. See Exclusion Criterion [29 ] for details.
mInterferon signature [CONTACT_832719] .
nUrine should be collected as a clean catch sample.Autoantibodies Serum immunoglobulins ( IgG, IgA, IgM)
Anti-nuclear antibody ( ANA) Stored serum, plasma, urine, mRNAm, and DNA samples for 
exploratory biomarker analyses
Anti-double -stranded DNA (anti -dsDNA) 
antibodyBaricitinib plasma concentration (PK sample)
Anti-Smith Lupus anticoagulant (dRVVT)
Autoantibodies (anti-RNP, anti -Sm, 
anti-SSA/Ro, anti -SSB/La)ComplementC3 and C4
Anti-cardiolipin antibodies IgG, IgA, IgM Anti-beta2 glycoprotein -I (IgG, IgM)
I4V-MC-JAIA(b) Clinical Protocol Page 94
LY3009104Appendix 3. Study Governance Considerations
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156054] igator is responsible for:
ensuring that the patient understands the nature of the study , the potential 
risks and benefits of participat ing in the study , and that thei r participation is 
voluntary.
ensuring that i nformed consent i s given by [CONTACT_229204].  This includes obtaining the appropriate signatures and dates 
on the informed consent form (ICF) prior to the performance o f any protocol 
procedures and prior to the administration of invest igational product.
answering any quest ions the pati ent may have throughout the study  and 
sharing in a t imely manner any  new informat ion that may be relevant to the 
patient’s willingness to continue his or her participation in the study .
ensuring that a cop y of the ICF is provi ded to the participant or the 
participant’s legal representative and is kept on file.
ensuring that the medical record includes a statement that written informed 
consent was obtained before the participant was enrolled in the study  andthe 
date the written consent was obtained.  The authorized person obtaining the 
informed consent m ust also sign the ICF.
Appendix 3.1.[ADDRESS_1156055] (ERB) was properly  constituted and convened as requi red by [CONTACT_735501] (ICH) guidelines and other applicable laws and regulations.
Documentation of ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study may begin at the investi gative site(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP).
The study  site’s ERB(s) shoul d be provi ded with the following:
the protocol and related amendments and addenda, current Invest igator 
Brochure (IB) and updates during the course of the study
informed consent form
Other relevant documents (for example, curricula vitae, advertisements)
I4V-MC-JAIA(b) Clinical Protocol Page 96
LY3009104Appendix 3.1 .4.Regulatory Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
consensus ethics principles derived fro m international ethics guidelines, including 
the Declaration of Helsinki and CouncilforInternational Organizati onsof
MedicalSciences (CIOMS) Internati onal Ethical Guidelines
applicable ICH GCP Guidelines
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party.
Appendix 3.1.5. Investigator Information
Physicians wi th a specialt y in rheumatology  will participate as invest igators in this clinical trial.
Physicians with other specialt ies and experience in treatment of patients with systemic lupus 
erythematosus (SLE) m ay also parti cipate as investi gators.
Appendix 3.1.6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study.
After reading the prot ocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1.7. Final Report Signature
[CONTACT_314867](CSR) coordinating investigator [INVESTIGATOR_832672] f or this study , 
indicating agreement that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendix 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provide instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This
training will give instruction on the protocol, the complet ion of the CRFs, and 
study procedures.
make periodic visits to the study  site
be available for consultation and stay  in contact [CONTACT_129237], telephone, and/or fax
I4V-MC-JAIA(b) Clinical Protocol Page 97
LY3009104review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qual ity review of the database
In addition, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audited by [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the invest igator will pr ovide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
documents.
Appendix 3.2.1. Data Capture System
An electronic data capture sy stem will be used in this study .  The site maintains a separate source 
for the data entered by  [CONTACT_129238] -provided electronic data capture system.
Electronic pat ient-reported outcome (ePRO) measures (e.g., a rating scale) and electronic clinical 
outcome assessments (eCOAs) are entered into an ePRO/eCOA instrume nt at the time that the 
information is obtained.  In these instances where there is no prior written or electronic source 
data at the site, the ePRO/eCOA instrument record will serve as the source.
If ePRO/eCOA records are stored at a third party  site, investigator sites will have cont inuous 
access to the source documents during the study  and will receive an archival copy  at the end of 
the study for retention.
Any data for which the ePRO/eCOA data record will serve as source data will documented by  
[CONTACT_832716].
Case report form data collected by a third -party will be encoded by  [CONTACT_92364]-party and stored 
electronically in the third- party’s database system.  Validated data will subsequently be 
transferred to the sponsor’s data warehouse, usin g standard Lilly file transfer processes.
Data managed by  a central vendor, such as laboratory  test data, will be stored electronically  in 
the central vendor’s database system.  Data will subsequent ly be transferred fro m the central 
vendor to the Lilly dat a warehouse. 
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management sy stem.
I4V-MC-JAIA(b) Clinical Protocol Page 98
LY3009104Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study site participation may be discontinuedif Lilly or its designee, the investigator, or the ERB 
of the study  sitejudges it necessary for medical, safety, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for medical, safet y, 
regulatory, or other reasons consistent with applicable laws, regulat ions, and GCP.
The publicat ion policy for Study I4V-MC-JAIAis described in the Clinical T rial Agreement.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156056]
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti-smooth muscle antibody (or anti -actin antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normali zed 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssayed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I4V-MC-JAIA(b) Clinical Protocol Page 100
LY3009104Appendix 5. Monitoring Tests for Confirmed VTE
Selected tests m ay be obtained in the event of a confirmed venous thromboembo lic event(VTE)
and may be required in follow-up with patients in consultation wit h Eli Lillyand Company, its 
designee, or the Lilly  designated medical mo nitor.  The choi ce and optimal timing of these tests 
will be directed by  [CONTACT_102]’s m anagement and may require ongoing fo llow-up after study  
discontinuat ion.
Protein C Functional
Protein S Clottable
Antithrombin III
APC Resistance
PT
APTT
Fibrinogen
Cardiolipin Antibodies
PT Gene
Factor VIII C Assay
Hexagonal Phase Phospholipid Neutralization
C-Reactive Protein
PTT Incubated Mixing 
Dilute Russell Viper Venom 
Platelet Neutralization 
Factor V Leiden 
MTHFR 
Thrombin Time 
Reptilase 
Fibrinogen Antigen 
ProteinC Immunologic 
ProteinS Immunologic 
Heparin fXa Inhibition 
Abbreviations:  APC = activated protein C; APTT = activated partial thromboplastin time; MTHFR = methylene 
tetrahydrofolate reductase; PT = prothrombin time; PTT = partial thromboplastin time.
I4V-MC-JAIA(b) Clinical Protocol Page 101
LY3009104Appendix 6. Protocol A mendment I4V-MC-JAIA(b) 
Summary  -A Randomized, Double -Blind, 
Placebo- Controlled, Parallel -Group, Phas e 3 Study of 
Baricitinib in Patients with Sy stemic Lupus Ery thematosus
Overview
Protocol I4V-MC-JAIA,A Randomized, Double -Blind, Placebo-Controlled, Parallel -Group, 
Phase 3 Study  of Baricitinib in Patients with Systemic Lupus Ery thematosus, has been amended.  
The new protocol is indicated by  [CONTACT_61504] ( b) and will be used to conduct the study  in place 
of any preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are described in the 
following table. Editorial revisions with no impact on protocol design or implementation were 
also made.  These revisio ns are not noted in this protocol amendment summary  except where
contained in a se ction with substantive changes.
I4V-MC-JAIA(b) Clinical Protocol Page 102
LY3009104Amendment Summary for P rotocol I4V -MC-JAIA Amendment (b )
Section # and Name [CONTACT_19523] 1 –Synopsis Objectives and En dpoints
Section 4 -Objectives and En dpoints
Section 9.1.1 –Primary Efficacy Assessment SRI-4 response definition clarified by [CONTACT_3866] 
“or” with “and” in the following: “no new BILAG 
A andno more than [ADDRESS_1156057] a typographical error
Section 1 –Synopsis Number of Patients and 
Statistical Analysis
Section 10.1 –Sample Size Determination
Section [IP_ADDRESS] –Analysis Methods
Section [IP_ADDRESS] –Missing Data Imputation
Section [IP_ADDRESS] –Primary Efficacy Assessment
Section [IP_ADDRESS] –Major Secondary AnalysesAdded the possibility of enrolling 75 more patients 
and added an explanation of how missing data for 
COVID-19 impacted patients will be imputed.Updated patient number and statistical analysis to 
account for COVID -19 affected patients.
Section 1 –Synopsis Treatment Arms and Duration
Section 2 –Schedule of Activities
Section 5.1 –Overall Design
Section 7.8.1 –Study Extensions
Section 10.3.1 -General Statistical Considerations
Section [IP_ADDRESS] –Missing Data ImputationTo mitigate COVID -[ADDRESS_1156058] on analyses:
Added potential for patients who were unable 
to complete Visit 16 in the protocol specified 
timeframe to participate in Study JAIM .
Added potential fo r delaying Visit 16 and 
dispensing additional IP.
Added clarification that Week 52 is considered 
to be equivalent to Visit 16, even if the timing 
of Visit 16 was not within the protocol defined 
window.
Added considerations for COVID -[ADDRESS_1156059] in order to assurethe safety of trial 
participants and minimizing risks to trial integrity 
during the COVID -19 pandemic.
Section 2 -Schedule of Activities Added “and” to clarify that the C-SSRS andSelf-Clarified that both the C -SSRS and Self -Harm 
I4V-MC-JAIA(b) Clinical Protocol Page 103
LY3009104Section # and Name [CONTACT_832720]. The 
footnote was updated to include both the C -SSRS 
and the Self -Harm Supple ment Form.Supplemental Form are required to reduce risk for 
missing data.
Section 4 –Objectives and Endpoints
Section 9.1 .2.10 –British Isles Lupus Assessment 
Group Based Composite Lupus AssessmentSubsection added to add BICLA as o ther secondary 
(non-multiplicity controlled) endpoint, and included 
a description of the assessment.Analysis of BICLA endpoint was included in the 
protocol to supplement efficacy analyses.
Section 6.1 –Inclusion Criteria Hormonal contraception dosage forms were 
corrected from oral, intravaginal, or transdermal to 
oral, injectable, or implantable.Updated to correct a typographical error
Section 6.2 –Exclusion Criteria Exclusion criterion 18, which excludes patients 
with a history of recurrent ( ≥ 2) VTE s, was revised 
to include “ (DVT/PE )” as a clarifier.
Exclusion criterion 32, which excludes patients 
who have received a JAK inhibitor, was updated to 
specify that those who have received a TYK -[ADDRESS_1156060] on the similar mechanisms as 
JAK inhibitors.
Section 6.4 –Screen Failure Text was changed from “The interva l between 
initial screen failure and rescreening Visit 1…” to 
“The interval between initial screening and 
rescreening Visit 1.”Updated to correct a typographical error.
Section 7.7. -Concomitant Therapy Added statement to clarify that reductions in dose
of treatments for SLE or other concurrent illnesses 
for safety reasons are permitted per protocol.
In Section 7.7.2, a dded “for SLE” to the conditions 
under which patients who require prohibited 
corticosteroid doses will be discontinued from 
study drug.Updated to clarify that while most concomitant 
medications should remain stable during the trial, 
reductions in dose for safety are permitted.
Updated to clarify that prohibited use of 
corticosteroids for SLE requires discontinuation 
from study drug, while use of prohibited doses of 
corticosteroids for other reasons may not require 
I4V-MC-JAIA(b) Clinical Protocol Page 104
LY3009104Section # and Name [CONTACT_832721] 7.7.2, a dded “as defined in the SAP” to 
descriptions of prohibited changes in concomitant 
therapy.discontinuation of study drug. 
Clarified that defi nitions of in creases in 
corticosteroids, antimalarials, and 
immunosuppressants are fu rther detailed in the 
SAP.
Section [IP_ADDRESS] –Venous Thromboembolic Event 
AssessmentText was changed from “All suspected VTE events 
will be independently adjudicated…” to “All 
suspected VTEs will be independently 
adjudicated…”.Updated to correct a typographical error.
Section [IP_ADDRESS] –Missing Data Imputation Added “as defined in the SAP” to NRI and MMRM 
descriptions.Clarified that increases in corticosteroids, 
antimalarials, and immunosuppressants that trigger 
missing data imputation are futher detailed in the 
SAP.
Section 10.3.6 –Interim Analyses Text outlining an interim analysis was added.
Text that indicated that there is no planned futility 
assessment and that an adjustmen t to type I error 
would be made if an unplanned futility analysis for 
efficacy is performed, was removed.An interim analysis has been added to assess the 
likelihood of trial failure time prior to trial 
conclusion in order to minimize patient exposure to 
an ineffective drug. Because an interim analysis to 
assess inadequate efficacy has been added, the text 
about ‘no planned futility assessment’ was 
removed.
I4V-MC-JAIA(b) Clinical Protocol Page 105
LY3009104Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Additions have been identified by  [CONTACT_58002] .
I4V-MC-JAIA(b) Clinical Protocol Page 106
LY30091041.Synopsis and Table JAIA.1.
…
Objective(s)/Endpoints :
Objectives Endpoints
Primary
To evaluate the effect of baricitinib [ADDRESS_1156061] -of-care (SoC) therapy compared 
to placebo and SoC on SLE disease activity.Proportion of patients achieving an SRI -4 response at 
Week 52, defined as:
Reduction of ≥4 points from baseline in 
SLEDAI-2K score; and
No new British Isles Lupus Assessment Group 
(BILAG) A orandno more than 1 new BILAG B 
disease activity score; and
No worsening (defined as an increase of 
≥0.3points [10 mm] from baseline) in the 
Physician’s Global Assessment of Disease 
Activity.
Treatment Arms and Duration
At Week 0, p atients will be rando mized to 1 of 3 treatment groups: placebo once daily (QD), 
baricitinib 2-mg QD, or baricit inib 4-mg QD. The study duration will be up to 62 weeks 
(Screening Period: up to 6 weeks prior to randomization; Double -Blinded Treatm ent Period: 
52weeks; [In some circumstances, due to COVID- 19 related logistical issues, Visit 16 may be 
completed outsi de of the protocol specified timeframe, thus the treatment period may be 
extended.  Where allowed locally, addit ional IP (typi[INVESTIGATOR_832673] 1extra month ’s supply) 
may be dispensed to prevent interruption of study  drug.]; Follow-up Period:approximately [ADDRESS_1156062].
Number of Patients:
The study  will include approximately  750 patients with SLE who will be rando mized 1:1:1 to 
receive placebo QD, baricit inib 2-mg QD, or baricitinib 4- mg QD (250 patients in each treatment 
group).  An addit ional 10% (75 patients) may  be enrolled due to COVID -19 related trial impacts.
Statistical Analysis
…
Treatment comparisons of categorical efficacy and healt h outcomes variables will be made using 
a logistic regressio n analysis wit h Firth correction (F irth 1993; Heinze and Schemper 2001 ).  
Baseline disease act ivity, baseline corticosteroid dose, region, an d treatment group will be 
explanatory  variables in the m odel.  The p-value and 95% confidence interval (CI) for the odds 
ratio from the logistic regressio n model will be used for primary  statistical inference.  Patients 
who discont inue treatment early, inc reased use of corticosteroids above the baseline dose other 
than the permitted burst ,as defined in the SAP , or have init iation of or an increase above the 
baseline dose in immunosuppressant or antimalarial treatment any t ime after baseline ,as defined 
I4V-MC-JAIA(b) Clinical Protocol Page 107
LY3009104in the SAP,will be defined as nonresponders and the data will be imputed using the 
nonresponder imputation (NRI) method.
…
Missing data for patients who have COVID -19-related issues (that are not related to an adverse 
event of COVID -19 infection) may be impu ted using al ternative method, based on consultation 
with regulatory bodies,as appropriate.  Specific imputation methodologies, for this subgroup of 
patients, will be detailed in the SAP prior to the primary  endpoint database l ock.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156063]-Treat
ment 
Follow-up
Visit Number V1 V2aV3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15 V16b,cETdcV801ed
Procedure s and Assessments
Physical examination feX
Symptom-directed 
physical examination feX X X X X X X X X X X X X X X X X
Vital signs (BP gf, 
pulse, temperature)X X X X X X X X X X X X X X X X X X
Substance use 
(caffeine, alcohol, 
tobacco)X
ECGhg X
Administer TB test ih X
Read [COMPANY_003] test (if 
applicable) jiX
Chest x-raykj X
Confirm SLE 
CriterialkX
C-SSRSmland 
Self-Harm Supplement 
FormX X X X X X X X X X X X X X X X X X
Self-Harm Follow -up 
FormnmX X X X X X X X X X X X X X X X X X
QIDS-SR16 X X X X X X X X
Randomization on Xon
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156064] 
returned and 
compliance assessedX X X X X X X X X X X X X X X
ePRO (patient diary) 
dispensed /returned po,q
pXoX X X X X X X X X X X X X X XpoXpo Xpo
Physician- Completed Scales rq
Patient Questionnaires
Worst Pain NRS qp X X X X X X X X X X X X X X X X X X
Worst Joint Pain 
NRSqpX X X X X X X X X X X X X X X X X X
Worst Fatigue NRS qp X X X X X X X X X X X X X X X X X X
Joint Stiffness 
Duration qpX X X X X X X X X X X X X X X X X X
Joint Stiffness Severity 
NRSqpX X X X X X X X X X X X X X X X X X
Patient’s Global 
Impression of Severity 
(PGI-S)qpX X X X X X X X X X X X X X X X X X
Patient’s Global 
Impression of Change 
(PGI-C)srX X X
SF-36v2 sr X X X X X X
FACIT-Fatiguesr X X X X X X X X X X X X X X X X X X
WPAI-Lupussr X X X X X X X
EQ-5D-5Lsr X X X X X X X X X X
Laboratory Tests
Hepatitis C virus 
(HCV) antibody 
testingtsX
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156065] vu X X X X X X X X X X X X X X X X X
FSHwv X
Clinical chemistry xw X X X X X X X X X X X X X X X X X X
Fasting lipid panel yx X X X X X
Urinalysis zbb X X X X X X X X X X X X X X X X X X
Baricitinib plasma 
concentrations (PK 
sample)Xaa
zXaa
zXaa
zXaa
zXaa
zXaa
z
Pharmacogenetic 
(DNA) collection bbaaX X X
Abbreviations:  ANA=antinuclear antibody; BILAG =British Isles Lupus Assessment Group; BP =blood pressure; CLASI =Cutaneous Lupus Erythematosus 
Disease Area and Severity Index; COVID-19 = coronavirus disease;
I4V-MC-JAIA(b) Clinical Protocol Page 111
LY3009104bPatients who complete the treatment period through Visit 16 may be eligible to participate in the long -term extension study (I4V -MC-JAIM [JAIM]).  For 
patients enrolled in JAIM, Visit 1 of Study JAIM should occur on the same day as Visit 16 of Study I4V -MC-JAIA (JAIA ).  In some circumstances, due to 
COVID-[ADDRESS_1156066] (IP, typi[INVESTIGATOR_832674] 1extra month ’s supply) may be dispensed to prevent interruption of study drug during the 
treatment period.
cdThose patients who discontinue from the study prior to Visit [ADDRESS_1156067] -treatment follow -up visit, 28 ±5days after the last dose of investigational product.  Patients who complete the 
treatment period through Visit 16and enter the long-term extension (LTE; JAIM) will not complete V isit [ADDRESS_1156068] ( IP)but remain in the study for at least 28±5days 
without IP can combine their Visit 16/ET with their Visit 801 (post-treatment follow -up visit).
efOne complete physical examination (excluding pelvic and rectal examinations) will be performed at Visit 1.  All subsequent physical examinations may be 
symptom-directed.  A complete physi cal examination may be repeated at the investigator’s discretion any time.
fgAt each time point, [ADDRESS_1156069] one of the readings at each time point (Section 9.4.2. Vital Si gns).
gh12-lead ECGs (single) will be performed locally and will be locally (machine) read.
ihTB test(s) include [COMPANY_003], QuantiFERON® -TB Gold, and T SPOT®.  See Exclusion Criterion [2 9]for details of TB testing.  In countries where the 
QuantiFERON -TB Gold test or T -SPOT is available, either test may be used instead of the [COMPANY_003] TB test.  The QuantiFERON -TB Gold test m ustbe performed 
centrally; the T-SPOT must be performed locally.  Note :  Exception:  Patients with a history of active or latent TB who have documented evidence of 
appropriate treatment, have no history of re -exposure since their treatment was completed, have no clinical features of active TB, and have a screening chest 
x-ray with no evidence of active TB are not required to undergo the protocol -specific TB testing (i.e., [COMPANY_003], QuantiFERON® -TB Gold, orT SPOT® )but must 
have a chest x- ray at screening (i.e.:  chest imaging performed withinthe past6 months will not be accepted) .
jiFor those patients with a [COMPANY_003] placed at Visit [ADDRESS_1156070] be read 2 to 3 days ( 48 to 72 hours )post-Visit 1.  P urified protein derivative does not need to be 
read at the site, but must be read by a trained medical professional and results must be presented to the site at Visit 2.
kjA chest x-ray(posterior -anterior view) will be performed at screening unless chest imaging (excluding ultrasound) has been performed withinthe past6 
months andthe imagingand report sare available for reviewby [CONTACT_093] .
lkPrior to randomization, there must be documentation of a patient having met at least 4 of 11 Revised Criteria for Classificat ion of Systemic Lupus 
Erythematosus according t o the 1997 Update of the 1982 ACR criteria for classification of SLE (Tan et al. 1982; Hochberg et al. 1997) .  See Inclusion 
Criterion [3].
mlSuicidal ideation and behavior subscales excerpt ; adapted for the assessment of 11 preferred ideation and behavi or categories .  C-SSRS and Self-Harm 
Supplement Form should be completed after collection of unsolicited adverse events.
nmThe Self-Harm Follow -up Form is only required if triggered by [CONTACT_47584] -Harm Supplement Form.
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156071] also be 
entered into IWRS for appropriate dose adjustment to occur if necessary.
poePRO devices (daily patient diaries) should be dispensed to all patients at screening and will need to be collected from scre en-failed patients.  Patients are 
encouraged to bring the ePRO device to every visit; however, if they do not bring the device, this will not be a protocol dev iation.  For patients NOT entering 
the LTE, the patient diary will be returned at Visit 801or the patient’s last visit .  For patients entering the LTE, the patient diary will be returned at Visit 16.
qpWorst Pain NRS, Worst Joint Pain NRS, Worst Fatigue NRS, Joint Stiffness Duration, Joint Stiffness Severity NRS, and PGI-S will be collected on an 
electronic patient diary daily (ePRO device) starting atVisit 1 (screening) through Visit 16(or Visit 801 for those not entering the LTE Study JAIM) and 
should be completed prior to any clinical assessments on days when study visits occur.
rqSLE assessments mu st be completed by a physician and will be documented on an eCOA (electronic clinical outcome assessment) device.
srPatient-reported questionnaires will be administered via an on-site eCOA device and should be administered prior to any clinical assessments.
tsFor patients who are positive for HCV antibody, a follow -up test for HCV RNA will be performed automatically .  Patients who are positive for HCV antibody 
and negative for HCV RNA may be enrolled.
utFor patients who are positive for HBcAb, a follow-up test for HBV DNA will be performed automatically.  Patients who are positive for HBcAb and negative 
for HBV DNA may be enrolled.   Any enrolled patient w ho is HBcAb positive, regardless of HBsAb status or level, must undergo HBV DNA testing per the
schedule of events (see Section 9.4.8 for details of HBV DNA monitoring).
vuFor all women of child -bearing potential, a serum pregnancy test (central laboratory) will be performed at Visit 1.  Urine pregnancy tests (local laboratory) 
will be performed at Visit 2 prior to randomization and at all subsequent study visits.
wvFor female patients ≥50and <55years of age who have had a cessation of menses for at least [ADDRESS_1156072] will be performed to 
confirm non -child-bearing pot ential (FSH ≥40 mIU/ mL).
xwClinical chemistry will include the following value calculated by [CONTACT_832676]:  estimated gl omerular filtration rate (eGFR; 
calculated using the Modification of Diet in Renal Disease [MDRD] isotope dilution mass spectrometry traceable method).
yxFasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to sample collection .  If a patient attends these visits in a 
nonfasting state, the sample should sti ll be collected.  T his will not be considered a protocol violation.
zbbUrine should be collected as a clean catch sample .
aazSee Section 9.5for details.
bbaaPatients choosing not to provide consent for whole blood samples to be collected for pharmacoge netic research will still be eligibl e to participate in the 
study.
I4V-MC-JAIA(b) Clinical Protocol Page 113
LY30091044. Objectives and Endpoints
Table JAIA.2. Objectives and Endpoints
Other Secondary (Non -Multiplicity Controlled)
To evaluate the effect of baricitinib 4 -mg or 2-mg 
QD plus SoC compared to placebo plus SoC on 
SLE disease activity.Change from baseline in total SLEDAI -2K scores 
over time through Week 52.
Change from baseline in PGA score over time 
through Week 52.
Proportion of patients achieving an SRI -4 response 
over time through Week 52.
Proportion of patients achieving an SRI -5, -6, -7, 
and -8 response over time through Week 52.
Proportion of patients achieving reduction of ≥4 
points from baseline in SLEDAI -2K score at Week 
52.
Proportion of patients with no new British Isles 
Lupus Assessment Group (BILAG) A orandno 
more than 1 new BILAG B disease activity score at 
Week 52.
Proportion of patients with no worsening (defined as 
an increase of ≥0.3 points [10 mm] from baseline) in 
the Physician’s Global Assessment of Disease 
Activity at Week 52.
Proportion of patients achieving a British Isles Lupus 
Assessment Group Based Composite Lupus 
Assessment (BICLA) response at Week 52, defined 
as: 
Reduction of all baseline BILAG A to B/C/D and 
baseline BILAG B to C/D, and no BILAG 
worsening in other organ systems, where 
worsening is defined as ≥1 new BILAG A or ≥2 
new BILAG B
No worsening from baseline in SLEDAI -2K, 
where worsening is defined as an in crease from 
baseline of >0 points in SLEDAI-2K
No worsening from baseline in participants' lupus 
disease activity, where worsening is defined by [CONTACT_788865] ≥0.30 points on a 3 -point PGA visual 
analogue scale (VAS).
5.1.Overall Design
Treatment Period
…
Investigational product will be taken daily for 52 weeks .  In some circumstances, due to COVID -
19 related logistical issues, Visit 16 may be co mpleted outside of the protocol specified 
I4V-MC-JAIA(b) Clinical Protocol Page 114
LY3009104timeframe, thus the treatment period may be extended.  Where allowed locally, addit ional IP 
(typi[INVESTIGATOR_832658] 1extra month ’s supply) may be dispensed to prevent interruption of 
study drug.  Clinical assessments and laboratory  samples, including addit ional PK sampling, will 
be obtained at scheduled visits according t o the Schedule of Act ivities (Section 2).  Speci al 
timing considerations of administration of invest igational product relative to PK sample 
collection at study  visits are described in Sect ion 9.5.
Follow-up Period: Patients who com plete the treatm ent period of the study  through Week 52 
(Visit 16) are eligible to parti cipate in the long-term extension(LTE), Study  I4V-MC-JAIM
(JAIM).  In some circumstances, due to COVID -[ADDRESS_1156073] -treatment follow-up visit (Visit 801) approximately [ADDRESS_1156074].
6.1.Inclusion Criteria
Patient Characteristics
[9]Male or nonpregnant, nonbreastfeeding female patient
d.The following contraception methods are considered acceptable (the 
patient should choose 2, and [ADDRESS_1156075] be highly effective [defined as less 
than 1% failure rate per year when used consistent ly and correctly ]):
Highly effective birth control methods:  
Combined (estrogen and progestogen containing) hormonal 
contraception associated with inhibit ion of ovulat ion:  oral, 
intravaginal, or transdermal
Progestogen -only containing hormonal contraceptio n associated 
with inhibition of ovulation:  oral, injectable intravaginal, or 
implantable transdermal
intrauterine device (IUD)/intrauterine hormone -releasing system 
(IUS)
…
…6.2.Exclusion Criteria
Patients will be excluded from  study enrollment if they meet any o f the following criteria:
Medical Conditions
…
[32]Have received a JAK inhibitor or TYK-2 inhibitor .
6.4.Screen Failures
I4V-MC-JAIA(b) Clinical Protocol Page 115
LY3009104Individuals who do not meet the criteria for participation in this study  (screen failure) may be 
rescreened one time.  The interval between init ial screen ingfailure and rescreening Visit [ADDRESS_1156076] ivities,and will be assigned a 
new ident ification number .
7.7.Concomitant Therapy
Patients will maintain their usual medicat ion regimen for SLE and for any  other concomitant 
diseases throughout the study  unless specifically  excluded in the protocol (see Sect ion 6.2, 
Exclusion Criteria).  Patients taking these medicat ions should be on chronic stable d oses at the 
time of rando mization, as specified by [CONTACT_832694] (Section 6.1, Inclusio n Criterion 
[8]).
…
Any changes to the patient’s medicat ion must be discussed with the investigator.  Treatment sfor 
SLE or other concurrent illnesses may be re duced for safet y reasons. Patients should be 
instructed to consult the invest igator or other appropriate study personnel at the site before taking 
any new medicat ions or supplements.
…
7.7.2.Prohibited Changes in Concomitant Therapy
Initiation of or increase in dose of an ant imalarial or immunosuppressant is not permitted during 
the treatment period.  Patients requiring an init iation or increase above baseline dose of 
antimalarials or immunosuppressants ,as defined in the SAP ,during the treatment period will be 
discontinued fro m the study drug (see Section 8.1.12).
Patients requi ring an increase above the baseline dose of corticosteroid for SLEduring the 
treatment period, other than the permitted burst ,as defined in the SAP , will be discont inued from 
study drug (see Secti on 8.1.12).
7.8.Treatment after the End of the Study
7.8.1.Study Extensions
Patients who com plete this study through Week 52 (Visit 16) m ay be eligible to participate in 
Study JAIM, if enro llment criteria for Study JAIM are met .In some circumstances, due to 
COVID-19 related logistical issues, patients who were unable to complete Visit 16 in the 
protocol specified timeframe and had study  drug temporarily interrupted, but otherwise 
completed the treatm ent period, may be eligible to pa rticipate in Study  JAIM.
9.1.Efficacy Assessments
9.1.1.Primary Efficacy Assessment
I4V-MC-JAIA(b) Clinical Protocol Page 116
LY3009104…
•No new BILAG A orandno more than [ADDRESS_1156077] ivity scores (Secti on 
[IP_ADDRESS]); and
…
[IP_ADDRESS]. British Isles Lupus Assessment Group Based Composite Lupus Assessment 
The BICLA is a composite index used to assess disease act ivity in SLE.  The BILAG component 
is used to capture clinically meaningful improvement in disease act ivity, while the BILAG, 
SLEDAI-2K,and Physician’s Global Assessment of Disease Act ivity components ensure that the 
improvement in overall disease is not accompanied by  [CONTACT_629291].  
The BICLA response is defined as fo llows:
Reduction o f all baseline BILAG A to B/C/D and baseline BILAG B to C/D, and no 
BILAG worsening in other organ systems, where worsening i s defined as≥1 new 
BILAG A or ≥2 new BILAG B
No worsening fro m baseline in SLEDAI -2K, where worsening is defined as an 
increase from baseline of >0 points in SLEDAI -2K
No worsening fro m baseline in participants' lupus disease act ivity, where worsening 
is defined by [CONTACT_522104] ≥0.30 points on a 3 -point PGA visual analogue scale (VAS)
9.4.10.1Venous Thromboembolic Event Assessment
If a patient develops clinical features of a DVT or PE, appropriate local laboratory  tests and 
imaging should be performed, as necessary , for the diagnosi s of the event.  For confirmed cases, 
additional laboratory  testing is recommended as outli ned in Appendix 5.  All suspected VTE s
eventswill be independently adjudicated by  a blinded Clinical Event Committee.
10.1.Sample Size Determination
…
An additional 10% (75 pati ents) may be enrolled due to COVID -19 related trial impacts.
Sample size and power estimates were obtained from nQuery ® Advisor 7.0 using the χ2testof 
equal proportions.
10.3.Statistical Analyses
10.3.1. General Statistical Considerations
…
Any change to the data analysis methods described in the protocol will require an amendme nt 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the clinical study  report.  Addi tional exploratory analys es of the data will be conducted as 
deemed appropri ate.  Complete details o f the planned analyses will be documented in the SAP.
For all analyses, Week 52 is considered to be equivalent to Visit 16, even if the timing of Visit 
16 was not within the protocol defined window.
I4V-MC-JAIA(b) Clinical Protocol Page 117
LY300910410.3.1.1Analysis Methods
…
Missing data for patients who have COVID -19-related issues (that are not related to an adverse 
event of COVID -19 infection) may be imputed using alternat ive method, based on consultation 
with regulatory bodies,as appropriate.  Specific imputation methodologies, for this subgroup of 
patients, will be detailed in the SAP prior to the primary  endpoint database l ock.
10.3.1.2Missing Data Imputation
…
Nonresponder imputation (NRI) : For analysis o f categorical efficacy  and health 
outcomes variables such as SRI -4, missing data will be imputed using an NRI method.  
Patients who discont inue treatment early, increase use of corticosteroids above the 
baseline dose other than the permitted burst, as defined in the SAP, or have init iation of 
or an increase above baseline dose in immunosuppressant or antimalarial treatment ,as 
defined in the SAP ,any time after baseline will be defined as nonresponders.   In some 
circumstances, due to COVID -[ADDRESS_1156078] the 
discontinued medicat ions.  These medicat ions changes may not define patients as 
nonresponders.
Mixed-model repeated measure (MMRM) :  For continuous variables, the primary analysis 
will be a MMRM analysis wit ha missing at random assumpt ion for handling missing 
data.  This analysis takes into account both missingness of data and the correlat ion of the 
repeated m easurements.  For pati ents who increase use of corticosteroids above the 
baseline dose other than the permitted burst , as defined in the SAP, or have init iation of 
or an increase above baseline dose in immunosuppressant or antimalarial treatment ,as 
defined in the SAP, any time after baseline, any observed data after that visit will be 
excluded fro m the MMRM analysis.  Observed data after permanent discont inuation o f 
investigat ional product will be analyzed as observed, with the exception of any data that 
occur after i ncreaseinuse of corticosteroids above the baseline dose other than the 
permitted burst ,or initiation of or an increase above baseline dose in immunosuppressant 
or antimalarial treatment.  In some circumstances, due to COVID -[ADDRESS_1156079] the discontinued medicat ions.  For these speci fic 
COVID-19 cases, data will be treated as observed.

…
I4V-MC-JAIA(b) Clinical Protocol Page [ADDRESS_1156080] COVID -19-related issues (that are not related to an adverse 
event of COVID -19 infection) may be imputed using alternat ive methods, based on consultat ion 
with regulatory bodies, as appropriate.  Specific imputation methodologies, for this subgroup of 
patients, will be detailed in the SAP prior to the primary  endpoint database l ock.
10.3.3.1Primary Analyses
The primary  efficacy measure is SRI -4 response (define d in Section 9.1.1).  A logist ic regressio n 
model with Firth correcti on (as described in Sect ion [IP_ADDRESS] ) will be used to test the treatment 
difference between baricit inib 4-mg and placebo in the proportion of pat ients achieving SRI -4 
response at Week 52.   Missing data will be imputed using the NRI method described in Section 
[IP_ADDRESS].  Missing data for patients who have COVID -19-related issues (that are not related to an 
adverse event of COVID -19 infection) may be imputed using alternat ive method, based o n 
consultation wit h regulatory  bodies, as appropri ate.  Specific imputation methodologies, for this 
subgroup of patients, will be detailed in the SAP prior to the primary endpoint database lock.
[IP_ADDRESS] Major Secondary Analyses
…
Treatment comparisons in the proporti on of patients achieving a binary response will be 
analyzed using logist ic regressio n with Firth correcti on.  Treatment comparisons in the 
continuous measures will be analyzed using MMRM.  Treatment comparisons for t ime to first 
flare will be analyzed using a Cox proportional hazards model.  These m ethods are described in 
Section [IP_ADDRESS] .  Missing data for the binary  outcome measures will be imputed using the NRI 
method described in Section [IP_ADDRESS] . Missing data for patients who have COVID -19-related 
issues (that are not related to an adverse event of COVID- 19 infection) may be imputed using 
alternative method, based on consultat ion with regulatory bodies,as appropriate.  Specific 
imputation methodologies, for thi s subgroup of patients, will be detailed in the SAP prior to the 
primary endpoint database lock.
10.3.6.Interim Analyses
…
Access to the unblinded data will be l imited to the DMCand statist icians providing the data .  
Thesestatisticians will be independent from the study  team.  Thestudy team will not have access 
to the unblinded data .  Only the DMC is authorized to evaluate unblinded interim efficacy and 
safety analyses. The study  sites will receive information about interim results ONLY if they need 
to know for the safet y of theirpatients.  The DMC may request to review efficacy data to 
investigate the benefit /risk relationship in the context of safet y observations for ongoing patients 
in the study .However, the study  will not be stopped for posi tive efficacy results, and there is no
planned fut ility assessment. Hence, there will be no alpha adjust ment for these interim analyses. 
I4V-MC-JAIA(b) Clinical Protocol Page 119
LY3009104Adjustments to type I error will be made if an unplanned futilit y analysis for efficacy  is 
performed.
In addition to the planned safet y-related interim analyses, interim efficacy  analyses may be 
conducted pri or to com pletion of the study .  Using predefined thresholds, the trial may be 
stopped if the probabilit y of the trial meeting its primary  efficacy endpoint falls below an 
acceptable level.  The DMC ch arter will describe the precise decisio n guidelines governing the 
interim analyses.  The trial will not be stopped for posit ive efficacy; therefore, no alpha 
adjustment is needed.
In addition to the DMC members, a limited number of pre -identified individua ls may gain access 
to the limited unblinded data, as specified in the unblinding plan, prior to the final database lock, 
in order to init iate the popul ation PK/PD m odel development processes.  These analyses will not 
be considered interim analyses.  Information that may unblind the study  during the analyses will 
not be reported to study  sites or blinded study  team until the study  has been unblinded.
Leo Document ID = 80ea86ce-3caa-4cb9-ac5c-1c44d0819a7a
Approver: 
Approval Date & Time: 16-Apr-2020 21:28:45 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 20-Apr-2020 10:48:01 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]